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In this study, we have demonstrated that the preproghrelin derived hormones, ghrelin 
and obestatin, may play a role in ovarian cancer. Ghrelin and obestatin stimulated an 
increase in cell migration in ovarian cancer cell lines and may play a role in cancer 
progression. Ovarian cancer is the leading cause of death among gynaecological 
cancers and is the sixth most common cause of cancer-related deaths in women in 
developed countries.  As ovarian cancer is difficult to diagnose at a low tumour 
grade, two thirds of ovarian cancers are not diagnosed until the late stages of cancer 
development resulting in a poor prognosis for the patient. As a result, current 
treatment methods are limited and not ideal. There is an urgent need for improved 
diagnostic markers, as well better therapeutic approaches and adjunctive therapies for 
this disease.  
 
Ghrelin has a number of important physiological effects, including roles in appetite 
regulation and the stimulation of growth hormone release. It is also involved in 
regulating the immune, cardiovascular and reproductive systems and regulates sleep, 
memory and anxiety, and energy metabolism. Over the last decade, the ghrelin axis, 
(which includes the hormones ghrelin and obestatin and their receptors), has been 
implicated in the pathogenesis of many human diseases and it may t may also play an 
important role in the development of cancer. Ghrelin is a 28 amino acid peptide 
hormone that exists in two forms. Acyl ghrelin (usually referred to as ghrelin), has a 
unique n-octanoic acid post-translational modification (which is catalysed by ghrelin 
O-acyltransferase, GOAT), and desacyl ghrelin, which is a non-octanoylated form. 
Octanoylated ghrelin  acts through the growth hormone secretagogue receptor type 
1a (GHSR1a). GHSR1b, an alternatively spliced isoform of GHSR, is C-terminally 
truncated and does not bind ghrelin. Ghrelin has been implicated in the 
pathophysiology of a number of diseases Obestatin is a 23 amino acid, C-terminally 
amidated peptide which is derived from preproghrelin. Although GPR39 was 
originally thought to be the obestatin receptor this has been disproven, and its 
receptor remains unknown. Obestatin may have as diverse range of roles as ghrelin. 
Obestatin improves memory, inhibits thirst and anxiety, increases pancreatic juice 
secretion and has cardioprotective effects. Obestatin also has been shown to regulate 
cell proliferation, differentiation and apoptosis in some cell types.  
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Prior to this study, little was known regarding the functions and mechanisms of 
action ghrelin and obestatin in ovarian cancer. In this study it was demonstrated that 
the full length ghrelin, GHSR1b and GOAT mRNA transcripts were expressed in all 
of the ovarian-derived cell lines examined (SKOV3, OV-MZ-6 and hOSE 17.1), 
however, these cell lines did not express GHSR1a. Ovarian cancer tissue of varying 
stages and normal ovarian tissue expressed the coding region for ghrelin, obestatin, 
and GOAT, but not GHSR1a, or GHSR1b. No correlations between cancer grade and 
the level of expression of these transcripts were observed.  
 
This study demonstrated for the first time that both ghrelin and obestatin increase cell 
migration in ovarian cancer cell lines. Treatment with ghrelin (for 72 hours) 
significantly increased cell migration in the SKOV3 and OV-MZ-6 ovarian cancer 
cell lines. Ghrelin (100 nM) stimulated cell migration in the SKOV3 (2.64 +/- 1.08 
fold, p <0.05) and OV-MZ-6 (1.65 +/- 0.31 fold, p <0.05) ovarian cancer cell lines, 
but not in the representative normal cell line hOSE 17.1. This increase in migration 
was not accompanied by an increase in cell invasion through Matrigel. In contrast to 
other cancer types, ghrelin had no effect on proliferation. Ghrelin treatment (10nM) 
significantly decreased attachment of the SKOV3 ovarian cancer cell line to collagen 
IV (24.7 +/- 10.0 %, p <0.05), however, there were no changes in attachment to the 
other extracellular matrix molecules (ECM) tested (fibronectin, vitronectin and 
collagen I), and there were no changes in attachment to any of the ECM molecules in 
the OV-MZ-6 or hOSE 17.1 cell lines. It is, therefore, unclear if ghrelin plays a role 
in cell attachment in ovarian cancer.  
 
As ghrelin has previously been demonstrated to signal through the ERK1/2 pathway 
in cancer, we investigated ERK1/2 signalling in ovarian cancer cell lines. In the 
SKOV3 ovarian cancer cell line, a reduction in ERK1/2 phosphorylation (0.58 fold 
+/- 0.23, p <0.05) in response to 100 nM ghrelin treatment was observed, while no 
significant change in ERK1/2 signalling was seen in the OV-MZ-6 cell line with 
treatment. This suggests that this pathway is unlikely to be involved in mediating the 
increased migration seen in the ovarian cancer cell lines with ghrelin treatment. 
 
In this study ovarian cancer tissue of varying stages and normal ovarian tissue 
expressed the coding region for obestatin, however, no correlation between cancer 
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grade and level of obestatin transcript expression was observed. In the ovarian-
derived cell lines studied (SKOV3, OV-MZ-6 and hOSE 17.1) it was demonstrated 
that the full length preproghrelin mRNA transcripts were expressed in all cell lines, 
suggesting they have the ability to produce mature obestatin.  
 
This is the first study to demonstrate that obestatin stimulates cell migration and cell 
invasion. Obestatin induced a significant increase in migration in the SKOV3 ovarian 
cancer cell line with 10 nM (2.80 +/- 0.52 fold, p <0.05) and 100 nM treatments 
(3.12 +/- 0.68 fold, p <0.05) and in the OV-MZ-6 cancer cell line with 10 nM (2.04 
+/- 0.10 fold, p <0.01) and 100 nM treatments (2.00 +/- 0.37 fold, p <0.05). 
Obestatin treatment did no affect cell migration in the hOSE 17.1normal ovarian 
epithelial cell line. Obestatin treatment (100 nM) also stimulated a significant 
increase in cell invasion in the OV-MZ-6 ovarian cancer cell line (1.45 fold +/- 0.13, 
p <0.05) and in the hOSE17.1 normal ovarian cell line cells (1.40 fold +/- 0.04 and 
1.55 fold +/- 0.05 respectively, p <0.01) with 10 nM and 100 nM treatments. 
Obestatin treatment did not stimulate cell invasion in the SKOV3 ovarian cancer cell 
line. This lack of obestatin-stimulated invasion in the SKOV3 cell line may be a cell 
line specific result. 
 
In this study, obestatin did not stimulate cell proliferation in the ovarian cell lines and 
it has previously been shown to have no effect on cell proliferation in the BON-1 
pancreatic neuroendocrine and GC rat somatotroph tumour cell lines. In contrast, 
obestatin has been shown to affect cell proliferation in gastric and thyroid cancer cell 
lines, and in some normal cell lines. Obestatin also had no effect on attachment of 
any of the cell lines to any of the ECM components tested (fibronectin, vitronectin, 
collagen I and collagen IV).  
 
The mechanism of action of obestatin was investigated further using a two 
dimensional-difference in gel electrophoresis (2D-DIGE) proteomic approach.  After 
treatment with obestating (0, 10 and 100 nM), SKOV3 ovarian cancer and hOSE 
17.1 normal ovarian cell lines were collected and 2D-DIGE analysis and mass 
spectrometry were performed to identify proteins that were differentially expressed 
in response to treatment. Twenty-six differentially expressed proteins were identified 
and analysed using Ingenuity Pathway Analysis (IPA). This linked 16 of these 
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proteins in a network. The analysis suggested that the ERK1/2 MAPK pathway was a 
major mediator of obestatin action. ERK1/2 has previously been shown to be 
associated with obestatin-stimulated cell proliferation and with the anti-apoptotic 
effects of obestatin. 
 
Activation of the ERK1/2 signalling pathway by obestatin was, therefore, 
investigated in the SKOV3 and OV-MZ-6 ovarian cancer cell lines using anti-active 
antibodies and Western immunoblots. Obestatin treatment significantly decreased 
ERK1/2 phosphorylation at higher obestatin concentrations in both the SKOV3 (100 
nM and 1000 nM) and OV-MZ-6 (1000 nM) cell lines compared to the untreated 
controls. Currently, very little is known about obestatin signalling in cancer.  
 
This thesis has demonstrated for the first time that the ghrelin axis may play a role in 
ovarian cancer migration. Ghrelin and obestatin increased cell migration in ovarian 
cancer cell lines, indicating that they may be a useful target for therapies that reduce 
ovarian cancer progression. Further studies investigating the role of the ghrelin axis 
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TK   Tyrosine Kinase 
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A little more than a decade ago, the growth hormone secretagogue, ghrelin, was 
successfully isolated by Kojima et al. from stomach tissue as the endogenous ligand 
for the growth hormone secretagogue receptor (GHSR) [1]. Mature ghrelin is a 28 
amino acid peptide which may circulate as desacyl ghrelin (unacylated ghrelin), or as 
the octanoylated form known as acyl ghrelin (or ghrelin) [1]. The acylation of ghrelin 
is a unique post-translational modification mediated by the enzyme ghrelin O-
acyltransferase (GOAT) [2, 3]. Since the original discovery of ghrelin as a growth 
hormone (GH) releasing hormone, it has been established that it is ubiquitously 
expressed in the body and has a wide array of functions [4], including a role in 
appetite regulation [5]. In addition to being an orexigenic signal, ghrelin is involved 
in regulating the immune, cardiovascular and reproductive systems and regulates 
sleep, memory and anxiety, energy metabolism and bone, and plays a role in cell 
proliferation, apoptosis, migration and angiogenesis [4]. Several years after the 
discovery of ghrelin, Zhang et al. identified obestatin as a second peptide hormone 
which is derived from the preproghrelin peptide and encoded by the ghrelin gene 
(GHRL) [6]. Although obestatin was originally thought to oppose the effects of 
ghrelin on feeding, this finding proved difficult to replicate and has become 
controversial [7]. Despite this, obestatin is likely to be as widely expressed as ghrelin 
and may have a diverse range of functions. Obestatin has also been shown to have 
roles in thirst, adiposity, pancreatic function, reproduction, the cardiovascular 
system, sleep, memory, anxiety, and cell proliferation and apoptosis [7]. Some of 
these functions may be complementary, and a number have been shown to be similar 
to those of ghrelin including its role in sleep [8], memory [9] and cell proliferation 
[10-14].  
 
There is increasing evidence that the ghrelin axis plays a role in the progression and 
development of cancer [15]. Components of the ghrelin axis are expressed locally in 
a range of different cancers including astrocytoma [16], breast [17, 18], colorectal 
[19, 20], gastric[11, 19, 21-24], liver [20, 25], lung [26-29], pancreatic [30, 31], 
pituitary [32-37], prostate [38-40], renal [41], testicular [42], thyroid [43, 44] and 
ovarian cancer [45, 46] (Tables 1.3 and 1.4). There is emerging evidence that the 
ghrelin axis may alter functions which are critical to cancer progression, including 
cell proliferation [11, 17, 25, 38-40, 47-51], apoptosis [47, 49, 52, 53], and cell 
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migration [48, 54, 55] and invasion [48, 54]. In cancer cell lines, ghrelin has been 
demonstrated to increase [17, 25, 38-40, 47-51, 54, 56, 57], or decrease [38, 44, 53, 
56] cell proliferation, to have anti-apoptotic effects [47, 49, 52], and to increase cell 
migration [48, 54, 55] and invasion [48, 54]. Although there have been few studies 
into the role of obestatin in cancer, it has effects on cell proliferation [11, 56]. The 
ghrelin axis, therefore, may play a role in promoting progression of a number of 
cancers [15]. There have been few studies regarding the ghrelin axis in ovarian 
cancer and we hypothesise that ghrelin and obestatin may stimulate processes related 
to cancer progression in this disease.  
 
1.2 Ovarian cancer  
Ovarian cancer is the leading cause of death among gynaecological cancers and is the 
sixth most common cause of cancer-related deaths after breast, lung, colon, 
pancreatic and stomach cancer in women in developed countries [58]. In Australia, it 
is the 9th most commonly diagnosed cancer in women, and it is the second most 
commonly diagnosed gynaecological cancer [59]. Ovarian cancer is the 4
th
 leading 
cause of cancer disease burden for females in Australia accounting for 12,900 
disability-adjusted life years in 2010 [59]. It has an incidence of 9.4 per 100 000 
[58], and the risk of ovarian cancer increases with age. The incidence increases 
dramatically after 50 years of age, when 81% of all new cases of ovarian cancer are 
diagnosed [59]. There has been less than a 1% decline in the incidence of ovarian 
cancer over the past 2 decades and the mortality rate has remained largely unchanged 
[60].  
 
There are three major types of ovarian cancer, defined by their tissue of origin. Of all 
cases of ovarian cancer diagnosed, 85-95% are an epithelial histotype, 5-8% are 
stromal and 3-5% are germ cell in origin [61, 62]. There are a number of different 
subtypes of each of these types of ovarian cancer. There are three major invasive 
types of epithelial cancers, which are defined as serous (75%-80%), mucinous (10%) 
and endometrioid (10%) ovarian cancer [61]. Ovarian cancer, like other cancers, is 
graded according to tumour development, as stages I-IV, with stage IV representing 
the most advanced disease (Table 1.1). The stage of the cancer at diagnosis 
significantly affects the five year survival rate of the patient and influences the 
choice of treatment [62-64].  
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Table 1.1 International Federation of Gynaecology and Obstetrics Stages of 
ovarian cancer showing the spread of cancer according to the stage and the five 
year prognosis. Adapted from Roett et.al. 2009 [65] 
 
Stage Spread 5-year survival rate 
I Limited to ovaries 90 percent 
II Pelvic extension 60 to 80 percent 
III Peritoneal implants and/or retroperitoneal or inguinal lymph 
nodes 
20 percent 
IV Distant metastases Less than 10 percent 
 
Very little is known about this disease and patients often present with few symptoms. 
Symptoms include non-specific pelvic and abdominal problems, particularly during 
initial tumour development, making ovarian cancer difficult to diagnose at a low 
tumour grade [64, 66, 67]. Current initial diagnostic tests, in addition to an 
examination of the patient’s history, include pelvic examination, transvaginal 
ultrasonography and measuring serum for cancer antigen 125 (CA125). These 
methods do not provide a specific diagnosis of ovarian cancer, however [64, 67-74], 
and two thirds of ovarian cancer cases are not diagnosed until the late stages of 
cancer development (either stage III or IV) resulting in a poor prognosis for the 
patient [61]. The surgical approach to ovarian cancer is influenced by the stage at 
diagnosis. If the cancer is found at an early stage, the prognosis for patients is 
significantly better and fertility-conserving measures may be possible. This may 
include unilateral salpingo-oophorectomy (removal of the ovary and uterine tube on 
the affected side), and adjunctive chemotherapy is used if the patient displays 
residual disease, or has unidentifiable invasive peritoneal implants [63]. As ovarian 
cancer is often diagnosed at an advanced stage, complete removal of the tumour may 
not be possible. The patient often requires surgical tumour cytoreduction, followed 
by a course of combination chemotherapy, using drugs such as carboplatin and 
paclitaxel [75]. The degree of surgery ranges from unilateral or bilateral salpingo-
oophorectomy to total abdominal hysterectomy and removal of pelvic and para-aortic 
lymph nodes, depending on the stage of cancer progression. These treatment methods 
are not ideal, as the 5 year survival rate still remains low once the disease has 
metastasised, dropping to 20% or lower (Table 1.1) [65]. A greater understanding of 
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the underlying mechanisms of ovarian cancer progression, better prognostic and 
diagnostic markers for early detection and more effective treatments are urgently 
needed.  
 
In the ovary, normal function is under the control of an array of hormones and 
growth factors [76, 77]. Hormones and growth factors play a central role in 
regulating cell proliferation, differentiation, and apoptosis [78]. Dysregulation of 
these proteins is likely to be of aetiological importance in ovarian cancer [78, 79]. 
Some of the hormones proposed to play a role in ovarian cancer pathogenesis include 
pituitary gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone 
(FSH), as well as androgens, oestrogens, progesterone and insulin-like growth factors 
I and II (IGF-I and IGF-II) [80-82]. Gonadotropins [83-86], androgens [84, 87, 88] 
and oestrogens [84, 89] have all been shown to stimulate cell proliferation of the 
normal ovarian surface epithelium (OSE), the site of origin of most ovarian cancers. 
There is, however, recent genetic evidence that the Fallopian tube epithelium may be 
the site of origin for primary ovarian tumours [90]. It is hypothesised that excessive 
stimulation of ovarian tissue by pituitary gonadotropins (LH and/or FSH) directly, or 
indirectly through stimulation of ovarian production of sex steroids, influences 
malignant transformation of cells [80, 91]. Similarly, excess androgenic stimulation 
of ovarian epithelial cells has been linked to increased ovarian cancer risk [78, 80] 
and also to increased proliferation of ovarian cancer cell lines [84, 92-94].  
 
The oestrogens, oestradiol and oestrone, are secreted from granulosa cells of the 
follicle in the ovary at ovulation, exposing OSE to concentrations that are four times 
higher than levels in the circulation [80]. Experiments have shown that oestrogens, in 
addition to stimulating proliferation of OSE cells, can promote formation of serous 
ovarian cysts [95] and these have been hypothesised to lead to tumour formation 
[96]. Treatment with oestradiol has been shown to increase vascular endothelial 
growth factor (VEGF), and cell adhesion in oestrogen receptor (ER) positive cells 
and increase the migratory potential of ovarian tumours [97]. Progesterone, however, 
appears to confer a protective effect against ovarian cancer, decreasing proliferation 
[98], inhibiting invasion [99], suppressing tumourigenesis [100] and inducing 
apoptosis [101, 102], and higher levels are associated with lower risk of ovarian 
cancer [78].  
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IGF-I and -II are potent regulators of ovarian secretory activity, stimulating the 
release of progesterone, testosterone, oestradiol and other factors [103, 104]. 
Blocking signalling of the IGF-1 receptor inhibits proliferation in ovarian cancer cell 
lines [105]. Other growth factors in the ovary may also play a role in the aetiology of 
ovarian cancer. Proliferation, apoptosis and secretory activity of ovarian cell are 
influenced by growth factor like epidermal growth factor (EGF) [104], 
thrombopoietin [106], erythropoietin (EPO) [107], hedgehog protein [108] and their 
receptors. These influences over ovarian cell function may have significance in 
ovarian cancer development. Inhibition of the EPO receptor decreases 
tumourigenesis and invasiveness of ovarian carcinoma cells [109]. The EGF receptor 
also plays an important role in ovarian cell malignancy, influencing proliferation, 
survival, adhesion, motility, invasion, and angiogenesis in tumours [110, 111]. Over 
expression of this receptor has been linked to poor prognosis and decreased 
therapeutic responsiveness in ovarian cancer patients [110, 111]. Increased vascular 
endothelial growth factor (VEGF) expression has also been found in ovarian tumours 
and blocking this receptor can inhibit ovarian carcinogenesis and this shows 
therapeutic potential [111-113]. Further experimental data is required to establish 
whether these hormones are driving ovarian cancer development, or whether 
differences in hormone levels may be a result of the presence of the tumour (through 
inverse causation bias) [78]. 
 
We hypothesise that the ghrelin axis, which includes the peptide hormones ghrelin 
and obestatin, may play a role in the progression of cancer and may be a useful 
therapeutic target [15]. Elevated fasting plasma levels of octanoylated ghrelin and 
obestatin have been described in ovarian cancer patients [114]. In addition, GHSR1a, 
the ghrelin receptor, is expressed in benign and ovarian cancer tissues [45]. These 
proteins may provide new targets for the diagnosis and treatment of ovarian cancer. 
 
1.3 The ghrelin axis  
 
1.3.1 Ghrelin, desacyl ghrelin and GOAT 
The ghrelin gene (GHRL) is located on the chromosomal locus 3p25.3-p26.2 [115]. 
The gene was originally thought to have a fairly simple structure, with 4 coding 
exons (exons 1-4), which encode the 117 amino acid preproghrelin peptide, and a 
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short, 20 bp first exon (Fig. 1.1) [6, 116, 117]. It has more recently been established 
that the ghrelin gene is complex and contains other upstream exons, (exon -1 and an 
extended exon 0), as well an extended exon 1 (Fig. 1.1) [116-118]. Research in our 
group has demonstrated that alternative splicing leads to the production of a large 
number of mRNA isoforms, including a number of ghrelin antisense transcripts 
[119]. In humans, parts of exons 1 and 2 of the ghrelin gene code for the ghrelin 
peptide [116] and exon 3 encodes the peptide hormone obestatin. 
 
The preproghrelin peptide is processed to give a number of peptides, including a 23 
amino acid secretion-signal peptide, the 28 amino acid peptide ghrelin and a 66 
amino acid C-ghrelin peptide, from which the 23 amino acid peptide obestatin is 
cleaved [6, 120]. The processing of the preproghrelin peptide to form mature ghrelin 
and obestatin involves a number of proteins [121]. Cleavage of the ghrelin peptide 
from preproghrelin is mediated by prohormone convertases (PC) PC1/3, PC2 and 
furin [122, 123]. The proteins mediating the proteolytic cleavage of obestatin from 
preproghrelin, remain unclear, although they may include the same prohormone 
convertases [4, 124].  
 
The major mature form of ghrelin is a 28 amino acid hormone that circulates in two 
forms, desacyl ghrelin (the major circulating form) and acylated ghrelin (or ghrelin). 
Ghrelin is octanoylated post-translationally, with the addition of an acyl group to the 
third amino acid, serine [1, 125-128]. It is the only mammalian peptide known to be 
post-translationally octanoylated. This unique post-translational modification, which 
increases the lipophilicity of the molecule [1] (Fig. 1.2), is mediated by the enzyme 
ghrelin O-acyltransferase (GOAT) in the endoplasmic reticulum [2, 3]. In humans, 
the highest levels of GOAT mRNA expression are in the stomach and pancreas, 
where it is co-expressed with ghrelin [2, 129]. Lower levels of GOAT transcripts are 
present in a number of other tissues including brain, colon, oesophagus, fat, heart, 
small intestines, kidney, liver, lymph node, muscle, pituitary, placenta, salivary 
gland, testis, thymus, thyroid, uterus [2], adrenal glands [130] and chondrocytes 
[131] and it is over-expressed in breast tumours and cell lines compared to normal 
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Figure 1.1 The exon structure of the ghrelin gene for the coding of the 
preproghrelin peptide. (A) The original ghrelin gene structure with 4 exons. (B) 
Updated genomic organisation of the human and mouse ghrelin genes showing their 
relationship to the preproghrelin peptide. Exons shaded in white indicate exons that 









Figure 1.2 Post-translational processing and acylation of the proghrelin peptide. 
The acylation of proghrelin occurs after the signal sequence is cleaved by a signal 
peptide peptidase. GOAT is located in the endoplasmic reticulum (ER) and mediates 
the translocation of the octanoyl-CoA from the cytosolic side of the ER. Once the 
proghrelin precursor reaches the trans-Golgi compartment, it appears to be cleaved 
by protein convertases, packaged in vesicles, and released into the blood. Two main 
forms of ghrelin circulate in the plasma, acylated and desacyl ghrelin, and low levels 









The GOAT enzyme is a member of the membrane-bound O-acyl transferase  
 (MBOAT) family [133-135] and it is encoded by the MBOAT4 gene [2]. It adds the 
octanoyl group, (C7H15CO), to the serine-3 residue of ghrelin [2, 3]. This fatty acid 
modification is essential for the activation of its receptor, GHSR1a, and has been 
hypothesised to assist mature ghrelin in crossing the blood brain barrier via 
specialised transporters [136, 137]. The N-terminal amino acids, glycine-1, serine-3, 
and phenylalanine-4 of ghrelin are crucial for recognition by GOAT, and the addition 
of only two extra amino acids to this N-terminus significantly reduces the ability of 
GOAT to bind to ghrelin and to attach the octanoyl group [3]. This suggests that the 
octanoylation of ghrelin occurs after the cleavage of the preproghrelin signal peptide 
[3]. GOAT is located at the endoplasmic reticulum (ER) and mediates the 
translocation of the octanoyl-CoA from the cytosolic side of the ER [3]. Although 
ghrelin is modified by n-octanoic acid, GOAT actually has strong preference for n-
hexanoyl-CoA as an acyl donor [138]. This may account for the observed variations 
in the length of acyl groups which modify mature ghrelin which have been described. 
These variant forms, however, are only expressed at low levels. Analogues of ghrelin 
with acyl chains of 10 (decanoylated) or 11 carbon atoms also exist [139-141] and 
appear to be more common in other organisms [120, 142-144]. In order to produce 
octanoylated ghrelin, prohormone convertases and GOAT must be expressed in the 
cells, and n-octanoic acid must be supplied in the culture medium [122]. 
 
The ghrelin peptide is unstable in cell culture and likely to have a short half-life, as 
the octanoyl group is rapidly removed and the ghrelin peptide is proteolytically 
cleaved [145, 146]. Although a number of des-acylation mechanisms have been 
hypothesised, the conversion of acylated ghrelin to unacylated ghrelin was recently 
discovered to be mediated by the enzymatic action of acyl-protein thioesterase 
1/lysophospholipase 1 [147]. Desacyl ghrelin, the non-octanoylated form of ghrelin, 
circulates in plasma at much higher levels than octanoylated ghrelin [1, 125, 126], 
while other ghrelin analogues circulate at much lower concentrations [120, 148].  
 
Ghrelin is expressed in many cells and tissues throughout the body, however, the 
major source of circulating ghrelin is the stomach [1, 149] and gastrectomy greatly 
reduces circulating levels [150]. Lower levels of ghrelin are present in many tissues 
including the small and large intestine [151], pituitary [152], kidney [153], placenta 
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[154] and hypothalamus [1] and we have demonstrated ghrelin expression in the 
ovary, testes, prostate and breast [17, 39, 42, 155]. In the stomach, ghrelin is 
produced by chromogranin A-immunoreactive X/A-like endocrine cells, or ghrelin-
producing cells (Gr cells), located in the mucosal layer of the fundus [151]. These 
cells lie in close association with capillary networks, allowing transport of secreted 
ghrelin into the bloodstream for endocrine action [1].  
 
1.3.2 Ghrelin variants and isoforms 
Multiple biologically active isoforms of ghrelin exist in addition to full-length, 
wildtype mature octanoylated ghrelin, and desacyl ghrelin [120]. Other forms of 
ghrelin include des-Gln14-ghrelin (which is missing the 14th amino acid, glutamine) 
[120, 148], and ghrelin analogues which are modified by acyl groups of different 
lengths [120, 126]. Until recently, only two alternatively spliced variants of the 
wildtype preproghrelin sequences, prepro-des Gln14-ghrelin [120, 148] and exon 3-
deleted preproghrelin [17, 156], have been shown experimentally to be translated 
into peptides. Prepro-des Gln14-ghrelin arises from a three base pair, 5’ truncation of 
exon 2, producing a 116 amino acid preproghrelin peptide and has similar functions 
to ghrelin [120, 148, 157]. Recently, alternative splicing has been shown to give rise 
to a number of new variants of the preproghrelin sequence, including obestatin-only 
transcripts [118]. These variants have the potential to alter the physiological ratio of 
ghrelin to obestatin, suggesting that alternative splicing is one method of regulation 
of this gene locus [119]. In addition to producing multiple sense transcripts, the 
ghrelin gene locus has also been shown to be further complicated by the presence of 
antisense transcripts, termed ghrelinOS (ghrelin opposite strand) [118]. These 
transcripts span from an alternative exon -1, with two novel exons (exon 2* and 2**) 
in intron 2, to an alternative exon 4 of the preproghrelin gene [118]. The 
physiological significance of these transcripts is yet to be determined. 
 
Exon 3-deleted preproghrelin, as the name suggests, results from the splicing out of 
exon 3 of the ghrelin transcript [17, 156]. This variant produces a 91 amino acid 
prepropeptide that, unlike the wildtype and prepro-des Gln14-ghrelin, encodes only 
ghrelin and does not contain the obestatin-coding region [17, 40, 156]. This causes a 
frame-shift, which would still allow the synthesis of the mature ghrelin peptide and 
the production of a novel C-terminal peptide (RPQPTSDRPQALLTSL), the function 
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of which is unknown [40]. Other novel C-ghrelin and obestatin-only transcripts have 
also recently been discovered, however, the function of these peptide has not been 
widely studied [118]. 
 
1.3.3 The growth hormone secretagogue receptor (GHSR)  
Ghrelin acts through the cognate ghrelin receptor, the growth hormone secretagogue 
receptor (GHSR) [1]. The GHSR is a highly conserved, seven transmembrane 
domain G protein coupled receptor (GPCR) [158]. GHSR was originally cloned from 
the pituitary and hypothalamus of humans and swine [159]. It was discovered as the 
target for synthetic growth hormone secretagogues (GHS), a class of peptide and 
non-peptide compounds which stimulate the release of growth hormone (GH) from 
the anterior pituitary [159]. The GHSR gene consists of two exons, with exon 1 
encoding transmembrane domains I-V and exon 2 encodes transmembrane domains 
VI and VII [160]. The exons are separated by a single 2 kb intron (Fig. 1.3). There 
are two known GHSR mRNA isoforms, GHSR1a and GHSR1b. The GHSR type 1a 
transcript, encodes the full-length, functional 366 amino acid receptor (Fig. 1.3) 
[160]. Activation of the GHSR1a in the pituitary leads to the release of intracellular 
calcium, which is the trigger for growth hormone (GH) release [160]. It is widely 




Figure 1.3 A representation of the human growth hormone secretagogue 
receptor (GHSR) gene and the GHSR 1a and GHSR 1b mRNA isoforms. The 
GHSR1b isoform has putative alternative polyadenylation and splice sites and 
contains intron-coding sequence. TMD: transmembrane domains. Adapted from 
Jeffery et al. 2003 [156]. 
  
13 
cardiovascular and metabolic functions of ghrelin [4]. This receptor has strong 
constitutive activity (in the absence of ligand), which is 50% of its maximal activity, 
[161-165] and this high level of activity is comparable to that of the ORF74 receptor 
oncogene, encoded by human herpes virus 8 [166, 167].  
 
Ghrelin was initially demonstrated to stimulate and increase intracellular calcium in 
Xenopus oocytes, acting through the GHSR [1, 159]. Ghrelin has a wide range of 
physiological effects, and has been demonstrated to stimulate signalling through a 
number of different pathways (Fig. 1.4). The mitogen activated protein kinase 
(MAPK)/extracellular signal-regulated kinase 1/2 (ERK1/2) pathway has been 
shown to mediate a number of the functions of ghrelin (Fig. 1.4), including ghrelin-
stimulated cell proliferation [25, 40, 57, 168-172], regulation of inflammation [173], 
angiogenesis [171, 172, 174], inhibition of apoptosis [175-180] and cell migration 
[171, 172, 174]. It has also been reported that ghrelin signals through the 
Akt/phosphatidylinositol-3-kinase (PI3K) pathway to regulate proliferation [25, 168, 
169], angiogenesis [172], cell migration and invasion [54, 172], to inhibit apoptosis 
[175-183], and to influence metabolism [184]. 
 
GHSR1b is a truncated transcript, resulting from the inclusion of intronic sequence in 
the mRNA, and it produces a truncated, 289 amino acid peptide (Fig. 1.3). The 
inclusion of intronic sequence leads to the introduction of a premature stop codon, 
and a novel 24 amino acid C-terminus is encoded after the 5
th
 transmembrane 
domain of the GHSR [185]. This receptor isoform was believed to be biologically 
inactive, however, there is evidence that it may regulate the expression of the 
GHSR1a at the cell surface [186]. Co-expression studies of GHSR1a and GHSR1b 
demonstrated that dimerisation of these two receptors reduces constitutive GHSR1a 
signalling [162, 186]. This reduces GHSR1a-stimulated activation of 
phosphatidylinositol-specific phospholipase C (PI-PLC) activity, leaving ghrelin-
dependent signalling, such as extracellular signal-regulated kinases 1/2 (ERK1/2) 
activation, unaffected [162, 186]. This inhibition of constitutive signalling is thought 
to be due to the translocation of GHSR1a to the nucleus as a result of the formation 








Figure 1.4 An overview of ghrelin signalling pathways, (other than those 
involved in appetite and gastrointestinal functions), and the functions that they 
mediate. The diagram shows whether ghrelin activates (→) or inhibits (←) 
signalling  pathways, or whether both activation and inhibition have been described 
(↔) and these are linked to the observed physiological effects that are mediated by 













1.3.4 The alternative ghrelin receptor and desacyl ghrelin 
In addition to the GHSR, there is strong evidence that an unidentified alternative 
ghrelin receptor exists. Ghrelin has physiological effects in cell types that do not 
express the GHSR1a [195, 196]. Desacyl ghrelin circulates in plasma in far higher 
concentrations than ghrelin (representing approximately 80% of total circulating 
ghrelin) [126, 151], and it does not bind or activate GHSR1a [1, 126]. It has become 
evident that desacyl ghrelin also has physiological effects, which are independent of 
the GHSR1a. Some of the actions of ghrelin, including GH release [1, 197-200], and 
the regulation of appetite require ghrelin to be octanoylated, however. The role of 
desacyl ghrelin in feeding is controversial [201], and a number of studies have 
suggested that desacyl ghrelin may suppress appetite [202-204].  
 
Ghrelin and desacyl ghrelin have similar or identical actions in a number of cell and 
tissue types (Table 1.2). For example, in rat pregnancy, both peptide variants (ghrelin 
and desacyl ghrelin) bind to foetal tissues and they lead to increased Ca
2+
 influx in 
discrete cultured foetal skin cells [205]. They also promote rat bone marrow 
adipogenesis through mechanisms which are independent of GSHR1a [206]. Desacyl 
ghrelin displays comparable cardioprotective effects to ghrelin [157, 178, 207-209], 
and both forms inhibit apoptosis in primary adult and H9c2 cardiomyocytes and 
endothelial cells [178]. The H9c2 cell line does not express the GHSR1a and these 
functions, therefore, must be mediated by the alternative ghrelin receptor [178]. In 
the H345 small cell lung carcinoma (SCLC) cell line, both forms of ghrelin increase 
apoptosis [28]. Ghrelin and desacyl ghrelin also display other similar cellular 
functions. Ghrelin and desacyl ghrelin both increase proliferation in human 
osteoblasts, which do not express GHS-R1a [168], while both forms of ghrelin 
decrease proliferation in the CALU-1 small cell lung carcinoma (SCLC) cell line 
[28]. Although this list of studies is not exhaustive it demonstrates that both forms of 
ghrelin are likely to act via an alternative receptor [210]. 
 
As ghrelin and desacyl ghrelin can both regulate proliferation, apoptosis, 
adipogenesis and cardioprotective effects, often in the absence of the GHSR1a, it is 
likely that they are acting through the alternative ghrelin receptor [210]. Ghrelin is 
known to function in a number of cell types in the absence of GHSR1a [50, 195, 
206]. Ghrelin binding sites have been demonstrated in normal thyroid glands, thyroid  
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Table 1.2 Summary and comparison of ghrelin gene derived products effects. 













tumours, and thyroid cancer cell lines, in the absence of the specific GHSR mRNA 
[44]. GHSR1a expression is also absent in the HepG2 cell line [195], although 
ghrelin stimulates cell signalling and cell proliferation in this cell line [147, 195, 
211]. Similarly, ghrelin stimulates cell proliferation in the HEL human 
erythroleukemic cell line, although GHSR1a is undetectable [50].  
 
1.3.5 Ghrelin function 
Ghrelin has a wide array of functions [119] (Fig. 1.5), including roles as a growth 
hormone secretagogue and in regulating appetite and energy balance [1]. Since its 
isolation and identification in 1999, ghrelin has proven to be a multifunctional 
peptide, with roles in regulating the immune system, metabolism, reproduction, 
sleep, memory and anxiety [4]. It also appears to have roles in regulating the 
cardiovascular system and bone, and in regulating cell proliferation, apoptosis, 
migration and angiogenesis [4]. 
 
 
Figure 1.5 A diagram illustrating the diversity of ghrelin functions. Ghrelin is 
highly expressed in the stomach and at lower levels in many other tissues. Its effects 
on appetite, gastric activity and energy metabolism are mediated via the 
hypothalamus, brainstem and afferent vagal nerve fibres. Ghrelin is produced in 
lower amounts in other tissues where it may have a number of direct effects, 
including the regulation of apoptosis, cell proliferation and cardiovascular and 
immunological function. Adapted from Gil-Campos et al., [212]. 
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1.3.5.1 Ghrelin and growth hormone (GH) release  
Ghrelin was originally discovered as the endogenous ligand for the GHSR, based on 
its ability to act as a growth hormone secretagogue [1]. Acting at the pituitary and 
hypothalamic levels, it stimulates the release of growth hormone (GH) from the 
pituitary both in vitro and in vivo in a range of species including humans [1, 197-
199]. This is a dose-dependent response, mediated through the GHSR1a which is 
expressed by somatotroph cells in the anterior pituitary [200]. It induces activation of 
growth hormone releasing hormone (GHRH) neurons and inhibits somatostatin 
neurons in the hypothalamus [213]. This function is not shared by desacyl ghrelin, as 
it is unable to activate GHSR1a, or stimulate GH release. Ghrelin also stimulates the 
release of adrenocorticotrophic hormone (ACTH) and prolactin (PRL), albeit to a 
much lesser extent, from the anterior pituitary, and antidiuretic hormone (ADH) 
release from the posterior pituitary and it inhibits the pituitary-gonadal axis [214-
220].  
 
1.3.5.2 Ghrelin in appetite regulation, energy balance and metabolism 
Ghrelin plays a role in regulating energy homeostasis [221] and promotes 
adipogenesis [222]. It originates from the stomach, and it induces adiposity and 
provides information about nutrient availability to the brain [1, 223]. Ghrelin 
octanoylation appears to be essential for these functions [201]. Acylated ghrelin 
increases food intake, gut motility and weight gain in humans [224] and it increases 
gastric acid secretion in rats [225], as well as reducing energy utilisation and 
inhibiting leptin-induced feeding reduction [223, 226]. Plasma ghrelin levels rise 
during fasting (or prior to meals) and fall after feeding [149, 227-229]. The effects on 
appetite are believed to be independent of its effects on bodyweight and adiposity 
[222, 223, 230]. Ghrelin contributes to the regulation of body weight, adjusting 
levels in response to weight gain and loss [231]. Fasting circulating ghrelin 
concentrations correlate inversely with body weight (and body mass index) and 
levels increase after weight loss [232]. The chronic administration of ghrelin 
promotes weight gain and adiposity [221]. Notably this weight gain is not driven 
solely by food intake, ghrelin also influences preference towards dietary fat [221].  
 
Ghrelin regulates lipid metabolism in the liver, skeletal muscle and adipose tissue 
[233]. Both ghrelin and desacyl ghrelin promote lipogenesis [206] and inhibit 
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isoproterenol (isoprenaline)-induced lipolysis [196]. Ghrelin increases triglyceride 
deposits in the liver, inhibiting fatty acid oxidation, and decreases triglyceride 
deposition in muscle, increasing mitochondrial oxidative enzyme activity and fat 
metabolism [233]. 
 
Ghrelin exerts its orexigenic actions by activating neuropeptide Y (NPY), agouti 
related peptide (AgRP) and oxytocin neurons in the arcuate nucleus of the 
hypothalamus, while neurones expressing the anorexigenic neurotransmitters, 
cocaine and amphetamine related transcript (CART) and pro-opiomelanocortin 
(POMC), are inhibited [234, 235]. The hypothesised mechanism of the orexigenic 
effects of ghrelin that are mediated by GHSR1a and are highly complex (Fig. 1.6). 
This pathway involves activation of the GHSR1a, which induces Ca
2+
 flux, and 
phosphorylation and the sequential activation of a number of signalling molecules 
including calmodulin kinase kinase 2 (CaMKK2) and AMP-activated protein kinase 
(AMPK) [236, 237]. 
 
The role of desacyl ghrelin in regulating energy homeostasis and food intake is more 
controversial. It is clear that acylated ghrelin has a strong stimulatory effect on 
appetite, mediated by GHSR1a. As GHSR1a mediates the effects of ghrelin on 
appetite, and desacyl ghrelin does not signal through this receptor, it is unsurprising 
that a number of reports have demonstrated that it has no effect on feeding [201, 
238]. A number of other studies, however, have shown that desacyl ghrelin may have 
a suppressive effect on appetite [202-204].  
 
Ghrelin may also play a part in water consumption. Centrally and peripherally 
administered ghrelin has been shown to potently inhibit water intake in rats [239, 
240] and this function is not shared by desacyl ghrelin [196, 241]. 
 
1.3.5.3 Ghrelin and the regulation of blood glucose and insulin release  
Ghrelin has been implicated in glucose homeostasis [242], although its role is 
currently controversial. Ghrelin appears to have a modulatory effect on glucose-
sensing neurons in the dorsal vagal complex [243, 244], and may also regulate 
insulin secretion [245-247] and hepatic glucose production [25, 248]. Systemic 




Figure 1.6 A diagram showing a simplified representation of the molecules 
which comprise the ghrelin signalling cascade in the appetite-inducing effect of 
ghrelin. The activation of signalling molecules (highlighted in pink) leads to 
increased food intake, whereas the activation of inhibiting molecules (highlighted in 
blue) would lead to inhibition of food intake. It is hypothesized that ghrelin, through 
the activation of GHSR1a, induces Ca
2+
 flux, which induces the phosphorylation and 
activation of calmodulin kinase kinase 2 (CaMKK2), either with or without the prior 
induction of endocannabinoids activating cannabinoid receptor type 1 (CB1). This 
leads to a secondary Ca
2+
 flux. CaMKK2 then activates AMP-activated protein 
kinase (AMPK) which in turn phosphorylates and inhibits acetyl-CoA carboxylase 
(ACC), preventing the production of malonyl-CoA. This allows carnitine palmitoyl 
transferase 1 (CPT1) and fatty acids to be transported into the mitochondria, 
facilitating mitochondrial fatty acid oxidation. These then undergo mitochondrial β-
oxidation, producing reactive oxygen species (ROS), and promoting expression of 
uncoupling protein 2 (UCP2), which buffers the production of ROS. UCP2 
stimulates hypothalamic mitochondrial respiration, mediating the activation of 
NPY/AgRP neurons, stimulating food intake and inhibiting POMC neurons that 





insulin release [245, 246, 249, 250]. Furthermore, ghrelin also stimulates insulin-
induced glucose uptake in adipocytes [251]. Intriguingly, physiological  
concentrations of glucose or insulin were shown to have little effect on plasma 
ghrelin levels [252]. This function of ghrelin appears to be dependent upon 
octanoylated ghrelin, as GOAT knockout mice, placed on 60% calorie restricted diet, 
became moribund with hypoglycaemia and were rescued by the injection of acylated 
ghrelin or GH [253]. This study has recently been refuted, however, in studies using 
knockout mice subjected to prolonged 60% calorie restriction, which have shown 
that GOAT and the ghrelin axis are not required for survival during caloric restriction 
[254]. Blood glucose levels, however, were not measured at the same time in these 
two studies, ½ hour prior to feeding versus 8 hours prior in the later study. 
Additionally, these studies were in different strains of mice. 
 
1.3.5.4 Gastrointestinal effects of ghrelin 
Ghrelin increases gut motility [225], and acting independently of the hormone 
motilin, it accelerates gastric emptying and colonic motility [255-258]. Ghrelin 
stimulates the secretion of pancreatic fluid and secreted proteins [259, 260]. 
Interestingly, desacyl ghrelin inhibits gastric emptying without influencing the small 
intestine, or altering gastric secretions [204, 261-263]. It is currently unclear whether 
ghrelin affects gastric acid secretion, as different studies have reported that ghrelin 
stimulates [225, 264], inhibits [263] or has no effect [262] on acid secretion. 
 
1.3.5.5 The role of ghrelin in the normal immune system 
Ghrelin has immunoregulatory functions [265] and is expressed in a number of cell 
types in the immune system including human T cells, B cells, and neutrophils [266], 
however, its exact role is yet to be defined. In human monocytes and T lymphocytes, 
ghrelin, acting through the GHSR, inhibits the expression of pro-inflammatory 
cytokines such as IL-1β, IL-6, and TNF-α [267, 268]. In murine macrophages, pre-
treatment with ghrelin resulted in inhibition of lipopolysaccharide (LPS)-induced 
pro-inflammatory cytokines, IL-1β and TNF-α, and it decreased nuclear factor-kappa 
B (NFκB) activation, a transcription factor that plays important roles in the immune 
system [269]. In response to ghrelin treatment, LPS-stimulated murine macrophages 
significantly increased the release of the anti-inflammatory cytokine, IL-10, in a 
dose-dependent and time-dependent manner [269]. Ghrelin also inhibits leptin-
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induced cytokine expression in a dose-dependent manner [267], suggesting a link 
between the metabolic axis and the immune system. These studies show potential for 
a significant role for ghrelin in inflammation.  
 
These immune responses may be limited to octanoylated ghrelin and may not be 
shared by desacyl ghrelin [268-270]. This however, may be challenged by recent 
studies that have shown that ghrelin induced the release of histamine from rat 
peritoneal mast cells in the absence of GHSR1a, and this was likely to occur through 
a receptor-independent mechanism [271]. 
 
1.3.5.6 The role of ghrelin in the cardiovascular system 
Ghrelin also has regulatory roles in the cardiovascular system [272, 273]. The 
intravenous administration of ghrelin decreases arterial blood pressure without 
affecting heart rate [274, 275], and it increases cardiac index (cardiac output divided 
by the body surface area in square meters) and stroke volume index (obtained by 
dividing cardiac index by heart rate) [215, 276]. Intracoronary infusion of ghrelin 
caused coronary vasoconstriction through the inhibition of a vasodilatory β2-
adrenergic receptor-mediated effect related to a release of nitric oxide [277]. 
Similarly, in another study ghrelin acutely stimulated increased production of nitric 
oxide in bovine aortic endothelial cells (BAEC) in primary culture in a time- and 
dose-dependent manner, using a signalling pathway that involves GHSR1a, PI3K, 
Akt, and endothelial nitric oxide synthase (eNOS) [278].  
 
In vitro ghrelin also has a range of effects on cardiomyocytes and endothelial cells. 
Ghrelin can increase AMPK activity in heart muscle and modulate intracellular 
energy balance in a cell-specific manner [192]. In isolated rat ventricular myocytes 
ghrelin and the synthetic growth hormone secretagogue, hexarelin, increase the 
amplitude of intracellular T-type and the L-type Ca
2+
 currents [279]. They decrease 
in the transient outward potassium current (Ito) and lead to subsequent prolongation 
of action potential duration [280] through the activation of GHSR1a and PKC [279, 
280], as well as phospholipase C for the decreased Ito current [280]. Furthermore, in 
cardiomyocytes ghrelin has been reported to inhibit apoptosis [178, 281], promote 
cell survival by modification of MAPK pathways and activation of GHSR1a [281], 
decrease inotropy (force of contraction) [157, 282] and lusitropy (relaxation) [282] 
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and improve myocardial function during ischemia, or myocardial injury [209, 281, 
283, 284]. In endothelial cells, ghrelin stimulates angiogenesis [172] and inhibits 
pro-inflammatory cytokine production [268]. Ghrelin also inhibits angiotensin II-
induced migration [190] and stimulates proliferation [169] in aortic endothelial cells, 
whereas in aortic smooth muscle cells it inhibits angiotensin II-induced proliferation 
and smooth muscle contraction [285]. 
 
Desacyl ghrelin has similar effects to ghrelin in cardiac function. It displayed 
comparable potency as an endothelium independent vasodilator [207, 208], and 
decreased inotropy [157] and inhibited cardiomyotcyte apoptosis [178]. It also 
retains the cardioprotective effect observed with myocardial injury [209]. 
 
1.3.5.7 The role of the ghrelin axis in reproduction 
Numerous studies suggest the ghrelin has a wide array of effects in reproduction [4, 
286]. Ghrelin is expressed in a number of reproductive organs including the placenta 
[154], ovary [155, 287-291], endometrium [292, 293] and Leydig cells of the testes 
[42, 294-296]. Ghrelin expression has also been demonstrated in embryos [297, 298]. 
There is increasing evidence that ghrelin can suppress a number of hormones 
involved in the gonadal axis, including gonadotropin-releasing hormone (GnRH) 
[299-301], luteinizing hormone (LH) [302-306], and follicle stimulating hormone 
(FSH) [304, 305], in both males and females in humans, rats and other higher 
mammals. It is interesting that these effects on LH and FSH appear to be attenuated 
in females during the menstrual cycle [307] and also in males when ghrelin is 
administered in combination with GnRH [305]. 
 
Ghrelin is expressed in female reproductive organs. It exerts an inhibitory effect on 
steroidogensis (lowering progesterone and oestradiol production) in the ovaries [308, 
309]. Ghrelin levels have been shown to fluctuate throughout pregnancy [310, 311], 
peaking at 18 weeks of pregnancy [310, 311], and it may contribute to weight gain 
during pregnancy [312]. In a study of mice, ghrelin may have an inhibitory effect on 
the early development of the embryo [298]. Porcine studies suggest that this may 
occur through an inhibition of the organisation of microtubules and microfilaments in 
the oocytes [313], or by having a negative effect on the structural integrity of 
blastocysts [314]. Ghrelin also appears to play further roles in foetal development, 
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playing a regulatory role in the late stages of pregnancy, and increasing birth weight, 
irrespective of a restricted maternal diet [205]. Umbilical-cord ghrelin levels exceed 
that of the mother [315] and high levels of desacyl ghrelin are present in foetal blood 
and amniotic fluid [205]. Both desacyl ghrelin and octanoylated ghrelin have binding 
sites in foetal tissues and increase Ca
2+
 influx in discrete cultured foetal skin cells 
[205]. Additionally, high levels of the ghrelin receptor (GHSR) have been found 
throughout peripheral tissues of foetal rat from embryonic day 14 until birth [205]. 
Postnatally, ghrelin is secreted into the colostrum and milk [316] and lactation 
induces the production of GHSR in both the hypothalamus and pituitary [317, 318]. 
 
1.3.5.8 The role of ghrelin in bone 
Ghrelin and its receptor have been identified in osteoblasts, which are mononuclear 
cells that form bone. In osteoblasts, ghrelin directly stimulates proliferation, DNA 
synthesis and differentiation, and inhibits apoptosis [168, 189, 319-321]. Ghrelin 
significantly increases levels of the bone formation markers, alkaline phosphatase 
(AP) and osteocalcin (OC), as well as increasing calcium accumulation in the bone 
matrix [320, 322, 323]. As a result, ghrelin is believed to stimulate osteogenesis 
(bone formation) in intramembranous bone growth and improves the repair of 
calvarial bone defects in rats [324]. 
 
It is unclear whether ghrelin has a direct impact on bone mineral density (BMD), as 
some studies have found that it directly increases BMD in rats [322] and others have 
found no effect in mice [325]. In a study of obese and healthy control children, it was 
concluded that the effect of ghrelin on BMD is mediated by specific body 
composition parameters (lean and fat mass) [326]. In another study in adult humans 
no association was seen between ghrelin and BMD [327].  
 
Interestingly, ghrelin has also been identified in teeth, a tissue that shares many 
similarities with bone, and its potential physiological roles are being investigated 
[328]. Ghrelin is also expressed in cartilage, where it has been identified as a 
potential chondrocyte growth factor [323]. While there have been few studies into 
the role of desacyl ghrelin, like ghrelin, it stimulates human osteoblast proliferation 
[168]. This is thought to be independent of GHSR1a, as these cells do not appear to 
express the GHSR1a mRNA transcript [168]. 
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1.3.5.9 The effect of ghrelin on sleep, memory, learning and behaviour 
Ghrelin has several effects on behaviour and higher order brain functions. It 
promotes slow-wave sleep in humans [329], and it has been used to modify sleep-
wake patterns in rats [330], as well as increasing non-rapid eye movement sleep 
(NREMS) [331]. In addition, ghrelin improves cognition, spatial learning and 
memory [332, 333] and ghrelin facilitates place-learning linked memory processes, 
acting in the amygdala [334]. Ghrelin increases memory retention in rats [335], 
however, it improves long-term memory, rather than short-term memory [336], 
suggesting that ghrelin is involved in the acquisition of memories rather than 
memory retrieval [336]. Based on these observations, the central ghrelin receptor 
could be considered as a new drug target to treat diseases affecting cognition, or to 
enhance learning and memory processes [332, 337].  
 
Ghrelin is also believed to mediate behavioural responses to stress, as circulating 
ghrelin levels rise following stressful stimuli [338, 339]. Studies on the relationship 
between ghrelin and mood are limited and reports are conflicting regarding whether 
or not ghrelin has an anti-depressant effect [338, 340]. Similarly, several studies 
suggest that ghrelin has an anxiolytic effect [338, 339, 341], whereas several others 
suggest that it has an anxiogenic effect [335, 342, 343]. 
 
1.3.6 Ghrelin in disease 
Ghrelin has been implicated in a number of diseases and disease processes. As 
ghrelin potently stimulates appetite, and has a role in energy balance and body 
composition, it has been a major focus of obesity research [223, 228, 344-347]. 
Ghrelin dysregulation is also associated with other appetite-related conditions, 
including the eating disorders, anorexia nervosa (typified by high ghrelin levels and 
insensitivity) [228, 348, 349] and bulimia nervosa (with high plasma ghrelin levels) 
[350-352]. It is unclear in these disorders whether ghrelin levels are influenced by 
the binge/purging process, or by the shortcomings in energy status [353], however, 
plasma ghrelin levels are generally strongly inversely correlated with body mass 
index (BMI) [353]. This is not the case in Prader-Will syndrome, however, where 
patients show high ghrelin levels, hyperphagia and adiposity [354-356]. As ghrelin 
plays a role in appetite and energy homeostasis, adiposity and glucose balance, it is 
also likely be involved in metabolic diseases including diabetes mellitus type II [357, 
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358] and metabolic syndrome [357].  
 
As ghrelin promotes feeding and positive energy balance, the ghrelin axis is useful as 
a treatment target for diseases associated with anorexia and chronic wasting 
(cachexia), including anorexia nervosa [359, 360], chronic kidney disease [361], 
chronic heart failure [362] and cancer. Ghrelin has also been reported to affect 
several gastrointestinal diseases such as inflammatory bowel disease, coeliac disease, 
infectious diseases, functional disorders and diabetic gastroenteropathy [363].  
 
Ghrelin also exerts many cardioprotective effects, including reduced peripheral 
resistance, and improved heart contractility and cardiac output, suggesting a 
beneficial effect in cardiovascular disorders [364].  
 
Ghrelin has been associated with polycystic ovary syndrome (PCOS). PCOS is 
characterized by chronic anovulation and hyperandrogenism, with symptoms 
including irregular menses or infertility, and cutaneous manifestations, including 
hirsutism, acne, or male-pattern hair loss [365]. There is some ambiguity over the 
levels of ghrelin in PCOS, with some studies showing ghrelin levels are decreased 
[366-370], unchanged [371-373], or elevated in PCOS women [374]. Ghrelin appears 
to be involved in secondary conditions that develop with PCOS. Ghrelin levels were 
highly correlated to the degree of insulin resistance in one study [366] and 
contributed to the abnormal hormonal pattern seen in PCOS in another [371]. It may 
also play a role in the development of obesity, hyperinsulinemia and insulin 
resistance seen with metabolic syndrome associated with PCOS [372]. The injection 
of ghrelin seems to over-ride the defect in GH secretion in obese women with PCOS 
and induces changes in glucose and insulin regulation in both control and obese 
patients with PCOS [375]. A number of these diseases have been linked to increased 
cancer risk. Metabolic syndrome [376], obesity [377], inflammatory bowel disease 
[378] and PCOS [379] have been shown to have a significant impact on the 







1.3.7 Ghrelin in cancer 
 
1.3.7.1 Expression of the ghrelin axis in cancer 
Ghrelin and the ghrelin axis have been associated with cancer progression. Ghrelin 
and the GHSR1a and GHSR1b isoforms are expressed in a wide array of cancer 
tissues (Table 1.3). In many cases, the expression of ghrelin and GHSR are different 
in cancer tissues compared to normal tissue. Ghrelin expression is increased in 
astrocytoma [16], breast cancer [17], thyroid cancer [43, 44] lung cancer [26] and 
ovarian cancer [380] and down-regulated, if not absent, in others, including stomach 
cancer [19, 22, 23], pituitary adenomas [32, 33], renal cancer [41], testicular cancer 
[42] and oesophagogastric adenocarcinomas [21]. In a number of tumours, including 
pancreatic endocrine tumours [31], pituitary adenomas [32, 33], prostate cancer [38, 
39] and breast cancer [17], ghrelin is co-expressed with its receptor and ghrelin 
could, therefore, play an autocrine role in these tumours. In a number of cancers, 
however, GHSR1a expression is down regulated or absent, while the non-functional, 
truncated form of the receptor, GHSR1b, is expressed, or up-regulated, compared to 
normal tissue [18, 27, 29, 48, 53]. 
 
Some studies, using small numbers of subjects, have investigated the levels of 
plasma ghrelin and demonstrated a relationship with cancer [381]. Plasma ghrelin 
levels have been shown to be elevated in ovarian cancer [114], non-small cell lung 
cancer [382], uterine leiomyoma [383] and prostate cancer [384] and decreased 
levels have been demonstrated in colorectal cancer [385] and liver cancer [386]. This 
increase, however, in not necessarily linked with an increase in total plasma ghrelin 
[114, 384, 387]. Many of these studies suggest that ghrelin has potential as a 
biomarker, however, to determine its efficacy larger studies need to be performed. It 
is likely that ghrelin levels are more directly correlated with nutritional status rather 
than cancer itself, and ghrelin levels are elevated in cachexia [381].  
 
1.3.7.2 Single nucleotide polymorphisms (SNPs) and epigenetic regulation 
(hypermethylation) in the ghrelin axis and cancer 
A number of single nucleotide polymorphisms (SNPs) in the ghrelin (GHRL) and 
GHSR genes have been linked to altered cancer risk. SNPs have been linked in breast  
cancer to tumour development [388]. A 20% increase in breast cancer risk was 
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Table 1.3 Protein and mRNA expression of ghrelin and the GHSR in tumour 
tissues and cell lines. (-) no expression, (++) is expressed or has moderate 
expression, (+) low expression, (+++) high expression, ↑ higher than normal tissue 
levels, ↓ lower than normal tissue levels.  
 
Cancer Type  Ghrelin    GHSR   
 









Adrenal Tumours         
Phaeochromocytoma (+)  [56]      
Adrenocortical adenoma (+)  [56]      
Non-functioning adrenocortical 
adenoma 
(+++)↑  [53] (-)↓ (++)↑   [53] 
Cortisol-producing adenomas (++)↑  [53] (++)↑ (+++)↑   [53] 
Aldosterone-producing adenoma (++)↑  [53] (-) (+)↑   [53] 
Adrenocortical carcinoma (+)  [53] (-) (++)↑   [53] 
Adrenocortical carcinoma cell 
lines (NCI-H295, SW13) 
(+)  [53] (+) (+++)   [53] 
Astrocytoma         
Low grade tumours  (+) 
(+++) 
[16]   (+) 
(+++) 
 [16] 
High grade tumours  (+) 
(+++) 
[16]   (+) 
(+++) 
 [16] 
Astrocytoma cell lines  
(U-118, U-87, CCFSTTG1, 
SW1008) 
     (+++)  [16] 
Breast Cancer         
Tumour  (++)↑ [17]   (++) (++) [17] 
Breast cancer cell lines         
 (MDA-MB 231, MCF7) (++)  [17] (+)(-) (++)   [17, 18] 
(T47D) (++)  [17] (+)(-) (+)   [17, 18] 
(MDA-MB 435) (++)  [17] (++) (++)   [17] 
Endometrial Cancer         
Endometrial cancer (++) (+)(-)↓ [46, 49] (+) (+)   [49] 
Endometrial cancer cell lines 
(HEC1B, KLE) 
(+) (+) [49] (+) (+) (+)  [49] 
Gastrointestinal Tract Cancer         
Oral squamous cell carcinoma  (+)(-)↓ [24]      
Oesophagogastric 
adenocarcinomas 
(-) (-) [21] (++)↑    [20] 
Stomach (+++) (+++)↓↓ 
(++) 




(-)   [19, 20] 
Gastric adenocarcinoma  (-) [22]      
Duodenum (-) (++) [19] (-) (-)   [19] 
Ileum (++) (-)(++) [19] (++) (++)   [19] 
Appendix (-) (++) [19] (-)(++) (-)   [19] 
Appendix- Well-differentiated 
neuroendocrine tumour 
 (-) [56]      






[19, 48] (-) 
(++)↑ 













[19, 20, 48] 
Colon cancer cell lines          
(SW-48)  (++)↑ (+)↑ [48] (++)↑ (++) (+) (++)↑ [48] 
(RKO) (++)↑ (++)↑↑ [48] (++)↑ (++) (+) (++)↑ [48] 
Small intestine (+) (++)(-) [56]      
Liver Cancer         
  
29 
Cancer Type  Ghrelin    GHSR   
 









Liver cancer tissue    (++)    [20] 
Hepatoma cell line (HepG2)    (++)    [25] 
Lung Cancer         
Lung tumour (++)↑  [26] (++)↑ (++)↑   [26] 
Lung endocrine tumours (++)(+) (++) [28, 56] (-)(++)↑    [27, 28] 
Non-endocrine lung carcinomas (++) (-) [28] (-)    [27] 
  Non-small cell lung carcinoma 
(NSCLC) 
        
Adenocarcinoma       (++)↑ [29] 
Squamous cell carcinoma       (++)↑ [29] 
Small cell lung carcinoma 
(SCLC) 
(++)  [56]    (++)↑ [29] 
  NSCLC cell lines         
(A549, NCIH358, NCI-H522, 
NCI-H1435, LC176, LC319, 
PC3, PC14)   
(-)  [29] (-) (++)   [29] 
(NCI-H23, NCI-H1793, LC174, 
PC9, SK-LU-1, RERF-LC-AI, 
SK-MES-1) 
(-)  [29] (-) (-)   [29] 
H345 Small cell lung carcinoma 
cell line 
(++)  [28] (-)    [28] 
Ovarian Cancer         
  Benign Tumours         
Serous cystadenoma  (++) [380]   (+++)  [45] 
Mucinous cystadenoma      (+++)  [45] 
Brenner tumour      (-)  [45] 
  Malignant Tumours         
Serous cystadeno  
carcinoma, low grade 
 (++) [380]   (+)  [45] 
Serous cystadeno Ca, 
 high grade 
 (+++)↑ [380]   (-)  [45] 
Mucinous cystadeno carcinoma      (-)  [45] 
Endometrioid cancer  (+)(-)↓ [46]   (-)  [45] 
Clear cell carcinoma      (-)  [45] 
Pancreatic Cancer         
Glucagonoma (++) (++) [30, 31] (-)    [31] 
Insulinoma (-)(++) (-) [30, 31] (+++)    [31] 
Non-Functioning (++) (++) [31] (+)  (++)  [31] 





(++) [56]      
Pancreatic adenocarcinomas cell 
lines 
        
 (MIAPaCa2, BxPc3, Capan2) (-) (-) [54] (++) (++) (++) (++) [54] 
(PANC1) (+) (-) [54] (++) (++) (++) (++) [54] 
Pituitary Adenomas         
Somatotroph I and II 
(+++) 
III and 
IV (+)   
(++) [32, 33, 37] (+++)↑ (+++)↑   [32-36] 
Corticotroph (+)↓  [32, 33] (++) (++)   [32-35] 





(++) [32, 33, 37] (++) (++)   [32, 33] 
Lactotroph (++) (++) [32, 33, 37] (++) (++)   [32-34, 36] 
Thyrotroph (++)  [33] (++)↑    [33, 35] 
Prostate Cancer         
Prostatic carcinomas (++) (-)(++) [38, 40] (-) (-)   [38] 
Benign hyperplasias (++) (-) [38] (-) (++)   [38] 
Androgen-independent cell lines 
(PC3, DU-145)  
(++) (++) [38-40] (++) (++)↑ (++)  [38, 39] 
Androgen-dependent cell lines  (++) [39, 40] (++) (++)↑ (++)  [39] 
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Cancer Type  Ghrelin    GHSR   
 










Renal Cancer         
Clear cell renal carcinomas  (++)↓ [41]      
Chromophobe type renal cell 
carcinomas 
 (++)↓ [41]      
Papillary type renal cell 
carcinomas 
 (++)↓ [41]      
Oncocytoma  (++)↓ [41]      
Salivary Glands         
Mucoepidermoid carcinoma  (-)↓ [22]      
Testicular Cancer         
  Leydig Cell Tumours         
Differentiated  (++) [42]   (++)  [42] 
Poorly differentiated  (-)↓ [42]   (++)  [42] 
  Germ Cell Tumours         
Seminoma  (-) [42]   (++)  [42] 
Embryonal carcinoma  (-) [42]   (++)  [42] 
Thyroid Cancer         
Medullary (++) (++)↑ [43, 56]      
Follicular (+) (++)↑ [44, 56] (-)    [44] 
Papillary (+)  [56]      
Poorly differentiated carcinoma (+)  [56]      
Medullary thyroid  
carcinoma cell line (TT) 
(++) (++) [43]      






















observed in carriers of the ghrelin gene SNPs rs171407-G and rs572169 [389]. This 
was correlated with a significant increase in height and IGF-I-circulating levels and 
interestingly, with rs171407-G, a decrease in BMI [389]. This contrasts with the 
association that has frequently linked increased cancer risk to increased BMI. This 
study also suggested that for the SNP, rs2948694, homozygotes had a 2-fold increase 
in the risk of breast cancer development [389]. Larger studies would be required to 
confirm this result, however [389]. Other SNPs in the ghrelin gene, rs27647 and 
rs35683, were associated with lower risk of colorectal cancer [388]. The GHRL SNP, 
rs27647, potentially shows a borderline protective effect against colorectal cancer, 
however, this requires further confirmation [388]. Another study in breast cancer also 
showed that some rare polymorphisms in the ghrelin gene (haplotypes
 
GGAC and 
GGAT of SNPs: G-1062C, Arg51Gln, Leu72Met and 30-UTR T+673C where bases 
are cited in the order and variant alleles are underlined) had a possible protective 
influence on breast cancer risk [390]. 
 
Hypermethylation of the GHSR gene is seen in cases of infiltrating ductal breast 
cancer and can be used to successfully differentiate between breast cancer and 
benign tissue at a specificity and sensitivity higher than any other biomarker 
currently described [391]. Interestingly this differential methylation led to 
downstream downregulation of GHSR1a mRNA [391], which may lead to increased 
tumourigenesis. This provides further evidence that GHSR may play a role in cancer.  
 
1.3.7.3 Ghrelin and processes related to cancer progression 
Ghrelin has been shown to have effects on a number of the hallmarks of cancer, 
including cell proliferation, migration, invasion, apoptosis and angiogenesis (Table 
1.4) [392, 393]. Ghrelin may, therefore, play a role in regulating cancer progression.  
 
1.3.7.3.1 Ghrelin and cell proliferation and differentiation  
Ghrelin is widely expressed and has an effect on a number of cellular functions that 
are key processes in cancer progression, including cell proliferation, migration and 
apoptosis. The role of ghrelin in cell proliferation has been widely studied, however, 
it appears to have different effects on some cell types and tissues of origin. Ghrelin 
increases proliferation in many normal cell types and cell lines, including skeletal 
muscle [394], placental [47], ovarian [395-398], pancreatic [399], brain [400], 
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preadipocyte [401-404], mesenchymal stem cell [405], bone [168, 189, 319], aortic 
[169], heart [172, 406], intestinal [407], adrenocortical [408, 409], microvascular 
endothelial [174], breast [17], pancreatic [54, 175], endometrial [49] and pituitary 
[57] cells or cell lines. Ghrelin decreased the rate of cell proliferation in some 
studies, in cell types including vascular smooth muscle [410, 411], aortic smooth 
muscle [285], lung [28], adrenal [13] and (testicular) Leydig [412] cells. While it has 
predominantly been demonstrated that treatment of normal cell lines with ghrelin 
increases cell proliferation [189, 320], this is not always the case in cancer cell lines. 
For example in thyroid cells, enhanced proliferation was seen in normal cells [413], 
while alternatively, in cancer an inhibition was observed [44]. 
Ghrelin has been shown to increase proliferation in a number of cancer and tumour 
cell lines (Table 1.4), including breast cancer [17], choriocarcinoma [47], colon 
cancer [48], endometrial cancer [49], erythroleukaemia [50], hepatoma [25], 
leukaemia [51], pancreatic adenocarcinoma [54], pancreatic neuroendocrine tumour 
[56], pituitary tumour [57], prostate cancer [38-40] and thyroid carcinoma [56]. 
Ghrelin has been demonstrated to decrease proliferation in adrenocortical carcinoma 
[53], thyroid carcinoma [44, 56] and prostate cancer [38]. Some of these differences 
may represent cell-type specific responses. In some breast and prostate cancer cell 
lines there is conflicting data, however [38-40, 414]. This may be the result of 
differences in the treatments, such as the concentration or purity of the peptide used 
[38-40], or due to differences in GHSR expression, even within the same cell line 
(Table 1.4). In the LNCaP and PC3 prostate cancer cell lines, an increase in cell 
proliferation has been demonstrated in some studies [39, 40] and a decrease in 
proliferation was described in the DU-145 and PC3 prostate cancer cell lines in other 
studies [38, 414]. In the TT thyroid cancer cell line the two forms of ghrelin had 
opposing effects on cell proliferation [56]. Acylated ghrelin caused a decrease in cell 
proliferation, while desacyl ghrelin led to an increase in proliferation [56]. 
Interestingly, both acylated and desacyl ghrelin induced an anti-proliferative effect in 
vitro in H345 small cell lung carcinoma cells and a dose-dependent pro-apoptotic 
effect was also seen, despite the absence of GHSR1a expression [28]. 
 
In a number of studies, ghrelin has been demonstrated to stimulate cell proliferation 
through the ERK1/2 MAPK signalling pathway [25, 40, 57, 168-172]. Ghrelin has  
also been shown to regulate proliferation through cAMP/PKA [169], NO/cGMP 
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Table 1.4 Summary of the effects of ghrelin on cell proliferation, apoptosis and 
cell migration in tumour cell lines. For each cancer type studied, the assay 
conditions (concentration of ghrelin used, use of inhibitors), the results of signalling 
studies linked to function, and presence of receptor expression and whether it is up or 
downregulated is given. Cell lines listed in bold indicate cell lines where conflicting 
data has been reported. * = statistically significant changes were observed with the 
treatment concentration compared to other concentrations tested; ↑ = increased 
expression/ phosphorylation; ↓ = decreased receptor expression/ or decreased 
phosphorylation 
 
Function Cancer cell line or cell 
type 
Assay Conditions Signalling  Receptor 
expression 
Reference 
Apoptosis      
Inhibition of 
apoptosis 
Choriocarcinoma cell line 
– JEG-3 
100, 250*, 500* or 
1000 pg/ml 
↓caspase-3  [47] 
Colon cancer cells 
 – HT-29 





Endometrial cancer cell 
lines – HEC1B, Ishikawa, 
KLE 















No effect Prostate cancer cell lines – 
LNCaP 






Invasion      
Increased Astrocytoma cell lines –  
U-118, U-87, CCFSTTG1, 
SW1008 
1 nM, 10 nM and 100 
nM* ghrelin  






Colon cancer cell lines – 
SW-48, ROK  
Inhibition with GHS-R 
antagonist D-[lys-3]-










adenocarcinomas cell line 
– PANC1, MIAPaCa2, 
BxPC3 
and Capan2 
10 nM* octanoylated 





















Astrocytoma cell lines –  
U-118, U-87, CCFSTTG1, 
SW1008 
1 nM, 10 nM and 100 
nM* ghrelin  






Colon cancer cell lines – 
SW-48, ROK 
Inhibition with GHS-R 
antagonist D-[lys-3]-









Glioma tumour cell lines – 








Function Cancer cell line or cell 
type 
Assay Conditions Signalling  Receptor 
expression 
Reference 









10 nM* octanoylated 
ghrelin  






























































Breast cancer cell lines – 
MDA-MB-231, MDA-
MB-435 
0.1 nM* to 100 nM*, 
1000 nM octanoylated 
ghrelin (note 0.1 nM 









Choriocarcinoma cell line 
– JEG-3 
100, 250, 500 or 1000 
pg/ml 
  [47] 
Colon cancer cell lines – 
SW-48, ROK  
Inhibition with GHS-R 
antagonist D-[lys-3]-









Endometrial cancer cell 
lines – HEC1B, Ishikawa, 
KLE 
0.1 nM, 1 nM* to 100 





Erythroleukaemia cell line 
– HEL 
Inhibition with SB801* 
and SB969* ghrelin 
antisera 
 ↑GHSR1b, no 
GHSR1a 
[50] 










Leukemic cell lines – HL-
60 and THP-1 
Inhibition with SB801* 
ghrelin antisera 




adenocarcinomas cell line 
– PANC1, MIAPaCa2, 
BxPC3 
and Capan2 
1 nM, 10 nM* and 100 
nM octanoylated 
ghrelin 
Inhibition with GHS-R 
antagonist D-Lys-
GHRP6 caused a 
significant decrease 







cell line – BON-1  
1 nM, 10 nM, 100 nM* 
octanoylated ghrelin 
  [56] 
Pituitary tumour cell line – 
GH3  
0.001 nM, 0.1 nM* to 





















Function Cancer cell line or cell 
type 








Prostate cancer cell lines – 
LNCaP, PC3 
0.01 nM* to 10 nM*, 
100 nM to 10000 nM 
octanoylated and des-



















Thyroid carcinoma cell 
line – TT  
1 nM, 10 nM*, 100 
nM* des-octanoylated 
ghrelin 







cell line – NCI-H295, 
SW13 
0.1 nM*, 1 nM*, 10 





Thyroid carcinoma cell 
lines – N-PAP, ARO, TT 
10 nM, 100 nM*, 1000 
nM* 
TT- 1 nM, 10 nM*, 100 
nM octanoylated 
ghrelin 







Prostate cancer cell line – 
DU-145,  
0.01 nM, 0.1 nM, 1 







Prostate cancer cell line – 
PC3 
1 nM* treatment only in 
one of two assay 
 No GHSR1a or 
GHSR1b 
[38] 
1 nM, 3 nM, 10 nM*, 





No change Breast cancer cell lines – 
MCF-10A, MCF7 
0.1 nM to 1000 nM 
octanoylated ghrelin) 
 




MCF7 cell line) 
[17] 
Erythroleukaemia cell line 
– HEL 
1 μm octanoylated 
ghrelin or des-
octanoylated ghrelin 
 ↑GHSR1b, no 
GHSR1a 
[50] 
Gastric cancer cell line – 
KATO-III 
500 nM   [11] 
Leukemic cell line – HL-
60, THP-1, and SupT1 
1 nM, 10 nM, 100 nM, 
and 1 μm octanoylated 
ghrelin or desacyl 
ghrelin 
 GHSR1b, no 
GHSR1a 
[51] 
Lung carcinoma cell line – 
CALU-1 
1 nM to 1000 nM 
 
 No GHSR1a [27] 
Prostate cancer cell line - 
LNCaP 
0.01 nM to 10000 nM 
octanoylated and des-
octanoylated ghrelin 












[189], IRS-1 [25], GRB2 [25] and p38 [40] pathways.  
 
Ghrelin may also promote differentiation in some cell types. In vitro, ghrelin 
promoted C2C12 skeletal myoblasts to differentiate and to fuse into multinucleated 
myotubes [394]. Ghrelin also stimulated differentiation of the osteoblastic cell lines, 
MC3T3-E1, ROS 17/2.8, UMR-106, MG63, and SaOS2 cells [319] and 3T3-L1 
adipocytes/preadipocytes [401, 404]. 
 
Another important hallmark of cancer is the evasion of apoptosis (programmed cell 
death), allowing the propagation of damaged cells and a decrease in the rate of cell  
attrition [393]. In many studies, ghrelin has been demonstrated to inhibit apoptosis in 
cancer and normal cells and cell lines [47, 175-178, 181, 188, 395, 397-399, 410, 
415-421] and to promote cell survival [175, 177, 415]. Additionally, the inhibition of 
apoptosis by ghrelin is often accompanied by increased proliferation [47, 319, 395, 
397, 398], but it has also been associated with the inhibition of proliferation [411]. In 
contrast to most studies, a study in H345 small cell lung carcinoma cell line 
described an increase in apoptosis with ghrelin treatment, accompanied by the 
inhibition of proliferation [28]. Although in most studies in normal cell lines ghrelin 
inhibits apoptosis, this may differ with cell type, and a wide range of different stimuli 
have been used to elicit apoptosis. Ghrelin also has an anti-apoptotic effect in 
choriocarcinoma [47], colon cancer [52] and endometrial cancer [49] cell lines. A 
single study has indicated that ghrelin promotes apoptosis in the PC3 prostate cancer 
cell line [414]. The majority of studies suggest that ghrelin promotes cancer 
progression.  
 
Desacyl ghrelin appears to have mostly similar effects to ghrelin on cell proliferation 
and apoptosis. Desacyl ghrelin, like ghrelin, increases proliferation in a number of 
normal cell types including bone [168], HIT-T15 and INS-1E pancreatic beta-cell 
lines [175] and the 3T3-L1 adipocyte cell line [422] and inhibits apoptosis in 
cardiomyocyte cells and the H9c2 cell line [178], endothelial cells [178] and 
pancreatic cells and cell lines [175, 177, 415]. Both desacyl ghrelin and acylated 
ghrelin were shown to promote cell survival in pancreatic β-cell lines and human 
pancreatic islets [175, 415] and in cardiomyocytes and endothelial cells [178]. Both 
major forms of ghrelin protect cortical neurons against ischaemic injury [421] and 
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glucose deprivation-induced apoptosis [180]. Desacyl ghrelin inhibits proliferation 
and increases apoptosis in the H345 small cell lung carcinoma cell line in a dose-
dependent manner [28].  
 
Ghrelin inhibits apoptosis by signalling through the ERK1/2 MAPK signalling 
pathway [175-183]. Protection against apoptosis has also been shown to be mediated 
by cAMP/ protein kinase A (PKA) [177], TNF-α/NF-κB [187], protein kinase C 
(PKC) [188], caspase-3 [47, 52, 180], Bax [52, 180], Bcl-2 [52, 180] and glycogen 
synthase kinase-3beta (GSK-3β) [180]. Inhibiting adenylyl cyclase/cAMP/PKA 
signalling prevented the ghrelin cytoprotective effect against apoptosis induced by 
serum starvation or interferon (IFN)-γ /TNF-α in HIT-T15 β -cells [175]. 
 
1.3.7.3.2 Ghrelin and cell migration and invasion 
Ghrelin stimulates cell migration in normal derived cell lines, including human  
microvascular endothelial cells (HMVEC) [174], cardiac microvascular endothelial 
cells (CMECs) [171], and in cancer cell lines including U251 and C6 glioma cell 
lines[55], CCFSTTG1, U118, U87 and SW1008 astrocytoma cell lines [16], PANC1, 
MIAPaCa2, BxPC3 and Capan2 pancreatic adenocarcinoma cell lines [54], and SW-
48 and RKO colon cancer cell lines [48]. These studies showed that the increased 
migration could be inhibited by antagonising the ghrelin receptor [48, 54, 55, 190]. 
The effect of ghrelin on promoting migration in the colon cancer cell lines was also 
demonstrated by blocking ghrelin using an antibody [48]. Migration is a complex 
process involving the extension of a protrusion, through the polymerisation of actin 
filaments, from the leading edge of the cell membrane, adhesion of this protrusion 
and retraction of the rest of the cell in the direction of motility [423-425]. Studies 
have shown that ghrelin may influence the remodelling of the cytoskeleton needed 
for migration. In human T cells, human astrocytoma cell lines and rat hippocampal 
slice cultures, ghrelin stimulates actin polymerisation [16, 267, 426]. In astrocytoma 
motility studies, using scratch and Transwell assays, ghrelin stimulated increased 
migration with increased actin polymerisation [16]. Increases in intracellular calcium 
mobilisation, PKC activation, MMP2 activity and co-localization of the small 
GTPase, Rac1, with GHSR on the leading edge of the cells and membrane ruffling 
on cells was also observed [16]. In the astrocytoma cell lines, the increased migration 
was shown to be dependent on GHSR1a by disrupting the endogenous ghrelin-GHSR 
  
38 
pathway by siRNA [16]. 
 
Ghrelin also appears to stimulate cell invasion in the PANC1, MIAPaCa2, BxPC3 
and Capan2 pancreatic adenocarcinoma cell lines [54]. Inhibition of ghrelin receptor 
signalling with the GHSR inverse agonist D-[lys-3]-GHRP-6 reduced cell invasion in 
SW-48 and RKO colon cancer cell lines [48] and pancreatic adenocarcinomas cell 
lines [54]. 
 
Ghrelin-stimulated migration and invasion is mediated through a variety of signalling 
pathways. In glioma cell lines, rat C6 and human U251, ghrelin-stimulated cell 
migration was prevented by inhibition of GHSR using an antagonist, and through 
inhibition of the CaMKII, AMPK and NF-κB signalling pathways, indicating a role 
for these signalling pathways [55]. Inhibition of the cAMP/PKA pathway and AMP 
cyclase has also been demonstrated to knockdown ghrelin-stimulated migration in 
human aortic endothelial cells [190, 285]. Ghrelin also stimulates cell migration and 
invasion by stimulating the ERK1/2 MAPK pathway [172, 174], and in astrocytoma, 
ghrelin signalling stimulates cell migration by signalling through PKC [16]. 
 
1.3.7.3.3 Ghrelin and angiogenesis 
Ghrelin plays a role in regulating angiogenesis, and we hypothesise that ghrelin may 
also play a role in angiogenesis in cancer progression. Angiogenesis currently 
represents a major therapeutic target for cancer, because of the potential to control 
the growth of tumours which are dependent upon abundant vascularisation [427], and 
synthetic ghrelin analogues (agonists) could be useful anti-angiogenic therapeutics 
[428]. Ghrelin is expressed in blood vessels [275, 429], however, its ability to 
influence angiogenesis has not been widely explored. Ghrelin and GHSR are 
expressed in human umbilical vein endothelial cells (HUVECs), in human 
microvascular endothelial cells (HMVEC) [174] and in cardiac microvascular 
endothelial cells (CMECs) [171, 172]. In HUVECs, ghrelin inhibits FGF-2-mediated 
angiogenesis [428]. Ghrelin also stimulates antiangiogenic action in rat brain 
microvascular endothelial cells [191]. In rat CMECs and in HMVECs, ghrelin 
significantly increased angiogenesis, cell proliferation and migration [171, 172, 174]. 
In a study comparing neonatal (neo) HMVECs and HMVECs derived from aging 
individuals (66 years and 90 years old) who were known to have impaired 
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angiogenesis, ghrelin levels were reduced in the aged group compared to the neo 
HMVECs [430]. Treatment with exogenous ghrelin significantly reversed impaired 
angiogenesis displayed by the aged HMVEC line. [430].These studies found that 
ghrelin-stimulated angiogenesis is mediated through the ERK1/2 MAPK pathway 
[171, 172, 174, 430], whereas a previous study suggested that ghrelin was causing an 
inhibition of MAPK pathway [191]. Ghrelin-stimulated angiogenesis has also been 




1.4.1 Obestatin peptide 
Processing of the preproghrelin peptide gives rise to at least two different peptide 
hormones, ghrelin [1] and obestatin. Obestatin is a highly conserved, 23 amino acid 
peptide hormone [6] and it is cleaved from preproghrelin and the C-terminal, C-
ghrelin peptide [6]. The C-ghrelin peptide is derived from the cleavage of the ghrelin 
peptide from preproghrelin by prohormone convertases PC1/3, PC2 and furin (Fig. 
1.2) [122]. The coding region for obestatin begins at the start of exon 3 of the 
preproghrelin transcript [6]. The region encoding obestatin is flanked by potential 
convertase cleavage sites, and at its C-terminus, it has conserved glycine residue 
suggesting a requirement for amidation [431]. Currently, little is known about the 
processing of preproghrelin into obestatin, or its regulation. It is predicted that 
obestatin is derived by enzymatic cleavage from the full-length preproghrelin 
transcript [432], however, this mechanism has yet to be demonstrated. Obestatin is 
expressed in the same cells in the stomach as ghrelin [433] and circulates in the 
plasma as a hormone, but is rapidly degraded [434]. Unlike acylated ghrelin, it is 
unable to cross the blood-brain barrier [136, 435]. 
 
Like ghrelin, the stomach is the primary site of obestatin expression [6, 433, 436, 
437]. It is also expressed in a range of other peripheral tissues, including the pancreas 
[12, 56, 433, 436, 437], pituitary [56], gastrointestinal tract [56, 433, 436], lung [56], 
thyroid [56, 438], liver [437], testis [439] and mammary gland [436, 440]. Obestatin 
is present in seminal fluid and has been positively correlated with sperm 
concentration and motility [441]. Obestatin circulates at a much lower concentration 
in plasma than ghrelin [442]. The plasma levels of obestatin are correlated to body 
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weight, gender and food intake, but not to age [443, 444]. Plasma levels of obestatin 
in obese women are lower than normal weight and anorectic women [445]. The 
ghrelin to obestatin ratio is increased in anorectic patients. [445, 446] and a number 
of studies have demonstrated that the ghrelin to obestatin ratio changes in disease 
states, such as in obesity, anorexia nervosa and hypertension [445, 447]. 
Interestingly, C-ghrelin, the peptide from which obestatin is derived, circulates in the 
plasma at higher levels than ghrelin [448, 449]. Although the reason for this is 
unclear, this may indicate that the peptides are differentially regulated, or it may be 
due to differences in their half-lives [448, 449]. It is also possible that novel 
obestatin-specific transcripts are also translated and these could influence the 
circulating ghrelin to obestatin ratio [118].  
 
1.4.2 The obestatin receptor  
The obestatin receptor was originally thought to be the orphan receptor, GPR39 [6, 
450], a member of the small ghrelin receptor subfamily [159, 451]. Other research 
groups have failed to reproduce the initial findings and it is now widely accepted that 
GPR39 is not the obestatin receptor [452-455]. GPR39 is a G protein-coupled 
receptor, expressed in the brain and surrounding tissues [451, 456]. GPR39 mRNA is 
expressed in multiple tissues, including the stomach, adipose tissue, intestine, 
endocrine pancreas, liver and hypothalamus, and this is consistent with a role in 
energy balance [6, 451, 457-459]. It is now emerging the GPR39 may act as an 
important transducer of autocrine and paracrine Zn
2+
 signals, influencing cellular 
processes such as insulin secretion, gastric emptying, neurotransmission and 
epithelial repair [460]. It was hypothesised that the glucagon-like peptide 1 receptor 
(GLP-1R) could be an obestatin receptor [12], however, a subsequent study refuted 
this finding, showing that obestatin did not bind GLP-1R, nor displace the GLP-1R 
ligand [461]. Binding sites for obestatin have been identified in the pancreas, heart 
and white adipose tissue [12, 450, 462, 463], however, the identity of the obestatin 
receptor remains elusive.  
 
Although the identity of the obestatin receptor is unknown, some studies have 
investigated obestatin signalling pathways. Obestatin appears to activate an unknown 
GPCR [10, 11, 439, 462, 464-466]. There is also evidence that obestatin may 
stimulate receptors that are expressed by the vagus and signal to the brain through 
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vagal afferent pathways [467, 468], like ghrelin, to regulate gastrointestinal motility 
[469-471]. It also appears that, like ghrelin, obestatin stimulates the ERK1/2 
signalling pathway in mediating functions such as cell proliferation, the inhibition of 
apoptosis and in stimulating growth hormone secretion [10-12, 462, 465, 466]. 
Obestatin has also been shown to activate the Akt signalling pathway [464, 472] and 
inactivate AMPK [464]. Induction of Akt signalling has been linked to the 
stimulation of proliferation [473]. In 3T3-L1 adipocyte cells, obestatin activates Akt 
and its downstream targets, glycogen synthase kinase 3α/β (GSK3α/β), mTOR and 
S6 kinase 1 (S6K1), and Akt signalling plays a role in obestatin-stimulated adipocyte 
metabolism and adipogenesis [464]. This is accompanied by the simultaneous 
inactivation of AMPK and a decrease in Acetyl-CoA carboxylase (ACC) 
phosphorylation [464]. 
 
1.4.3 The function of obestatin 
Obestatin, which is produced from the same prepropeptide as ghrelin, was originally 
described as opposing the effect of ghrelin in appetite and bodyweight [6]. This 
appetite-suppressing function inspired the name, obestatin, which is derived from the 
Latin contraction for obese, obedere, meaning to devour, and statin, denoting 
suppression [6]. There has been much controversy, however, over the role of 
obestatin, as the effects on appetite and energy balance have proven difficult to 
repeat in other laboratories [474-479]. Some researchers have proposed that obestatin 
should be renamed ghrelin associated peptide, as it may not suppress appetite [476]. 
It has now been shown to have functions unrelated to the regulation of appetite [7]. 
 
1.4.3.1 The effect of obestatin on feeding, gut motility, energy balance and thirst 
Obestatin was originally demonstrated to oppose the effects of ghrelin, suppressing 
food intake, gut motility and weight gain in mice through GPR39 [6, 136]. This was 
opposite to the effect seen in mice in response to acylated ghrelin [1]. As indicated 
above, these results have not been readily reproducible. The anorexigenic effects of 
obestatin in fasted/refed mice and decreased gastrointestinal motility have not been 
reproduced by other groups [435, 439, 453, 474-476, 480-486], with the exception of 
two studies [9, 487]. In one of the studies in which decreased feeding was observed, 
obestatin was dissolved in dimethyl sulphoxide (DMSO)/saline immediately prior to 
intraperitoneal injection, while the control group received saline without DMSO 
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[487]. No other studies used DMSO to dissolve obestatin [6, 9, 435, 453, 474, 480-
484] and this may have confounded the data [487]. DMSO is likely to have 
independent effects and it is not recommended as a vehicle in feeding studies [488]. 
The negative findings obtained by other groups cannot be attributed to differences in 
experimental design, and a number of studies have mimicked the original test 
conditions [435, 482, 483], while others have been performed under comparable 
conditions [453, 474, 480, 481, 484]. The use of comparative control peptides, 
including ghrelin, revealed the expected food intake modifications under the same 
conditions [453, 474, 480-484]. Additionally, when obestatin was co-administered 
with ghrelin in fasted/refed mice or rats, as in the paper by Zhang et al., suppression 
of ghrelin’s effect was not seen [435, 474, 484]. Despite these results, a ghrelin-
opposing effect of obestatin was observed in one study when obestatin and ghrelin 
were injected peripherally at 1μmol kg-1 during the light-off period in freely fed mice 
[435]. Obestatin circulates at high levels in the serum (0.3ng/mL), however, unlike 
ghrelin, these level were unaffected by feeding and fasting, suggesting that its 
expression is not regulated by feeding [6, 136]. 
 
The initial finding that obestatin decreased gastrointestinal motility [6] has not been 
successfully reproduced in a number of in vivo or in vitro studies [439, 477, 483, 
485, 486]. The original study was performed in mice, however, while the subsequent 
gastrointestinal motility studies were performed on rats, except one which used both 
mice and rats [485]. Obestatin was found by one group to exert inhibitory effects on 
the motility of antrum of the stomach and the duodenum in fed rats [469-471].  
 
Despite controversies regarding its effect on feeding, obestatin may prevent thirst. 
Obestatin inhibited thirst in a number of rat studies [480, 489], in ad libitum-watered 
and angiotensin II - and hypovolemia- induced thirst [480, 489]. This was not 
validated by another independent study where the effect of obestatin administration 
on ad libitum-watered mice over a period of time showed no effect on water intake 
[490]. It has been suggested that effects of obestatin on feeding may be secondary to 
the inhibition of thirst as part of a phenomenon termed dehydration anorexia [480].  
 
1.4.3.2 Obestatin and adiposity 
Obestatin may play a role in regulating bodyweight by influencing adiposity. 
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Obestatin expression is increased during adipogenesis, and it promotes adipogenesis 
in an autocrine/paracrine manner by regulating adipocyte metabolism [7]. It has also 
been reported to have adipogenic effects in the 3T3-L1 adipocyte cell line [464]. 
Obestatin can induce AS160 phosphorylation, and translocation of the glucose 
transporter, GLUT4, to the plasma membrane, which allows insulin-regulated 
glucose transport into the cell, and augmented glucose uptake in 3T3-L1 adipocytes 
[464]. Neutralisation of endogenous obestatin using an anti-obestatin antibody 
decreases the rate of adipocyte differentiation [464]. In a recent study of mice fed a 
high fat diet obestatin prevented apoptosis of 3T3-L1 preadipocytes by stimulating 
PI3K/Akt and ERK1/2 signalling [491]. In the same study, obestatin also inhibited 
isoproterenol-induced lipolysis, promoted AMPK phosphorylation, and induced 
adiponectin, and reduced leptin secretion in both mouse (3T3-L1) and human 
(human subcutaneous and omental) adipocytes [491]. Peripheral injection of 
obestatin induces expression of the early response gene, c-fos, in gastric mucosa, 
intestinal villi, white adipose tissue, hepatic cords, and kidney tubules [450] and 
leads to decreased expression levels of the cholesterol transporter ABCA1 (ATP-
binding cassette A1) in adipose tissue, suggesting changes in cholesterol transport 
[492].  
 
1.4.3.3 Obestatin and growth hormone (GH) release 
While ghrelin stimulates the release of growth hormone (GH) from the anterior 
pituitary, the majority of studies indicate that obestatin does not influence GH release 
[6, 480, 482, 484, 487]. Nevertheless, one study in rat somatotroph tumour cells has 
reported that obestatin stimulated GH release within 30 min and this had dissipated 
by one hour [466]. These authors suggested that obestatin stimulates GH release 
through the ERK1/2 signalling pathway [466]. Other studies suggest that obestatin is 
only effective in inhibiting ghrelin-stimulated responses. Obestatin inhibited ghrelin-
stimulated excitation of growth hormone releasing hormone (GHRH) neurons and 
stimulated GHRH release through a receptor interaction which was independent of 
GHSR [493]. Obestatin has also been shown to inhibit ghrelin-stimulated GH release 
itself [435]. It is, therefore, currently unclear whether or not obestatin has a role in 





1.4.3.4 Obestatin and pancreatic function 
Obestatin is co-expressed with ghrelin in the β-cells of the endocrine pancreas and 
the pancreatic islets [12, 56, 124, 436, 494, 495]. Pancreatic β-cells and human islets 
also express obestatin and specific obestatin binding sites [12]. Obestatin appears to 
play a significant role in the endocrine pancreas, working as an autocrine/paracrine 
factor, promoting β-cell growth and survival, allowing maintenance of islet size, and 
protecting against diabetes [12, 495].  
 
The effects of obestatin on insulin release remain controversial, and reports have 
been conflicting. Studies have demonstrated that obestatin stimulates insulin 
secretion, inhibits secretion, or has no effect [12, 496, 497]. In human HIT-T15 β-
cell line assays, obestatin increases the secretion of insulin and regulates GLP-1R, 
insulin receptor substrate-2 (IRS-2), and pancreatic and duodenal homeobox-1 genes 
[12]. Studies in rat and mouse models have mostly shown that obestatin inhibits 
insulin release [498-500]. In a study in rats, 10 nM obestatin inhibited insulin release, 
and low concentrations of obestatin (1 nM) stimulated insulin secretion [497]. 
Further studies are required to determine whether the effects of obestatin are dose 
dependent, or whether obestatin has different effects in human compared to rats and 
mice. A recent study demonstrated that obestatin enhanced glucose uptake in the 
presence and absence of insulin, promoted GLUT4 translocation, and increased Akt 
phosphorylation and sirtuin 1 protein (increases insulin sensitivity) expression in 
mice fed a high fat diet [491]. This enhanced glucose uptake could be reversed by the 
inhibition of sirtuin 1 by small interfering RNA [491]. Obestatin has also been 
demonstrated to stimulate the exocrine pancreas and the production of pancreatic 
juice, which is essential for efficient digestion [467, 468]. 
 
Obestatin inhibits apoptosis and promotes survival in the HIT-T15 and INS-1E 
pancreatic β-cell lines by increasing cAMP and activating ERK1/2 and 
phosphatidylinositol 3-kinase (PI3K)/Akt [12]. It also exerts anti-apoptotic effects 
through the inhibition of adenylyl cyclase/cAMP/protein kinase A (PKA), PI3K/Akt, 
and ERK1/2 signalling [12].  
 
1.4.3.5 Obestatin and cardiovascular functions 
There is evidence that obestatin may also have cardiovascular effects. In an isolated 
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rat heart preparation, treatment with obestatin before the induction of ischemia 
reduced infarct size and contractile dysfunction in a concentration-dependent manner 
[462]. Additionally, it was demonstrated that obestatin reduced cardiomyocyte 
apoptosis and it reduced caspase-3 activation in the rat H9c2 cardiac cell line and in 
isolated ventricular myocytes [462]. Specific obestatin binding sites have been 
demonstrated predominantly in the membranes of the ventricular myocardium and 
cultured cardiomyocyte models of ischemia-reperfusion [462]. The cardioprotective 
effects of obestatin in rat H9c2 cardiac cells and isolated ventricular myocytes are 
also mediated by PI3K and PKC in addition to ERK1/2 [462].  
 
1.4.3.6 Obestatin and sleep, memory and anxiety and thermogenesis 
There have been few studies demonstrating a role for obestatin in higher order 
functions, including sleep, memory and mood. Obestatin may act as a sleep-
promoting factor when centrally administered to rats [8]. The pre-treatment of 
preproghrelin knockout mice with obestatin attenuated hypothermic responses, 
causing loss of sleep during torpor in mice [501]. Like ghrelin, obestatin improved 
memory retention, however, it also opposed the effects of ghrelin, causing reduced 
anxiety while ghrelin caused increased anxiety [9]. 
 
1.4.3.7 Obestatin and reproduction 
There is limited information describing a role for obestatin in reproduction. Obestatin 
has been detected in the rat stomach, pancreas and plasma in the perinatal period 
[316]. This concentration of obestatin in rats is abruptly reduced after birth, when 
levels of ghrelin increase [316]. The reduction in pancreatic obestatin is continued 
until weaning [316, 502]. Additionally, in pregnancy, obestatin has been associated 
with the regulation of maternal blood pressure during the third trimester [503]. 
Obestatin is also expressed in porcine ovaries, regulating granulosa cell function and 
secretion [465]. Obestatin increased the accumulation of proliferation markers cyclin 
B1, proliferating cell nuclear antigen (PCNA), MAPK and the apoptosis markers 
p53, Caspase 3 and Bax in granulosa cells [465]. Increased secretion of progesterone 
was also observed [465]. 
 
1.4.4 Obestatin in disease 
Obestatin has a diverse range of functions, however, there have been few studies 
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indicating a role in disease. Obestatin exerts cardioprotective effects in ischemic-
reperfused isolated rat heart [462]. A decreased obestatin/ghrelin ratio has also been 
linked to inflammatory bowel disease [504].  
 
1.4.5 Obestatin in cancer 
 
1.4.5.1 Expression of obestatin in cancer 
Obestatin is expressed in a number of cancer tissues and cell types (Table 1.5) and 
may be differentially expressed in cancer tissues compared to normal tissue. In a 
study of patients who underwent surgery for benign ovarian tumours (22 patients) 
and ovarian cancer (31 patients) and control women (32 patients), peripheral blood 
obestatin concentrations were measured [114]. Obestatin levels were higher in the 
blood of patients with both benign ovarian tumours and ovarian cancer compared to 
normal women with no expression of the disease [114]. In patients with prostate 
cancer [384] and uterine leiomyoma [383] levels of obestatin were not elevated 
compared to normal controls. Further studies are required to determine if plasma 
obestatin levels may be elevated in some cancers and if obestatin may be useful as a 
biomarker.  
 
1.4.5.2 Obestatin and processes related to cancer progression 
The role of obestatin in cancer has been the subject of few studies and its role in cell 
migration, invasion, apoptosis and angiogenesis has not been investigated. Obestatin 
has been shown to have differential effects on proliferation in cancer compared to 
normal cell lines [11, 56, 466].  
 
1.4.5.2.1 Obestatin and cell proliferation and apoptosis 
Cancer progression is characterised by a number of changes in basic cellular function 
including self-sufficiency in growth signals, insensitivity to growth-inhibitory (anti-
growth) signals, evasion of programmed cell death (apoptosis), limitless replicative 
potential (proliferation), sustained angiogenesis, and tissue invasion and metastasis 
[393]. Obestatin may act as a growth factor and, like ghrelin, it can alter cell 
proliferation in a number of cell types [7]. Exogenous obestatin treatment stimulates 
cell proliferation in some normal cell types, including human retinal epithelial cells 
[10], pancreatic β-cells and human pancreatic islet cells [12]. In porcine ovarian  
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Table 1.5 Expression of obestatin mRNA and protein in tumour tissues and cell 
lines. (-) no expression, (++) is expressed or has moderate expression, (+) low 
expression, (+++) high expression, ↓ lower levels of expression than normal tissue.  
 
Cancer Type  Obestatin  
 mRNA Protein References 
Adrenal tumours    
Phaeochromocytoma (+) (-) [56] 
Adrenocortical adenoma (+) (-) [56] 
Adrenocortical carcinoma  (-) [56] 
Appendix    
Well-differentiated neuroendocrine tumour  (-)(++) [56] 
Gastrointestinal Tract cancer    
Oral squamous cell carcinoma  (+)(-)↓ [24] 
Oesophagogastric Adenocarcinomas    
Stomach (+++) (++) [56] 
Colon-rectum  (-) [56] 
Small intestine (+) (-)(++) [56] 
Lung Cancer    
Lung endocrine tumours (+) (-) [56] 
Small cell lung carcinoma (SCLC) (++) (-) [56] 
Ovarian Cancer    
  Benign serous tumours  (++) [380] 
Borderline serous tumours  (++) [380] 
Malignant serous tumours  (++) [380] 
Pancreatic Cancer    
Gastrinoma    
Well-differentiated neuroendocrine carcinoma  (++) [56] 
Well-differentiated neuroendocrine tumour (+++) (++) (-)(++) [56] 
Pituitary Adenomas    
Adenoma  (-) [56] 
Thyroid Cancer    
Medullary (++) (-)(++) [56] 
Follicular (+) (-)(++) [56] 
Papillary (+) (-)(++) [56] 
Poorly differentiated carcinoma (+) (-)(++) [56] 















granulosa cells obestatin stimulated expression of proliferation markers (PCNA, 
cyclin B1, and MAPK) and markers of apoptosis (Bax, p53, Caspase 3) [465]. Like 
ghrelin, obestatin has different effects on cell proliferation in different cell lines. 
Obestatin inhibits proliferation in rat adrenocortical cells in a model of bilateral 
enucleation-induced adrenocortical regeneration [13], in the human C28-I2 rib 
chondrocyte cell line and the ATDC5 mouse embryonic carcinoma-derived cell line 
(after they are induced to differentiate into chondrocytes) [14].  
 
The effect of obestatin on cell proliferation varies with cell type. Obestatin enhances 
proliferation in the KATO-III gastric cancer cell line [11], but inhibits proliferation 
in the TT thyroid carcinoma cell line [56] (Table 1.6). Obestatin had no effect on cell 
proliferation in the BON-1 pancreatic neuroendocrine tumour cell line [56], or in the 
GC rat somatotroph tumour cell line [466] (Table 1.6). 
 
Table 1.6 The effects of obestatin on cell proliferation in tumour cell lines. 
Cancer cell type, the concentration of obestatin used in assays, the use of inhibitors 
and any signalling data linked to the function are listed. * = significant changes 
observed with that treatment concentration compared to other concentrations tested; 
↑ = increased expression/phosphorylation. 
 
Function Cancer Type Specifics Reference 
Proliferation    
Increased Gastric cancer cell line – KATO-III 50 nM* to 1000 nM* 
↑PKC, ↑ERK1/2 
Inhibition with pertussis toxin, PD98059 (ERK 
inhibitor), wortmannin (PI3K inhibitor), 
staurosporine (PKC inhibitor), PP2 (Src inhibitor) 
[11] 
Decreased Thyroid carcinoma cell line – TT  1 nM, 10 nM*, 100 nM* [56] 
No change Pancreatic neuroendocrine tumour 
cell line – BON-1  
1 nM, 10 nM, 100 nM [56] 
Somatotroph rat tumor  
cell line – GC  




In the KATO-III gastric cancer cell line, obestatin-induced proliferation was 
mediated by the ERK1/2 pathway [11]. Further analysis of the obestatin 
transmembrane signalling pathway revealed that PI3K, PKC and Src inhibitors 
blocked activation of ERK1/2, suggesting that they are upstream of ERK1/2 in the 
mediation of obestatin signalling [11]. In another study in the KATO-III and AGS 
gastric cancer cell lines, obestatin activated Akt signalling through two potential 
  
49 
pathways involving GPR39 [472], which is surprising as it is now thought that 
GPR39 is not the obestatin receptor. Obestatin was thought to induce an association 
between GPR39 and a β-arrestin 1/Src signalling complex, resulting in 
transactivation of the epidermal growth factor receptor (EGFR) [472]. This leads to 
downstream Akt signalling, which is recognised as a signalling pathway that 
mediates cell proliferation [473]. Activation of this pathway was paralleled by the 
phosphorylation of mTOR (mammalian target of rapamycin) which can lead to Akt 
phosphorylation, or it can be activated downstream of Akt [472]. In primary human 
retinal epithelial cells, obestatin stimulated cell proliferation through ERK1/2 
signalling, and the activation of Gi, PI3K, PKC and then Src [10].  
 
1.5 Ghrelin and obestatin in the ovary and in ovarian cancer 
In this study we have investigated the role of ghrelin and obestatin in processes 
related to cancer progression in ovarian cancer. We have previously demonstrated 
that ghrelin mRNA is expressed in the IOSE normal ovarian cell line, the HS 832 
benign ovarian cyst and PEO14, SKOV3, PEO1, JAM, TOV 112D, OV90, ES2 and 
OVCAR3 ovarian cancer cell lines and from ovarian cancer tissue (Jeffery, 
unpublished data) [505]. We have shown that GHSR1a is expressed in the OVCAR3 
ovarian cancer cell line using immunohistochemistry and in ovarian cancer 
specimens using RT-PCR [505]. Using real time RT-PCR, we demonstrated that 
exon 3 deleted isoform of ghrelin is relatively over-expressed in the more aggressive 
PEO14, SKOV3, PEO1, and JAM ovarian cancer cell lines compared to the IOSE, 
HS 832, TOV 112D, OV90 and ES2 cell lines (Jeffery, unpublished data) (Fig. 1.7).  
 
Ghrelin, obestatin and GHSR protein expression has been demonstrated in ovarian 
cancer. In a small recent immunohistochemical study of benign (n = 20), borderline 
(n = 7) and malignant (n = 20) serous tumours, ghrelin, but not obestatin 
immunoreactivity was increased in the malignant tissues compared to benign tissues 
[380]. GHSR1a protein expression has been demonstrated immunohistochemically in 
the ovarian surface epithelium and Műllerian duct derivatives, as well as in benign 
serous tumours resembling Fallopian tube epithelium and in highly differentiated 
serous cystadenocarcinomas [45]. GHSR1a was not expressed in other ovarian 
neoplasms in this study, including mucinous cystadenomas, cystadenocarcinomas, 
endometrioid tumours, clear cell carcinomas or Brenner’s tumours [45].  
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Figure 1.7 Real time RT-PCR expression of exon 3 deleted ghrelin in ovarian 
cancer cell lines. Data were normalised to 18s and are represented as fold changes, 
quantified as 2
-(∆Ct sample-∆Ct control)
, relative to expression of transcripts in IOSE normal 
ovarian cell line sample (1.0). Bars indicate mean +/- SEM. Unpublished data from 
Jeffery et.al.  
 
Ghrelin, obestatin and GHSR protein expression has been demonstrated in ovarian 
cancer. In a small recent immunohistochemical study of benign (n = 20), borderline 
(n = 7) and malignant (n = 20) serous tumours, ghrelin, but not obestatin 
immunoreactivity was increased in the malignant tissues compared to benign tissues 
[380]. GHSR1a protein expression has also been demonstrated 
immunohistochemically in the ovarian surface epithelium and Műllerian duct 
derivatives, as well as in benign serous tumours resembling Fallopian tube 
epithelium and in highly differentiated serous cystadenocarcinomas [45]. GHSR1a 
was not expressed in other ovarian neoplasms in this study, including mucinous 
cystadenomas, cystadenocarcinomas, endometrioid tumours, clear cell carcinomas or 
Brenner’s tumours [45].  
 
Our group and others, using immunostaining of histological tissue sections, have also 
shown that ghrelin and its receptor are expressed in the normal ovary, including 
ovarian follicles, and thecal cells within larger follicles, in larger oocytes, granulosa 
cells, hilus interstitial cells. They are expressed in the luteal compartment of the 
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ovary, and particularly in steroidogenic cells from corpus luteum (CL) of the current 
cycle and in the regressing CL [155, 287, 506]. In early development, however, 
ghrelin immunoreactivity was not detected in ovarian follicles at any stage, nor was 
it present in newly formed or regressing CL [155].  
 
At the mRNA level in rat ovaries, ghrelin expression varied depending on the stage 
of the oestrous cycle [287]. During pregnancy, however, expression was detected 
persistently in the rat ovary, with higher levels of ghrelin in early pregnancy and 
lower expression during the later part of gestation [287]. In human luteal cells 
isolated from corpora lutea (collected from 23 normally menstruating patients in the 
midluteal phase of the menstrual cycle), and primary cultures, both desacyl ghrelin 
and obestatin treatment reduced progesterone and vascular endothelial growth factor 
(VEGF) release [507]. Obestatin was also able to reduce prostaglandin E2 (PGE2) 
and prostaglandin (PG) F2α  release [507]. Ghrelin is also a potent regulator of the 
secretory activity of chicken ovarian cells and of tyrosine kinase (TK), mitogen-
activated protein kinase (MAPK) and protein kinase A (PKA) activity in the chicken 
ovary [291]. Furthermore, it has been suggested that MAPK-, cyclin-dependent 
protein kinase (CDK)- and PKA-dependent intracellular mechanisms are involved in 
the control of ovarian secretion, which may mediate the effects of ghrelin on these 
processes in the chicken [508]. In the porcine ovary ghrelin has been shown to 
stimulate cell proliferation and apoptosis mediated through the ERK1/2 and PI3 
kinase pathways [509]. In another study in the porcine ovary, it was suggested that 
ghrelin increased proliferation, however, this study only measured an accumulation 
of proliferation markers (PCNA, cyclin B1, MAPK) [395]. Little is still known about 
the function of ghrelin and obestatin in the human ovary and in ovarian cancer. 
 
1.6 Outline of project 
Ovarian cancer is the leading cause of death among gynaecological cancers world 
wide. The incidence of ovarian cancer increased dramatically after the age of 50, 
with 81% of all new cases being diagnosed in this age group. With less than a 1% 
decline in the incidence of ovarian cancer over the past two decades and the 
mortality rate remaining largely unchanged, improved adjunctive therapies and 
markers for this disease are urgently required, as current methods for diagnosis and 




There is increasing evidence for a functional role of the ghrelin axis (including 
ghrelin, obestatin and their receptors) in the progression of cancer [7, 15]. Cancer 
progression is characterised by a number of well defined steps named the hallmarks 
of cancer [392, 393] and ghrelin and obestatin have been demonstrated to influence a 
number of these hallmarks including cancer cell proliferation, migration (ghrelin 
only) and invasion (ghrelin only) [7, 15]. 
 
The effects ghrelin and obestatin on human ovarian cancer cell function remain 
unknown. In the porcine ovary, ghrelin has been shown to increase follicular and 
granulosa cell proliferation [395, 509]. Previous research in the Ghrelin research 
group has demonstrated that ghrelin mRNA is expressed in ovarian cancer cell lines 
and tissues [505]. Additionally, a recent immunhistochemical study has shown 
increased expression of ghrelin, but not obestatin, in malignant serous ovarian 
tumours compared to benign tissues [380]. In this thesis the effects of ghrelin and 
obestatin on ovarian cancer cell line functions, including cell proliferation, cell 
migration and invasion and cell attachment are investigated and compared to a 
normal ovarian cell line. This research may provide novel avenues for the 
development of novel biomarkers, or therapeutic strategies for ovarian cancer. 
 
1.6.1 Hypotheses 
We hypothesise that: 
 components of the ghrelin axis are expressed in human ovarian cancer 
tissues. 
 ghrelin and obestatin play a role in stimulating cell proliferation in ovarian 
cancer. 
 ghrelin and obestatin may play a role in stimulating cancer-related processes 
including cell migration, invasion and cell attachment in ovarian cancer. 
 
1.6.2 Specific Aims 
I therefore aim to investigate: 
(1) the cellular effects of exogenous obestatin and ghrelin in cell proliferation, 
migration, invasion and attachment in ovarian cancer cell lines. 
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(2) the involvement of ERK1/2, a known ghrelin signalling pathway, in the 
ovarian cancer cells. 
(3) the signalling pathways that mediate the effects of obestatin based on the 
results of proteomic analyses.  







































Acylated ghrelin was obtained from Mimotopes (Clayton, Victoria, Australia) and 
amidated obestatin was obtained from Auspep (Parkville, Victoria, Australia), 
sequences in Table 2.1. 
 
Table 2.1 Peptide sequences. 
 
Peptide Sequence 
Acylated ghrelin GSS(n-octanoyl)FLSPEHQRVQQRKESKKPPAKLQPR 
Amidated obestatin FNAPFDVGIKLSGVQYQQHSQAL-NH2 
 
2.2 Cell lines and cell culture  
In this study, experiments were performed using two serous ovarian cancer cell lines, 
SKOV3 and OV-MZ-6, (as serous cancers are the most common form of ovarian 
cancer), and functional effects compared to a normal representative cell line, hOSE 
17.1.  The SKOV3 ovarian cancer cell line and the hOSE 17.1 normal-derived 
human ovarian surface epithelial cell line (all obtained from the American Type 
Culture Collection, Rockville, Maryland, USA) and the OV-MZ-6 ovarian cancer 
cell line (a gift from Dr Daniela Lossener, Institute of Health & Biomedical 
Innovation, QUT) [510]. The SKOV3 ovarian cancer cell line is an epithelial ovarian 
serous adenocarcinoma cell line derived from ascitic fluid [511]. The hOSE 17.1 cell 
line is a normal human ovarian surface epithelial cell line immortalised with a 
retroviral vector expressing human papillomavirus oncogenes [512]. The human 
ovarian cancer cell line OV-MZ-6, is derived from malignant ascites from an 
advanced serous cystadeno ovarian cancer (International Federation of Gynecology 
and Obstetrics (FIGO) stage IV) [510]. 
 
The SKOV3 and hOSE 17.1 cell lines were routinely cultured in RPMI 1640 
medium (Invitrogen, Mulgrave, Victoria, Australia), containing 10% (v/v) New 
Zealand Cosmic calf serum (FCS) (Thermo Fisher Scientific, Scoresby, Victoria, 
Australia), penicillin (100 units/mL) (Invitrogen) and streptomycin (100 µg/mL) 
(Invitrogen). The OV-MZ-6 cell line was maintained in Dulbecco´s Modified Eagle 
Medium (DMEM) liquid (high glucose, 4500 mg/L) (Invitrogen), containing 10% 
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(v/v) FCS (Thermo Fisher Scientific), 10 mM HEPES (Invitrogen), 0.550 mM L-
arginine (Sigma-Aldrich), 0.272 mM L-asparagine (Sigma-Aldrich), 20 μg/ml 
gentamicin (Invitrogen), penicillin (100 units/mL) (Invitrogen) and streptomycin 
(100 µg/mL) (Invitrogen). All cell lines were maintained in an incubator at 37 ºC in 
5% CO2 and passaged at 70-80 % confluence by washing twice with phosphate 
buffered saline (PBS) and removal from the surface of the flask using 0.25% 
Trypsin/EDTA (Invitrogen). Cells were tested monthly for Mycoplasma 
contamination using RT-PCR (TaKaRa Bio Inc, Shiga, Japan) and found to be 
negative. 
 
2.3 Quantitative real-time RT-PCR and RT-PCR of ovarian cancer tissues and 
cell lines 
 
2.3.1 Statement of contribution for quantitative real-time RT-PCR and RT-PCR 
The practical work described in this section was performed by Dr Inge Seim. Dr Inge 
Seim performed the quantitative real-time RT-PCR and RT-PCR of the tissues and 
cell lines while the candidate performed all other methods in this Chapter.  
 
2.3.2 RNA extraction and reverse transcription-polymerase chain reaction (RT-
PCR) 
To determine expression in cell lines, total RNA was harvested from 70% confluent 
monolayers of OV-MZ-6, SKOV3, and hOSE 17.1 cell lines using QIAshredder and 
RNEasy Plus Mini kits (QIAGEN, Hilden, Germany) according to the manufacturer's 
instructions. Total RNA (3 μg) from cell lines or stomach tissue (FirstChoice, 
Ambion, Austin, TX) was reverse transcribed using 10 units SuperScript III reverse 
transcriptase (Invitrogen) and 50 μM oligo(dT)20 primers according to the 
manufacturer’s instructions. The resulting single-stranded cDNA was treated with 2 
U/μl ribonuclease H (Invitrogen) for 20 minutes at 37 C in order to destroy 
complementary RNA and improve the sensitivity of the subsequent RT-PCRs [513, 
514]. 
 
Expression of ghrelin, GHSR1a, GHSR1b and GOAT mRNA was assessed in the 
ovarian cell lines using RT-PCR. RT-PCRs for the housekeeping gene β2 
microglobulin were performed to check for genomic DNA contamination and to  
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Table 2.2 Primer sequences. Expected amplicon sizes (bp) and annealing 
temperatures (Ta) for RT-PCR. 
 
Primer Pair Primer Sequence (5’-3’) Size (bp) Ta (C) 
Ghrelin    
Sense GAGTCCAGCAGAGAAAGGAG 300 60 
Antisense ATGAGCGCTTCTAAACTTAGAG   
GHSR1a    
Sense CGCTACTTCGCCATCTGCTT 542 60 
Antisense ATGGGGTTGATGGCAGCACT   
GHSR1b    
Sense CGCTACTTCGCCATCTGCTT 433 60 
Antisense GGCACAGGGAGAGGATAGGA   
GHSR1a nested    
Sense CTCTACAGTCTCATCGGCAG 126 60 
Antisense CTGTAGTGGTGTTTGCCTTC   
ß2 microglobulin    
Sense TGAATTGCTATGTGTCTGGGT 248 55 

















determine the integrity of the cDNA. Unless otherwise specified, all primers were 
designed
 
using the Primer Express version 2.0 software (AB) and synthesised
 
by 
Proligo (Armidale, NSW, Australia) (Table 2.2). Commercially available primers 
were used for GOAT assays (MBOAT4, SABiosciences). RT-PCRs were performed 
in a total reaction volume of 50 μl using 10 U Platinum Taq Polymerase (Invitrogen) 
according to the manufacturer's instructions. A nested RT-PCR was performed for 
the detection of GHSR1a. Briefly, PCR products from the first GHSR1a RT-PCR 
were diluted 1/100 in water and used in a second PCR with nested GHSR1a primers 
(Table 2.2). In RT-PCR assays for GHSR1b [186], which contains intronic sequence, 
RNA was treated with DNase I and a no-reverse transcriptase control (RT-) was 
employed to ensure that only mRNA (and not genomic DNA) was amplified. 
Negative controls, with water substituted for template, were also performed for all 
PCRs. RT-PCRs were performed, as outlined in Table 2.2, with a PTC-200 thermal 
cycler (MJ Research, Watertown, MA). Sequencing was performed in order to 
confirm the identity of the RT-PCR products. The reaction products were purified 
using the PCR MinElute kit (QIAGEN), subcloned into pCR-XL-TOPO (Invitrogen), 
transformed into One Shot MAX Efficiency DH5α-T1R chemically-competent cells 
(Invitrogen), purified using a miniprep kit (QIAGEN) and sequenced at the 
Australian Genome Research Facility (AGRF, Brisbane, Australia) using BigDye III 
(Applied Biosystems, Victoria, Australia). 
 
2.3.3 Quantitative real-time RT-PCR of clinical specimens 
Real-time RT-PCR was used to detect ghrelin (GHRL) and GHSR1a mRNA levels in 
a range of samples of normal ovary and from ovarian carcinoma samples using an 
OriGene TissueScan qPCR Ovarian Cancer panel (panel II, OriGene, Rockville, 
MD). This array consists of pathologist-verified samples from eight non-tumour 
ovarian tissues and 40 different ovarian tumours.  The panel consisted of RNA from 
patients with stage I, II and III ovarian cancer. Ages of tissue donors ranged from 33 
to 91 years.  
 
Real-time RT-PCRs were performed using the AB 7000 sequence detection system 
(AB), in a total reaction volume of 20 μl. Platinum Quantitative PCR SuperMix-
UDG w/ROX (Invitrogen) was used to detect GHRL and GHSR1a expression, while 
the RT-PCRs for the β-actin housekeeping gene (ACTNB) and MBOAT4/GOAT were 
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performed using 2 × SYBR green master mix (AB). β-actin primers were supplied 
with the cDNA panel (OriGene), and primers for MBOAT4/GOAT  were purchased 
from SABiosciences (Frederick, MD). Primers and TaqMan probes for GHRL 
(Hs01074051_g1, spanning the ghrelin-peptide coding exons and Hs01074053_m1, 
spanning the obestatin-peptide coding exons), and GHSR1a (Hs01026313_m1) were 
obtained from Applied Biosystems (AB). Each gene was evaluated using two 
separate array plates and normalised against β-actin. Fold changes were quantified as 
2
-(∆Ct sample-∆Ct control)
, as described previously [515]. Negative control RT-PCRs were 
also performed where template was substituted with water.  
 
2.4 Cell proliferation assay  
Proliferation was measured using 2 different types of assays to confirm that results 
obtained were due to a difference in cell number and not just changes in metabolism. 
Cell proliferation was measured using a WST-1 (Roche, Nonnenwald, Penzberg, 
Germany) assay, which is based on the cleavage of the WST-1 tetrazolium salt by 
mitochondrial dehydrogenases in viable cells, and CyQuant (Invitrogen), which 
quantifies cell DNA content as a direct representation of cell number.   
In order to determine the optimal cell density for these assays, a seeding density test 
was performed by seeding a range of cell numbers into a 96-well plate and their 
percent confluence was observed under the phase contrast microscope over 96 h. 
Standard curves of cell number were also performed to confirm that cell number was 
proportional to absorbance or luminescence. Cells (1 x 10
4
 cells/mL for SKOV3 and 
OV-MZ-6 and 5 x 10
4
 cells/mL for the hOSE 17.1) were plated in 200 µL phenol red 
free medium with 10% FCS (v/v) in each well of duplicate 96-well plates (black and 
clear) and incubated at 37ºC for a total of 96 h. After 24 h, cells were treated with a 
range of ghrelin or obestatin concentrations (0.1, 1.0, 10, 100, 1000 nM) or no 
treatment controls (0 nM) for 3 days (with ghrelin being replenished every 24 hours). 
Cells were then treated with WST-1 reagent (Roche) for 1.5 h in phenol red free 
medium, according to the manufacturer’s instructions, and absorbance was 
determined (450/650 nm) using a Benchmark Plus Microplate Spectrophotometer 
System (BioRad, Regents Park, NSW, Australia). CyQuant NF assays for cell DNA 
content (Invitrogen) were performed in black plastic plates (PerkinElmer Life 
Sciences, Melbourne, Vic, Australia) according to the manufacturer’s instructions 
and fluorescence (520 nm) was measured after excitation at 480 nm using a 
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microplate reader PolarSTAR Optima (BMG Labtech, Victoria, Australia). Each 
treatment (and vehicle only controls) was performed using 16 replicate wells and 
each experiment was performed independently at least 3 times. 
 
2.5 Transwell migration and invasion assay  
Cell migration and invasion assay were performed using a modified Transwell 
protocol (Fig 2.1) [516]. Cells were split into T25 flasks (Nunc Nalge, Thermo 
Fisher Scientific, Victoria, Australia), and 24 h after seeding they were treated with 
10 or 100 nM ghrelin, or obestatin, or medium only for 48 h. Migration and invasion 
assays were performed in 24-well plates (Nunc Nagle) with Transwell
TM
 cell culture 
inserts with 8 µm pores (Falcon; BD Biosciences, NSW, Australia) and 10% FCS 
was added to the lower well as a chemoattractant. For invasion assays, the upper 
surfaces of the inserts were coated with growth factor-reduced synthetic extracellular 
matrix (ECM) Matrigel (BD Biosciences), where 50 uL Matrigel (10ug/ml) was 
overlaid with 200 uL ice-cold PBS and left in the incubator at 37°C overnight to set. 
Two hundred thousand cells from each cell line were seeded in 400 µL serum-free 
medium containing 0.1% (w/v) bovine serum albumin (BSA) with or without ghrelin 
or obestatin (0, 10 nM and 100 nM) into the top chamber of the well and incubated 
for 24 h (for migration assays), or 48-72 h (for invasion assays). Control inserts 
containing 400 µL serum-free medium with 0.1% (w/v) BSA were also set up to 
demonstrate any background staining. After these incubation periods, cells remaining 
on the upper surface of the insert were removed using a cotton bud. To quantify the 
number of cells that migrated, or invaded cells on the underside of the insert, cells 
were fixed with 100% ice-cold methanol and stained with 1% (w/v) crystal violet. 
After washing, the stain was extracted from the cells using 10% (v/v) acetic acid and 
absorbance (595 nm) measured. For each experiment 3 replicates per treatment were 
performed and the experiments were repeated independently 3 times. Standard 
curves for cell number were also performed in 96 well plates with the same fixing 
and staining protocol to confirm that cell number was proportional to absorbance. 
 
2.6 Attachment assay  
Attachment assays were performed using a modified version of protocols reported by 
Festuccia et al. (1999) and Romanov et al. (1999) [517, 518]. Cells were pre-treated 
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Plates with 96 wells were coated overnight with purified ECM molecules and 
basement membrane components, fibronectin (BD Biosciences), vitronectin (BD 
Biosciences), collagen I (Calbiochem; EMD Biosciences, Merck PTY, Kilsyth, 
Victoria, Australia) or collagen IV (Calbiochem; EMD Biosciences, Merck PTY), 
diluted to a concentration of 10 µg/mL (50 µL/well) in RPMI, or DMEM/F12 
(medium without additives). Matrix solution was overlaid with ice-cold PBS to 
prevent the coating from drying out and to ensure an even coating. After overnight 
incubation, PBS was removed and non-specific binding sites were blocked with 1% 
(w/v) BSA. Cells from each cell line (20 000 cells per well) were seeded in 100 µL 
serum-free medium with 0.1% (w/v) BSA into each well of the matrix coated plate or 
in a BSA blocked only plate (for background adherence) and incubated for 1 h at 37 
ºC. A third plate with no coating or blocking was also seeded with cells (including 
5% FCS) and incubated for 5 h to ensure total cell attachment to estimate the 
absorbance of total cell adherence (100% plate). After 1h, or 5 h, media was 
aspirated from the wells and the cells carefully washed twice with PBS to remove 
any non-adhered cells. Adherence was then determined by staining the cells using 
CyQuant, as per the manufacturer’s instructions. Results were corrected for 
background attachment and expressed as a percentage of adhesion to the 100% plate, 
a representation of 100% potential adhesion. The assay was performed in triplicate 
with 3 independent replicates of each ECM molecule per assay. 
 
2.7 Western immunoblotting using anti-phosphorylation antibodies  
Western analysis was performed using an antibody for activated (phosphorylated) 
ERK1/2 to determine if ghrelin treatment activates this signalling pathway. Ovarian 
cells were seeded at 3 x10
5
 cells/well in 6-well plates. After 48h, cells were 
incubated in phenol red free medium without FCS for 24 h. To determine an 
appropriate time-point to investigate ERK1/2 signalling, cells were treated with 
ghrelin or obestatin (0, 10 or 100 nM) and incubated for 0, 5, 15, 30, 45, or 60 min 
and whole cell lysates were collected for Western analysis. A time-point at which 
strong stimulation of ERK1/2 occurred was determined to be 15min for the SKOV3 
ovarian cancer cell line and 30min for the OV-MZ-6 cell line. This is consistent with 
another study in porcine ovarian co-culture cells that observed maximum stimulation 
of phospho-ERK 1/2 levels after 15 min of cell incubation [509]. To determine if the 
ERK1/2 signalling is dose dependent, cells were also treated with a range of ghrelin 
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or obestatin concentrations (0, 0.1, 1, 10,100 and 1000nM) at the timepoint where 
maximal activation occurred for each cell line. 
 
Whole cell lysates were collected using lysis buffer consisting of 20 mM Tris, pH 
7.5, 150 mM NaCl, 1% (w/v) Triton X-100, 1 mM EDTA, 1 mM EGTA, 50 mM 
beta-glycerophosphate, 50 nM NaF, complete EDTA-free protease inhibitor cocktail 
(Roche) and Phosphate Inhibitor Cocktail 2 (Sigma-Aldrich). Lysates were vortexed, 
and centrifuged (10000 x g for 20 min at 4 ºC) to remove cell debris and protein 
content was estimated using a biciconinic acid kit (BCA), according to the 
manufacturer’s instructions (Pierce Protein Research Products, Thermo Fisher 
Scientific, Victoria, Australia). Protein lysate samples (30 μg) were boiled in loading 
buffer (0.1 M Tris, pH 6.8, 4% (v/v) SDS, 20% (v/v) glycerol, 0.2% (w/v) 
bromophenol blue, 10 mM DTT) for 5 min, and samples were electrophoresed using 
11% (w/v) SDS polyacrylamide reducing gels in Laemmli buffer (0.0255 M Tris, 
0.25 M glycine, 0.1% (w/v) SDS, pH 8.3). The proteins were transferred onto 
nitrocellulose membranes (Schleicher and Schuell; Medos, Mt Waverley, Victoria, 
Australia) in Tris-Glycine buffer (25 mM Tris, 40mM Glycine, 10% (v/v) methanol) 
at 350 mA for 90 mins at 4 ºC. The membrane was blocked with 5% (w/v) skim milk 
or 2.5% (w/v) BSA (Sigma) in TBS-Tween 20 (0.05 M Tris, 0.25 M NaCl, pH 7.4, 
0.05% (v/v) Tween-20) for 1 h at room temperature to prevent non-specific binding.  
 
Western immunoblotting for signalling molecules was performed using primary anti-
human antibodies (Cell Signalling, Genesearch, Arundel, Qld, Australia), mouse 
anti-phospho-p44/42 MAPK (Thr202/ Tyr204) (E10) and rabbit anti-p44/42 MAP 
Kinase antibodies. Anti-phosphorylated ERK1/2 antibodies were used at a 
concentration of 1:2000 and antibodies against total ERK1/2 protein at 1:5000. 
Mouse anti-Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH, MAB374, 
Chemicon, 1:20000) was used to demonstrate even protein loading. The 
nitrocellulose membranes were incubated overnight with primary antibody at 4 ºC, 
(diluted in either 5% (w/v) skim milk or 2.5% (w/v) BSA (Sigma) in TBS-Tween 
20). Membranes were washed with TBS-Tween 20, then incubated for an hour at 
1:5000 with either goat anti-rabbit (Thermo Fisher Scientific, Victoria, Australia), or 
goat anti-mouse (Pierce) horseradish peroxidase-conjugated IgG as the secondary 
antibody. After further washing in TBS-Tween 20 for 5 x 5 min, blots were 
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incubated with West Femto chemiluminescent substrate (Pierce) for 5 min and 
exposed to X-ray film which was developed using a Curix 60 automatic developer 
(Agfa, Stafford, QLD, Australia).  
2.7.1 Densitometry 
Western immunoblots were quantitated by scanning the X-ray film and analysing 
images using the Image J software program [519]. The Image J software generates a 
profile plot based on the intensity of the band of interest, quantitates the area under the 
curve and exports the values to Excel. These values were used for comparisons of 
band intensity using the GraphPad Prism v.5.01 software (GraphPad Software, Inc., 
San Diego, CA). 
 
2.8 Statistics 
Statistical analyses were undertaken using GraphPad Prism v.5.01 software 
(GraphPad Software, Inc., San Diego, CA). For proliferation, migration, invasion and 
attachment assays, statistical significance was determined using one-way ANOVA, 
































Ghrelin stimulates cell migration in ovarian cancer 




Ghrelin is a multifunctional hormone with a wide range of effects, including the 
potent stimulation of appetite and a role in regulating gut motility, metabolism and 
energy balance [1, 125, 126]. Ghrelin also has roles in regulating the reproductive, 
cardiovascular and immune systems and has effects on sleep, memory and mood [4, 
337]. The ghrelin axis has potential as a therapeutic target for inflammation and heart 
disease [4] and may be useful in treating cachexia, which is associated with a number 
of diseases including cancer [360, 520]. Ghrelin also appears to have a role in cancer 
and stimulates processes related to cancer progression including cell proliferation 
[17, 25, 38-40, 47-49, 54, 56, 57], and cell migration and invasion [48, 54] and it also 
has anti-apoptotic effects [47, 49, 52].  
 
Ghrelin circulates in the plasma as acylated ghrelin, and as a non-octanoylated form, 
desacyl ghrelin [1]. The octanoylation of ghrelin is mediated by the enzyme, ghrelin 
O-acyltransferase (GOAT) [2, 3, 122]. Octanoylated ghrelin acts through the type 1a 
isoform of the growth hormone secretagogue receptor, GHSR1a, while GHSR1b is a 
truncated isoform, does not bind ghrelin and was originally thought to be non-
functional [1, 185]. There is evidence, however, that the GHSR1b isoform could 
regulate the expression and action of the GHSR1a [521-523]. Ghrelin and desacyl 
ghrelin are also thought to act through an alternative ghrelin receptor, as a number of 
studies have demonstrated that they function in the absence of GHSR1a expression 
[38, 44, 50, 51]. Although originally thought to be an inactive form of ghrelin, 
desacyl ghrelin has a number of functions in common with ghrelin, such as the 
modulation of proliferation [38-40, 56, 57]. Desacyl ghrelin can also have the 
opposite effect to ghrelin, for example it inhibits gastric emptying, while ghrelin 
promotes emptying [204, 261-263]. 
 
Ghrelin has also been demonstrated to have functional effects in cancer, and the most 
studied of these is its role in proliferation. It stimulates cell proliferation in a number 
of cancer cell lines including prostate cancer [39], breast cancer [17], and 
endometrial cancer cell lines [49], although ghrelin inhibits cell proliferation in 
adrenocortical carcinoma [53], thyroid carcinoma [44, 56] and prostate cancer [38] 
cell lines. Ghrelin treatment has been shown to stimulate cell proliferation, acting 
through the ERK1/2 MAPK (mitogen-activated protein kinase) pathway in a number 
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of cell lines, including prostate cancer [39, 40], pituitary tumour cells [57] and 
hepatoma cell lines [25]. Inhibition of the ERK1/2 signalling pathway, using ERK1/2 
inhibitors, reversed ghrelin-stimulated proliferation in prostate cancer cell lines [40].  
 
It has also been recently demonstrated that ghrelin may stimulate cell migration in 
some cancer cell types [16, 48, 54, 55]. Studies that have used exogenous ghrelin 
treatments, inhibited endogenous ghrelin with a ghrelin antibody, used antagonists 
for GHSR1a, or inhibited ghrelin signalling pathways have demonstrated that ghrelin 
stimulates cell migration, or induces a motile phenotype in a number of cell types 
[16, 48, 54, 55, 190]. Ghrelin stimulates migration in some normal cell types, 
including human microvascular endothelial cells (HMVEC) [174], and cardiac 
microvascular endothelial cells (CMECs) [171]. Although a number of studies have 
shown that ghrelin stimulates migration, there have been few studies investigating 
the signalling pathways that mediate this response and there is little consensus. In a 
study of glioma cells, ghrelin-mediated migration was attenuated by inhibition of the 
calcium/calmodulin-dependent kinase II (CaMKII), AMP-activated protein kinase 
(AMPK), and nuclear factor-kappaB (NF-κB) signalling pathways [55]. In pancreatic 
adenocarcinoma cell lines, increased motility, in addition to increased invasiveness 
and proliferation, coincided with increased phosphorylation of Akt [54]. In this 
study, however, inhibition of Akt phosphorylation downregulated proliferation and 
invasion, but not cell motility. Cell motility and invasiveness were suppressed by 
Wortmannin, a phosphoinositide 3 kinase (PI3K) inhibitor [54]. Motility of 
astrocytoma cell lines was mediated by an increase in intracellular calcium 
mobilisation and PKC activation [16]. In normal cell types, ghrelin-stimulated 
migration, proliferation and angiogenesis in CMECs and in HMVECs was 
accompanied by increased ERK1/2 signalling [172, 174].  
 
Currently, the role of ghrelin in ovarian cancer is unknown. Ghrelin treatment has 
previously been shown to stimulate ERK1/2 activation in the SKOV3 ovarian cancer 
cell line and this was linked to an anti-apoptotic effect when apoptosis was induced 
by Paris Saponin I [524]. Interestingly, serum acylated ghrelin levels were elevated 
in a small study of patients with ovarian cancer and benign ovarian tumours [114], 
indicating that ghrelin could be a useful serum marker for ovarian cancer, or play a 
role in ovarian cancer development. There were a number of limitations to this study, 
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however, including small sample size. In a recent immunohistochemical study, 
ghrelin expression was demonstrated in a range of malignant serous ovarian tumours 
and was elevated compared to benign ovarian tumour specimens [380]. It is unclear 
if elevated plasma levels could be correlated with increased levels of expression in 
ovarian cancer, however, it is possible that ghrelin expressed by ovarian cancer cells 
could act as an autocrine/paracrine factor. GHSR1a expression has been 
demonstrated immunohistochemically in a number of ovarian pathologies, including 
inclusion cysts from the ovarian surface epithelium and in benign serous ovarian 
tumours [45]. GHSR1b expression has not been investigated in ovarian cancer, 
however, it has been demonstrated in other cancers including breast [17], lung [29] 
and colon [19, 20, 48] tumours.  
 
Epithelial ovarian cancers, derived from the ovarian surface epithelium, are the most 
fatal of all gynaecological cancers and they are frequently highly metastatic [525, 
526]. Ovarian cancer presents with few symptoms, particularly during initial tumour 
development, and, therefore, ovarian cancer is difficult to diagnose at a low tumour 
grade [66]. This contributes to the poor prognosis for many ovarian cancer patients, 
and two thirds of ovarian cancer patients are not diagnosed until the late stages of 
cancer development, (at either stage III or IV) [61]. The development of new markers 
for the early diagnosis of ovarian cancer and better adjunct treatments would lead to 
better patient outcomes.  
 
In this study we examined the expression of ghrelin, GHSR1a, GHSR1b and GOAT 
in ovarian cancer cell lines and tissues. We investigated the effect of exogenous 
ghrelin treatment on cell proliferation, migration, invasion and attachment, which are 
key processes in cancer progression in ovarian cancer cell lines [393]. We also 
investigated whether ghrelin stimulated the ERK1/2 signalling pathway in the 
ovarian cancer cell lines.  
 
3.2 Materials and methods 
 
3.2.1 Statement of contribution 
The practical work described in this Chapter was performed through a collaboration 
between the candidate, Carina Walpole, and Dr Inge Seim. Dr Inge Seim performed 
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the quantitative real time RT-PCR and RT-PCR of the tissues and cell lines (Results 
3.3.1) while the candidate performed all other experiments.  
 
3.2.2 Cell lines and Cell culture 
In this study assays were performed using the SKOV3 human epithelial ovarian 
serous adenocarcinoma cell line [511], the hOSE 17.1 human normal ovarian surface 
epithelium-derived cell line [512] and the OV-MZ-6 human epithelial ovarian serous 
adenocarcinoma cell line [510]. The SKOV3, OV-MZ-6 and hOSE 17.1 cell lines 
used in this study were propagated as described in the General Methods, Chapter 2.1.  
 
3.2.3 Expression of ghrelin axis components at an mRNA level in ovarian cell 
line and tissues. 
 
3.2.3.1 Quantitative real-time RT-PCR of tissue mRNA 
Real-time RT-PCR was performed to quantify expression levels of ghrelin (GHRL), 
GHSR1a and GOAT (MBOAT4) mRNA expression (as described in Chapter 2.3.3) 
using cDNA from normal ovary and from ovarian cancer patients using tissue cancer 
panels (OriGene TissueScan qPCR Ovarian Cancer panel II, OriGene, Rockville, 
MD). This array consists of pathologist-verified samples from eight non-tumour 
ovarian tissues and 40 different ovarian tumours.   
 
3.2.3.2 RT-PCR of cell line mRNA 
RT-PCR was used to determine the expression of components of the ghrelin axis 
(Table 3.1) in the normal and cancer ovarian cell lines. RNA was extracted and 
cDNA synthesised from SKOV3 and OV-MZ-6 cancer cell lines and normal hOSE 
17.1 cell lines (as described in Chapter 2.3). RT-PCR was performed using cDNA 
from the normal ovary and from ovarian cancer cells (as described in Chapter 2.3). 
Stomach tissue was used as a positive control and negative control RT-PCRs were 
also performed where template was substituted with water.  
 
3.2.4 Cell proliferation assays  
WST-1 and CyQuant cell proliferation assays were performed as described (Chapter 
2.4) using the SKOV3 and OV-MZ-6 ovarian cancer cell lines and hOSE 17.1 
normal-derived cell line with the addition of a range of acylated ghrelin 
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concentrations (0, 0.1, 1, 10, 100 and 1000 nM) and no treatment controls (0 nM). 
Each treatment (and control) was performed using 16 replicate wells and each 
experiment was performed independently at least 3 times.  
 
3.2.5 Cell migration and invasion assays 
Migration and invasion assays were performed (as described in Chapter 2.5) using 
the SKOV3 and OV-MZ-6 ovarian cancer cell lines and the hOSE 17.1 normal-
derived ovarian cell line. For invasion assays, the upper surfaces of the inserts were 
coated with growth factor-reduced extracellular matrix (ECM) Matrigel (BD 
Biosciences). Cells were seeded in the upper chamber of the Transwell in FCS-free 
0.1% BSA growth media, with or without ghrelin (0, 10 and 100 nM). Additional 
controls were performed to determine background staining using inserts without 
cells, containing medium only. For each experiment, 3 replicates per treatment were 
performed and the experiments were repeated independently 3 times. 
 
3.2.6 Attachment assays 
To assess whether ghrelin treatment had any effect on cellular attachment, the hOSE 
17.1 normal ovarian cell line and OV-MZ-6 and SKOV3 ovarian cancer cell lines 
were treated and then tested for their ability to attach to extracellular matrix (ECM) 
proteins fibronectin, vitronectin, collagen I and collagen IV. Attachment assays were 
performed as described in Chapter 2.6. The assay was performed in triplicate with 3 
independent replicates of each ECM molecule per assay. 
 
3.2.7 Western immunoblotting using anti-active antibodies for ERK1/2 
Western analysis was performed as previously described (Chapter 2.7) using an anti-
active antibody for phosphorylated ERK1/2 to determine if ghrelin treatment 
activates this signalling pathway. To determine if ERK1/2 signalling is dose 
dependent, cells were treated with ghrelin (0, 0.1, 1, 10,100 and 1000 nM).   
 
3.2.7 Statistics 
Statistical analyses (one way ANOVA with post hoc tests) were undertaken using 







3.3.1 Expression of the ghrelin axis in normal ovary, ovarian tumour tissue and 
in ovarian cell lines 
Using quantitative, real-time RT-PCR analysis we have demonstrated that ghrelin 
(Fig. 3.1) and the enzyme that octanoylates ghrelin, GOAT, are expressed in normal 
ovarian tissue and in a range of ovarian cancer tissues (Fig. 3.2). We investigated 
expression in a range of cancer stages (I-IV), where increasing stage reflects the 
transition of cells from a confined tumour to a metastasised cancer [65]. There was 
no clear correlation between cancer stage (stages I-IV) and the level of ghrelin or 
GOAT mRNA expression, although more than two times the level of expression of 
ghrelin and/or GOAT was observed in 7/34 ovarian cancer samples, compared to 
normal tissue. Using primers in exons 1 and 2 of the GHSR, expression of ghrelin 
receptor (GHSR1a) mRNA was not observed in any of the normal or cancer ovarian 
tissues examined using the Origene panel (data not shown).   
 
In order to investigate the expression of ghrelin in ovarian cell lines and to 
characterise a model for further functional analyses, we examined the mRNA 
expression of ghrelin, GOAT and the ghrelin receptor isoforms, GHSR1a and 
GHSR1b, using RT-PCR. Full-length preproghrelin (exon 1 to 4) and GOAT were 
expressed at the mRNA level in the SKOV3 and OV-MZ-6 ovarian cancer cell lines 
and in the hOSE 17.1 normal ovary derived cell line, giving RT-PCR products of the 
expected sizes (Fig. 3.3). In addition, the exon 3 deleted preproghrelin isoform [17] 
was also detected by RT-PCR in the SKOV3 ovarian cancer cell line (191 bp 
product, Fig. 3.3). A 433 bp product for GHSR 1b mRNA was expressed in the OV-
MZ-6 and SKOV3 ovarian cancer cell lines, but not in the hOSE 17.1 normal ovary-
derived cell line (Fig. 3.3). As expected, the no-RT control failed to amplify RT-PCR 
product, demonstrating that the GHSR1b cDNA was not amplified from 
contaminating DNA. GHSR1a mRNA was not expressed in any of the cell lines 
examined, but a product of the expected size was observed in the positive control 
from stomach tissue (Fig. 3.3). Positive controls gave bands of the expected size for 
β2 microglobulin, demonstrating the integrity of the cDNA used in these assays for 
the three cell lines and the no-template, negative controls failed to amplify product. 






Figure 3.1 Quantitative RT-PCR analysis of GHRL exon 1-2 expression in 
normal and stage I to IV ovarian cancer. Relative expression of ghrelin (GHRL 
exon 1-2) mRNA in normal ovary (N) and in stages I-IV of ovarian cancer was 
determined using quantitative real-time RT-PCR using an Origene TissueScan 
ovarian cancer panel. Data were normalised to β-actin, quantified using 2-(∆Ct sample-∆Ct 
control)
, and represented as fold change relative to expression of transcripts in a normal 
ovarian tissue sample (1.0). Bars indicate mean +/- SEM. 
 






Figure 3.2 Quantitative RT-PCR analysis of GOAT expression in normal and 
stage I to IV ovarian cancer. Relative expression of GOAT (MBOAT4) mRNA 
transcripts in normal ovary (N) and ovarian cancer samples (stages I-IV) was 
determined using quantitative real-time RT-PCR using an Origene TissueScan panel. 
Data were normalised to β-actin and are represented as fold changes relative to 
expression of transcripts in a normal ovarian tissue sample (1.0) and quantified using 
the equation 2
-(∆Ct sample-∆Ct control)
. Negative control RT-PCRs were also performed 
where template was substituted with water (data not shown). Bars indicate mean +/- 
SEM.  
 





Figure 3.3 Preproghrelin and GOAT (MBOAT4), but not GHSR1a, are 
expressed at the mRNA level in the OV-MZ-6 and SKOV3 ovarian cancer cell 
lines and in the hOSE 17.1 normal derived ovarian cell line. Ethidium bromide 
stained agarose gels demonstrating RT-PCR products of the expected size for ghrelin 
(300 bp), GHSR1a (125 bp), GHSR1b (433 bp) and GOAT (168 bp). The GHSR1b 
mRNA isoform is expressed in the SKOV3 and OV-MZ-6 cancer cell lines, but not 
in the normal-derived hOSE 17.1 cell line. An exon 3 deleted preproghrelin isoform, 
represented by a 191 bp product, is also expressed in the SKOV3 ovarian cancer cell 
line (and may be seen as a very faint band). The identity of these products was 
confirmed by cDNA sequencing. Human stomach tissue RNA was used as a positive 
control (+ve) for ghrelin, GHSR1a and GOAT expression, while the PC3 prostate 
cancer cell line was the positive control tissue for GHSR1b. As the GHSR1b isoform 
contains intronic sequence, RT-PCR was performed using RNA samples that were 
not reverse transcribed (+/-RT) as a control for genomic DNA contamination. 
Negative controls, where template was replaced with water, were used for all RT-
PCRs and no products were amplified. RT-PCRs for the β2 microglobulin 
housekeeping gene were performed to ensure that cDNA was present in the 
reactions. M = molecular weight marker.  
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3.3.2 Cell migration assays 
As ghrelin has also been demonstrated to stimulate cell migration in a number of cell 
types [16, 48, 54, 55, 171, 174], we investigated the role of ghrelin in stimulating cell 
migration of the SKOV3 and OV-MZ-6 ovarian cancer cell lines and the hOSE 17.1 
normal ovary-derived cell line. Ghrelin treatment (100 nM) significantly increased 
cell migration across the membrane in Transwell assays in the SKOV3 and OV-MZ-
6 ovarian cancer cell lines after 24 hours (P <0.05) compared to untreated controls. 
Ghrelin treatment led to an increase of 3.92 +/- 2.15 fold in the SKOV3 cell line and 
1.77 +/- 0.30 fold in the OV-MZ-6 cell line compared to the control (Fig. 3.4). No 
significant difference was seen with the 10 nM ghrelin treatment in these cell lines, 
and ghrelin had no significant effect on cell migration in the hOSE 17.1 normal 








































































SKOV3 OV-MZ-6 hOSE 17.1
 
 
Figure 3.4 Ghrelin stimulates cell migration in ovarian cancer cell lines. 
Transwell migration assays were performed with SKOV3 and OV-MZ-6 ovarian 
cancer cell lines and compared to the normal-derived ovarian surface epithelial cell 
line hOSE 17.1. Ghrelin (100 nM) stimulated cell migration in the SKOV3 and OV-
MZ-6 ovarian cancer cell lines, but not in the hOSE 17.1 normal ovary-derived cell 
line in Transwell assays with 8 µm pore membranes over 24 h. Migration was 
assessed by staining migrated cells with 1% crystal violet, and absorbance measured 
as a representation of the number of migrated cells. Graph represents mean fold 
change +/- SEM. *P < 0.05, assessed by Tukey’s post hoc test, compared to 0 nM 






3.3.3 Cell invasion assays 
As we demonstrated that treatment with ghrelin increases migration in ovarian cancer 
cell lines, we performed Transwell invasion assays to determine if ghrelin also alters 
the rate of cell invasion through Matrigel. No significant difference in invasion was 
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Figure 3.5 Ghrelin treatment did not alter cell invasion in the SKOV3 and OV-
MZ-6 ovarian cancer cell lines and the hOSE 17.1 normal ovarian epithelial-
derived cell line in Transwell invasion assays (where the membrane was 
overlaid with Matrigel). Transwell assays were performed over 48 h (SKOV3 and 
OV-MZ-6) or 72 h (hOSE 17.1). Mean absorbance +/- SEM. *P <0.05 compared to 0 
nM control using one way ANOVA and Tukey’s post hoc comparisons. n = 3 repeat 
experiments with 3 replicates per experiment. 
 
3.3.4 Cell proliferation assays 
As we have previously demonstrated that ghrelin stimulates cell proliferation in a 
range of cell lines, including breast [17], prostate [39] and endometrial cancer [49], 
we investigated the effect of a range of concentrations of ghrelin on cell proliferation 
in ovarian cell lines, using both a metabolic-based assay, WST-1, and a DNA-based 
assay, CyQuant. In contrast to our studies in other cell lines, no statistically 
significant changes in proliferation were observed in the SKOV3 or in the OV-MZ-6 


































































































































































































Figure 3.6 Ghrelin treatment does not stimulate cell proliferation in normal, or 
ovarian cancer cell lines. Histograms demonstrate that ghrelin (0-1000 nM) does 
not stimulate cell proliferation assays in the SKOV3 and OV-MZ-6 ovarian cancer 
cell line and the hOSE 17.1 ovarian cell line. Cell proliferation was measured using a 
CyQuant (DNA- based) assay and WST-1 (metabolic-based) cell proliferation assays 
and expressed as fold change over the untreated control (0 nM). No statistically 
significant differences were observed (one way ANOVA). Histograms represent 
combined data from n = 3 repeats with 16 replicates per independent experiment. 































3.3.5 Cell attachment assays 
To determine if ghrelin had an effect on cell adhesion, a process which is required by 
ovarian cancer cells to allow them to attach to the peritoneum and to grow at this 
distant site [527, 528], we performed attachment assays using a range of extracellular 
matrix proteins. The SKOV3 and OV-MZ-6 ovarian cancer cell lines and hOSE 17.1 
normal-derived cell line were cultured in the presence and absence of acylated 
ghrelin (0, 10 and 100 nM) and then assessed for their ability to adhere to the 
extracellular matrix proteins, fibronectin, vitronectin, collagen I and collagen IV 
(Fig. 3.7). A statistically significant mean 24.7 +/- 10.0 % decrease in adhesion to 
collagen IV was observed with the 10 nM ghrelin treatment in the SKOV3 ovarian 
cancer cell line (Fig. 3.7) (P <0.05). No significant changes were seen with any of the 
other matrix molecules, cell lines or concentrations of ghrelin tested. 
 
3.3.6 Ghrelin signalling assays 
Ghrelin is known to stimulate activation of the ERK1/2 pathway [169, 178, 180, 183] 
and a number of studies have shown that it mediates the effects of ghrelin on cell 
proliferation [25, 40, 57, 168-172]. It has been previously demonstrated that ovarian 
cell lines have a low level of basal ERK1/2 expression [529], and therefore, we 
investigated the activation of ERK1/2 by ghrelin. In the SKOV3 cell line, 100 nM 
ghrelin treatment resulted in a statistically significant decrease (0.58 fold +/- 0.23) in 
ERK1/2 phosphorylation compared to the untreated control (P <0.05) (Fig. 3.8). In 
the OV-MZ-6 cell line, ghrelin treatment caused a small, non-statistically significant 
increase in ERK1/2 phosphorylation at lower concentrations (0.1, 1 and 10 nM) and 
with 100 and 1000nM ghrelin treatments, decreased phosphorylation of ERK1/2 was 
observed compared to the untreated control, but this was not statistically significant. 
A dose-dependent increase in ERK1/2 phosphorylation in response to ghrelin 
treatment has been described in other studies [40, 169] 
 
3.4 Discussion 
We have demonstrated for the first time that ghrelin is expressed at the mRNA level 
in human ovarian cancer cell lines and in ovarian cancer specimens. Ghrelin 
treatment stimulates cell migration, but not proliferation, or invasion in the SKOV3 
and OV-MZ-6 serous ovarian cancer cell lines. Ghrelin may also influence the 











































































































































Figure 3.7 Attachment assays for SKOV3 and OV-MZ-6 ovarian cancer cell 
lines and the hOSE 17.1 normal ovarian epithelial cell line in response to ghrelin 
treatment. Attachment was measured using the CyQuant assay as a direct 
representation of the number of cells attached. Results are shown as a mean 
percentage (minus background) of the total number of cells that could possibly 
adhere to the uncoated 100% adherence plate with the aid of serum +/- SEM. *P 
<0.05, One way ANOVA and Tukey’s post hoc test, compared to 0 nM control. n = 3 
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Figure 3.8 Western immunoblot analysis of ERK1/2 phosphorylation after 
ghrelin treatment in the SKOV3 and OV-MZ-6 ovarian cancer cell lines. Serum-
starved cells were treated with a range of ghrelin concentrations (0, 0.1, 1, 10,100, 
and 1000 nM) for 15 min in the SKOV3 cell line and for 30 mins in the OV-MZ-6 
cell line (determined as the peak ERK1/2 signalling time points for these cell lines). 
Representative Western immunoblot of triplicate experiments showing cell lysate 
analysed using anti-phosphorylated ERK1/2 and anti-total ERK1/2 antibodies in the 
(A) SKOV3 and (B) OV-MZ-6 ovarian cancer cell lines. Densitometry was 
performed to quantify the changes in protein expression with different ghrelin 
treatments in the (C) SKOV3 and (D) OV-MZ-6 ovarian cancer cell lines. The 
densitometry data are a mean of triplicate experiments (n = 3) (mean +/- SEM), 
corrected for total ERK1/2 present in each protein extract. *P <0.05 compared to 0 
nM control using one way ANOVA and Tukey’s post hoc test. 
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protein. Ghrelin may, therefore, play a role in ovarian cancer progression.   
 
We have demonstrated that ovarian cancer cell lines and tissues express ghrelin 
mRNA, although expression was not correlated with the clinical stage of the 
specimens examined. It should be noted, however, that in this study the fold changes 
in expression are compared to normal ovarian samples. The normal tissue samples 
used are derived from the whole ovary and may contain little, if any ovarian surface 
epithelium, from which most ovarian cancers are derived. We have previously 
demonstrated the expression of ghrelin protein in normal ovarian specimens using 
immunohistochemistry [155]. In a recent semi-quantitative immunohistochemical 
study of serous ovarian tumours, ghrelin expression was increased in malignant 
tissue (n = 20) compared to benign samples (n = 20) [380]. In a small study, patients 
with benign ovarian tumours (31 patients) and ovarian cancer (22 patients) had 
higher blood levels of acylated ghrelin compared to a control group of women (n = 
32), while the levels of total ghrelin were similar [114]. These authors concluded that 
elevated ghrelin plasma levels could indicate that ghrelin plays a role in the 
progression of ovarian cancer [114], although larger studies are clearly required to 
confirm these findings. As circulating ghrelin levels are strongly inversely correlated 
to body mass index (BMI), and ghrelin levels are elevated in cancer-related cachexia 
[530-532], ghrelin levels should be corrected for BMI. It is possible that ghrelin may 
be secreted from the ovarian tumours themselves.  
 
GHSR1a mRNA was not found to be expressed in normal and cancerous ovarian cell 
lines and tissues, however, GHSR1b is expressed in the cell lines tested. Previous 
studies showed that GHSR1a protein could be detected in oocytes, as well as in 
somatic follicular cells, luteal cells from young, mature, old, and regressing corpora 
lutea, and interstitial hilus cells and strongly in the granulosa and thecal layers of 
healthy antral follicles of the normal ovary [155]. Expression has also been 
demonstrated in the ovarian surface epithelium and Műllerian duct derivatives, as 
well as in benign serous tumours resembling Fallopian tube epithelium and highly 
differentiated serous cystadenocarcinomas. It was not expressed in other ovarian 
neoplasms, such as mucinous cystadenomas, cystadenocarcinomas, endometrioid 
tumours, clear cell carcinomas, or Brenner’s tumours [45]. In this study, GHSR1a 
was also not expressed in high grade serous cystadenocarcinoma, and this lack of 
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expression was also observed for the ovarian cancer cell lines used in this study 
which are both derived from high grade serous ovarian cancers. These previous 
studies demonstrated GHSR1a expression at a protein level using 
immunohistochemistry, whereas in this study expression was examined at an mRNA 
level and this may account for the differences in results. It is possible, but unlikely 
that GHSR1a mRNA levels were too low to detect in our studies. Alternative 
GHSR1a isoforms may be expressed by ovarian tissue, or the antibodies used in our 
previous studies may be non-specific, or detect related receptors [533].  
 
Ovarian cancer and ovarian cancer cell lines also express GOAT (MBOAT4) mRNA, 
which encodes the enzyme that octanoylates ghrelin [534], and this indicates that 
ovarian cancer cells may be able to produce octanoylated (acylated) ghrelin, which 
could then act as a local factor on the cancer cells. We have hypothesized that locally 
produced ghrelin in tumours may play a more important role in cancer progression 
than circulating ghrelin [15]. In order to investigate the role of autocrine/paracrine 
ghrelin in ovarian cancer, tissue levels of octanoylated ghrelin should be measured to 
determine if octanoylated ghrelin is secreted from ovarian cancer cell lines after cells 
are treated with octanoic acid. Octanoic acid treatment is thought to be required for 
cells to produce octanoylated ghrelin in culture [122]. The expression of ghrelin and 
GOAT needs to be confirmed at the protein level in ovarian cell lines using a number 
of techniques including immunohistochemistry, Western immunoblotting, ELISA or 
mass spectrometry.  
 
In this chapter it was demonstrated that ghrelin treatment increases the rate of cell 
migration in Transwell assays in the OV-MZ-6 and SKOV3 ovarian cancer cell lines, 
but not in the hOSE 17.1 normal-ovary derived cell line. While there have been a 
number of reports demonstrating that ghrelin treatment increases cell proliferation in 
normal and cancer derived cell lines [17, 25, 39, 47-51, 54, 57, 132, 168, 169, 175, 
178, 189, 205, 319, 322, 395, 403, 404, 406, 409, 414, 509, 535-544], only a few 
studies have demonstrated that ghrelin can influence cell migration [16, 48, 54, 174]. 
Cell migration involves the accumulation of actin filaments at the leading edge of the 
cell producing a physical force that extends the membrane in the direction of the 
motility [423]. This protruding leading edge then adheres to the substratum, allowing 
the retraction of the rest of the cell and de-adhesion of the trailing end of the cell, 
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producing a crawling like motion [423-425]. Studies using phalloidin (an actin stain) 
have shown increased cellular staining in the presence of ghrelin in rat hippocampal 
slice cultures [426, 545]. In human T cells, human astrocytoma cell lines and rat 
hippocampal slice cultures, ghrelin stimulates actin polymerization [16, 267, 426]. 
The increased phalloidin-binding to F-actin in the rat hippocampal slice cultures was 
stemmed by the use of a ghrelin receptor antagonist [426]. The examination of 
astrocytoma Dixit et.al. demonstrated increased motility with increased actin 
polymerisation and membrane ruffling on cells with ghrelin treatment [16]. Increases 
in intracellular calcium mobilization, PKC activation, MMP2 activity and co-
localization of the small GTPase, Rac1, with GHSR on the leading edge of the cells 
and membrane ruffling on cells were also observed [16]. Confocal microscopy of the 
ovarian cell lines could be performed to investigate whether the membrane ruffling 
observed in the astrocytoma cell lines [16] and accumulation of actin [16, 267, 426] 
also occurs in ovarian cancer cells. In the astrocytoma cell lines, increased migration 
was shown to be dependent on GHSR1a by disruption of the endogenous ghrelin-
GHSR pathway by siRNA [16]. Collectively, all of these studies suggest that ghrelin 
may influence the remodelling of cytoskeleton proteins, and actin specifically, in the 
process of migration. The GHSR1a is unlikely to be expressed, or play a role in cell 
migration in ovarian cancer cell lines, however.  
 
Ghrelin has actions in a number of cell types that do not express the ghrelin receptor, 
indicating that an unknown ghrelin receptor type exists [157, 178, 195, 196, 206, 
207, 248, 394, 546, 547]. Despite previously demonstrating that GHSR1a mRNA is 
expressed in prostate, endometrial and breast cancer [17, 39, 49], neither the ovarian 
cell lines examined in our study, nor the 48 clinical specimens tested, expressed 
GHSR1a mRNA. Therefore, ghrelin must stimulate cell migration in ovarian cancer 
cell lines by signalling through the hypothesized alternative ghrelin receptor [548]. 
GHSR does appear to play a role in migration and invasion in the SW-48 and RKO 
colorectal cancer cell lines, as GHSR antagonists inhibit these effects [48]. GHSR1a-
independent stimulation of cell migration may exist in malignant colorectal cells, 
however, GHSR1a expression is dramatically lost with malignancy and the effects of 
ghrelin on proliferation, migration and invasion must be mediated through the 




Differences in receptor expression between cell types and cell lines could explain the 
different responses to ghrelin treatment. This could be investigated further in ovarian 
cancer cell lines by expressing GHSR1a and investigating the effects of ghrelin on 
proliferation and migration for any changes in response. The alternative receptor is 
thought to bind both ghrelin and desacyl ghrelin, as both forms of ghrelin are 
functional and can differentially regulate processes such as proliferation [168, 175, 
422] and apoptosis [175, 177, 178, 415]. As the alternative receptor can bind both 
forms of ghrelin, it is may also be susceptible to GHSR1a antagonists. The GHSR1a 
inverse agonist, D-Lys3-GHRP-6, has been shown to inhibit desacyl ghrelin-
stimulated growth of HECa10 murine endothelial cells [549]. D-Lys3-GHRP-6 is 
also non-specific, as it also binds the CCR5 chemokine receptor [550]. This could 
explain why there was an inhibition of the ghrelin-stimulated migration in the study 
of colorectal cell lines treated with the ghrelin antagonist when it was unlikely the 
response was being mediated through GHSR1a [48].  
 
Ghrelin treatment did not alter cell invasion through Matrigel in the SKOV3, OV-
MZ-6 or hOSE 17.1 ovarian cell lines compared to controls in Transwell assays, and 
ghrelin may, therefore, not play a role in increasing cell invasion in ovarian cancer. 
In pancreatic and colon cancer cell lines, ghrelin has been shown to increase invasion 
through Matrigel in Boyden chamber assays [48, 54]. Conversely, in patients with 
oral squamous cell carcinoma (OSCC), decreased or absent expression of ghrelin in 
oral biopsy specimens was correlated with increased invasiveness of the disease [24].  
 
We have previously demonstrated that ghrelin stimulates cell proliferation in 
prostate, breast and endometrial cell lines [17, 40, 49], and other studies have 
demonstrated that ghrelin stimulates cell proliferation in a wide range of normal and 
cancer cell lines [17, 25, 39, 47-51, 54, 57, 132, 168, 169, 175, 178, 189, 205, 319, 
322, 395, 403, 404, 406, 409, 414, 535-544]. In contrast, ghrelin treatment did not 
stimulate cell proliferation in the SKOV3 and OV-MZ-6 cancer cell lines, or the 
normal ovarian cell line, hOSE 17.1, in this study. Ghrelin may have different actions 
in different cell types and some studies have also demonstrated that ghrelin can 
reduce proliferation, or have no effect on cell proliferation in other cell lines [18, 28, 
44]. Given that ghrelin has a very short half life, it is unlikely that proliferation is 
being masked by endogenous ghrelin in the culture medium [145, 146]. To confirm 
  
85 
this, however, knockdown studies should be performed to confirm that endogenous 
expression of ghrelin is not interfering with this assay and to investigate the role of 
endogenous ghrelin further. 
 
In addition to migration and invasion, epithelial ovarian cancer cell metastasis 
requires the attachment of cells to the mesothelium and invasion into the 
mesothelium of the peritoneum, which lines the peritoneal cavity [527, 551]. This 
attachment is aided by the fact that mesothelial cells express a number of ECM 
molecules, including fibronectin, vitronectin and collagen I on their cell surface 
[552-554]. They do not express collagen IV, which is usually a component of the 
basement membrane. To investigate if ghrelin may influence adhesion, attachment 
assays were performed using wells coated with ECM components (fibronectin, 
vitronectin, collagen I and collagen IV) and cells were treated with different 
concentrations of ghrelin. In this study, ghrelin did not alter attachment to 
fibronectin, vitronectin or collagen I, but a significant decrease in attachment to 
collagen IV was seen in response to 10 nM ghrelin in the SKOV3 ovarian cancer cell 
line, but not in the OV-MZ-6, or hOSE 17.1 cell lines. Although collagen IV is not 
expressed by the mesothelial cells themselves, this may aid attachment to the 
underlying basement membrane, which is also required for cells to invade through 
the peritoneum.   
 
Although there have been no studies in cancer, other studies have demonstrated that 
the ghrelin axis may play a role in cell adhesion in immune cells [268]. In 
atherosclerosis, ghrelin increased the adhesion of THP-1 monocytes to an endothelial 
cell line, but decreased adhesion when cells were also treated with tumour necrosis 
factor-alpha (TNF-α), indicating that ghrelin may play a different role during 
inflammation [555]. In THP-1 monocytes, ghrelin inhibited the expression of the cell 
adhesion molecules, vascular cell adhesion molecule-1 (VCAM-1) and monocyte 
chemoattractant protein-1 (MCP-1) [555]. This contrasts with another study in 
monocytes which showed an increase in ICAM-1 (VCAM-1 expression inter-cellular 
adhesion molecule 1) expression with ghrelin treatment [556]. Although increases in 
the expression of adhesion molecules were seen in this study, ghrelin did not alter 
monocyte adhesion itself, but ghrelin may contribute to atherogenesis [556]. Ghrelin 
has also been demonstrated to reduce the TNF-α stimulated adhesion of the U937 
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human lymphoma cell line to human umbilical vein endothelial cells (HUVEC) 
[268].  
 
Dysregulation of growth factor expression and signalling pathways in tumour cells 
often results in autocrine/paracrine effects that ultimately promote cancer cell 
processes, such as proliferation and migration [557-559]. Characterising the effects 
of growth factors in cancer cells may, therefore, provide important insight into their 
function in normal physiology and disease. A number of studies have implicated 
ghrelin as an autocrine/paracrine growth factor in human tumours, including breast 
cancer [17], prostate cancer [39, 40], colorectal cancer [48], thyroid cancer [43, 560], 
lung cancer [27], leukemia [51], hepatoma [25], astrocytoma [16], and pituitary 
adenoma [57]. Activation of the ERK1/2 MAPK pathway is one of the most widely 
studied ghrelin signalling pathways which mediates a number of cell processes 
including cell proliferation [25, 38-40, 57] and apoptosis [40] in cancer and in 
normal cell lines [168-172, 175-180]. Ghrelin acts through the ERK1/2 pathway to 
stimulate cell proliferation in a number of cell lines, including prostate cancer cell 
lines [40], 3T3-L1 adipocytes [404], human adrenal zona granulosa cells [542] and 
the rat GH3 cell line [57]. In all of these cell lines this action appears to be the 
downstream effect of activation of GHSR1a by ghrelin. Ghrelin also stimulates cell 
proliferation through the ERK1/2 pathway in the absence of GHSR1a in human 
osteoblasts, presumably through the alternative ghrelin receptor [168]. Ghrelin 
signalling through ERK1/2 also protects a number cell types against apoptosis, 
including oligodendrocytes, endothelial cells, beta pancreatic islet HIT-T15 cells and 
porcine ovarian follicular cells [179, 183, 509, 561].  
 
While ghrelin has previously been shown to increase ERK1/2 activation in the 
SKOV3 cell line at high concentrations (1 μmol/L) [529], the effect of ghrelin 
treatment on ERK1/2 activation has not been investigated in ovarian cell lines at 
physiologically relevant concentrations. In contrast, in this study we have 
demonstrated by Western blot analysis, that ghrelin does not activate ERK1/2 in 
ovarian cancer cell lines. In fact the 100nM ghrelin treatment down-regulated 
ERK1/2 phosphorylation in the SKOV3 ovarian cancer cell line. A similar effect was 
also seen with the OV-MZ-6 cancer cell line, although this was not statistically 
significant. This contrasts with many other studies in other cancer tissues which 
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demonstrate that ghrelin function is accompanied by increased ERK1/2 
phosphorylation, often in a dose-dependent manner [39, 40, 57]. These studies, 
however, demonstrated proliferative effects with ghrelin treatment rather than cell 
migration. Regulation of proliferation via the ERK1/2 signalling pathway is a well-
documented effect of ghrelin [25, 40, 57, 168-172] and is often accompanied by the 
expression of GHSR1a [25, 39, 40, 57, 171, 172]. Additionally, blocking GHSR1a 
results in a down regulation of ERK1/2 signalling [171, 172]. This correlates with the 
results of this study, as the ovarian cancer cell lines did not activate ERK1/2 or 
expressed GHSR1a and had no effect on proliferation.  
 
In studies of microvascular endothelial cells, migration has been shown to coincide 
with increased ERK1/2 phosphorylation [171, 172, 174]. In these studies, however, it 
was not determined whether inhibition of the ERK1/2 signalling affected cell 
migration, but it did decrease angiogenesis [171, 172, 174]. Ghrelin did stimulate 
migration in the ovarian cancer cell line, however, the lack of stimulation of the 
ERK1/2 phosphorylation by ghrelin in these cell line suggest that it is not involved in 
this response. 
 
A number of studies have investigated the pathways activated by ghrelin-stimulated 
cell migration. A study on glioma cells demonstrated that ghrelin-stimulated cell 
migration was primarily mediated through GHSR1a, and through calmodulin-
dependent protein kinase II (CaMKII), AMP-activated protein kinase (AMPK), and 
nuclear factor-kappa B (NF-κB) pathway [55]. Pancreatic adenocarcinoma cell lines, 
PANC1, MIAPaCa2, BxPC3 and Capan2, displayed an increase in Akt activation 
and an increase in cell migration after ghrelin treatment [54]. Ghrelin-stimulated 
migration in these pancreatic adenocarcinoma cell lines was inhibited by the 
GHSR1a antagonist, D-Lys3-GHRP-6, and the PI3-K inhibitor, Wortmannin [54]. 
Ghrelin-stimulated astrocytoma motility is mediated through GHSR1a signalling, 
resulting in an increase in intracellular calcium mobilization, PKC activation, actin 
polymerization and increased MMP2 activity [16]. Although ovarian cancer cell lines 
do not express the GHSR1a, these signalling pathways could be activated by the 
alternative ghrelin receptor and also play a role in ghrelin-stimulated cell migration. 
Investigation of these other pathways in the ovarian cell lines using Western blots 
analysis, or ELISA, and assaying phosphorylation of signalling molecules is required 
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to determine if they play a role in the ghrelin-stimulated migration seen in the 
ovarian cancer cell lines. It is very likely that ghrelin-stimulated cell migration is 
regulated by a number of different signalling pathways.  
 
Ovarian cancer is the most fatal gynaecological cancer and epithelial ovarian cancers 
are highly metastatic [562]. Ovarian cancers are more frequently diagnosed at a late 
stage in the disease and this contributes to a poor prognosis. Markers for the early 
detection of ovarian cancer and new therapeutic approaches are urgently required. In 
one small study, plasma ghrelin levels have been shown to be elevated in ovarian 
cancer patients [114] and it is feasible that elevated plasma ghrelin may promote cell 
migration and cancer progression in ovarian cancer patients. As ghrelin is expressed 
by ovarian cancer cells, autocrine or paracrine ghrelin may also play a role in ovarian 
cancer progression and knockdown studies in ovarian cancer cell lines would be 
helpful in elucidating the mechanism of action of ghrelin and confirming the results 
seen in this chapter.  
 
In conclusion, our present study demonstrates that normal ovarian surface epithelial 
cells and ovarian cancer cells and cell lines express ghrelin mRNA, but not GHSR1a. 
It would be useful to quantify the level of ghrelin expression in ovarian cancer 
tissues themselves by Western blot analysis, ELISA or mass spectrometry. Ghrelin 
was demonstrated to promote cell migration, but not proliferation in cultured ovarian 
cancer cell lines. Antagonizing the effects of ghrelin in ovarian cancer could provide 
a new additional therapeutic approach which could reduce the rate of ovarian cancer 























CHAPTER 4  
 
Expression and function of obestatin in ovarian 




Obestatin is a 23 amino acid peptide hormone which is derived from the ghrelin 
preprohormone [6] and encoded by the ghrelin gene (GHRL). Ghrelin and obestatin, 
two distinct peptide hormones, are both cleaved from the 117 amino acid 
preproghrelin peptide [1, 6, 116]. Ghrelin potently stimulates appetite [1, 563] and 
obestatin was initially thought to have the opposite effect of ghrelin on appetite [7]. 
This study has proven controversial, however, and many studies have failed to 
replicate the effects of obestatin on feeding [435, 442, 452-454, 461, 475, 480, 481, 
483-485, 490, 564, 565]. Although it was originally reported that GPR39, a G protein 
coupled receptor in the ghrelin receptor family, was the obestatin receptor, it is now 
clear that GPR39 is a zinc receptor and not the obestatin receptor [7]. The identity of 
the obestatin receptor is currently unknown [7]. Despite these controversies, 
however, it is clear that obestatin is a multifunctional hormone, and it may play a role 
in cancer progression [4, 7].  
 
Ghrelin appears to play an autocrine/paracrine role in processes related to cancer 
progression [15], including the stimulation of cell proliferation [17, 25, 39, 40, 49, 
51] and cell migration [16, 48, 54] and the inhibition of apoptosis [47, 49, 52]. The 
ghrelin preprohormone derived peptide, obestatin, may also play a stimulatory role in 
cancer-related processes. Obestatin stimulates cell proliferation in some cell lines, 
including retinal pigment epithelial cells [10] and the KATO-III gastric cancer cell 
line [11], but inhibits proliferation in other cell lines, including the TT-human 
medullary thyroid carcinoma cell line and the BON-1 pancreatic endocrine tumour 
cell line [56]. The preproghrelin peptide is transcribed in the ovary (Chapter 3.3.1) 
and using immunohistochemistry, it has been shown that the ghrelin receptor, 
GHSR1a, is expressed in ovarian cancer [45]. Obestatin expression has been 
demonstrated immunohistochemically in benign and malignant serous tumours [380]. 
Although obestatin levels were not elevated in malignant tumours, compared to 
benign tumours, the level of expression of obestatin in normal ovarian surface 
epithelium was unclear in this study [380]. Obestatin expression did not appear to 
correspond to tumour grade [380]. Additionally, octanoylated ghrelin and obestatin 
plasma levels are elevated in benign ovarian tumours and in ovarian cancer patients 
[114], however, it is not clear if the ovarian tumours are the source of the elevated 
obestatin levels.  
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Ovarian cancer is the leading cause of death for all gynaecological malignancies 
[566] and as there are few symptoms, ovarian cancer is difficult to diagnose at a low 
tumour grade [66]. As a result, two thirds of ovarian cancer patients are not 
diagnosed until the late stages of cancer development, (at either stage III or IV), 
resulting in a poor prognosis [61]. Early diagnosis leads to better patient outcomes, 
and better biomarkers for the early detection of ovarian cancer are urgently required.  
 
In this study it was demonstrated that the coding region for obestatin is expressed in 
ovarian cancer cell lines and in ovarian tumour clinical specimens. We hypothesised 
that obestatin could be an autocrine/paracrine growth factor in ovarian cancer, or 
circulating obestatin may stimulate ovarian cancer cell progression. In this study, we 
have demonstrated that obestatin treatment stimulates cell migration in the SKOV3 
and OV-MZ-6 ovarian cancer cell lines and increases cell invasion in the OV-MZ-6 
ovarian cancer cell line and hOSE normal ovarian surface epithelium cell line, 
compared to the untreated control.  
 
4.2 Methods  
 
4.2.1 Statement of contribution 
The practical work described in this Chapter was performed in collaboration between 
the candidate, Carina Walpole, and Dr Inge Seim. Dr Inge Seim performed the 
quantitative real time RT-PCR of the ovarian cancer tissues (Results 4.3.1) in 
consultation with the candidate, while the candidate performed all other experiments.  
 
4.2.2 Cell lines and cell culture 
In this study, assays were performed using the SKOV3 [511] and OV-MZ-6 human 
epithelial ovarian serous adenocarcinoma cell lines [510] and the hOSE 17.1 normal 
human ovarian surface epithelium-derived cell line [512]. The SKOV3, OV-MZ-6 
and hOSE 17.1 cell lines used in this study were propagated as described in the 
General Methods, Chapter 2.1.  
 
4.2.3 Tissue immunohistochemistry 
In order to determine if there is a relationship between cancer grade and the level of 
expression of obestatin, a semi-quantitative, immunohistochemical approach was 
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used [40]. Twenty ovarian tissue slides, consisting of ovarian cancer samples of 
varying grade, benign samples and normal ovarian tissue were available through a 
collaboration with Dr Obermair (Queensland Centre for Gynaecological Cancer, 
Royal Brisbane and Women’s Hospital, Brisbane). Tissue sections were 
formaldehyde-fixed, paraffin embedded histopathology ovarian cancer specimens 
and normal ovarian tissue. Tissue sections were microwaved in citric acid buffer for 
10 minutes (pH 6) to enhance antigen retrieval. Tissue sections were incubated with 
an anti-obestatin antibody raised in rabbit (Phoenix pharmaceuticals) and with 
antibodies raised in rabbit (Institute of Medical and Veterinary Science) against the 
full length obestatin peptide (Mimotopes) and affinity purified. Primary antibody was 
diluted 1/200 in 0.01 M PBS with 1% bovine serum albumin (BSA) (Sigma, St 
Louis, MO, USA), and incubated with tissue sections overnight at 4ºC. After 
washing in 0.3% Triton X-100 (Merck Millipore, Billerica, MA, USA) in PBS, 
sections were incubated in goat anti-rabbit secondary antibody (DAKO Envision 
Plus Kit, Dako, Kyoto, Japan) for 30 min at room temperature. After washing, 
immunostaining was performed using a DAKO Envision Plus Kit using DAB as a 
chromogen (Dako), according to the manufacturer’s instructions and tissues were 
counterstained using haematoxylin (Australian Chemical Reagents, Moorooka, 
Australia). Negative controls were performed with the omission of the primary 
antibody. While it was not possible to accurately compare samples quantitatively 
(due to different fixation conditions of tissue samples), staining was described in 
terms of: non-staining, low, medium and high intensities of staining.  
 
4.2.4 Quantitative real-time RT-PCR of clinical ovarian cancer tissue specimens 
Real-time RT-PCR, used to quantify expression levels of obestatin-coding (GHRL 
exon 3 spanning) mRNA transcripts, was performed using cDNA from normal ovary 
and from ovarian cancer patients using cancer tissue panels (OriGene TissueScan 
qPCR Ovarian Cancer panel II, OriGene, Rockville, MD) as described in Chapter 
2.2. This array consists of pathologist-verified samples from eight non-tumour 
ovarian tissues and 40 different ovarian tumours, with a range of cancer stages.   
 
4.2.5 Cell proliferation assays  
WST-1 and CyQuant cell proliferation assays were performed as described (Chapter 
2.4) using the SKOV3 and OV-MZ-6 ovarian cancer cell lines and the hOSE 17.1 
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normal cell line with a range of obestatin concentrations (0, 0.1, 1.0, 10, 100, 1000 
nM) and no treatment controls (0 nM). Each treatment (and control) was performed 
using 16 replicate wells and each experiment was performed independently at least 3 
times. Standard curves were performed to confirm a linear correlation between cell 
number and absorbance or fluorescence values. 
 
4.2.6 Cell migration and invasion assays 
Migration and invasion assays were performed using the SKOV3 and OV-MZ-6 
ovarian cancer cell lines and the hOSE 17.1 normal-derived ovarian cell line using 
Transwell assays (as described in Chapter 2.5). For invasion assays, the upper 
surfaces of the inserts were coated with growth factor-reduced synthetic ECM 
Matrigel (BD Biosciences). Cells were seeded in the upper chamber of the Transwell 
in FCS-free growth medium with or without obestatin (0, 10 and 100 nM). Controls 
were performed to determine background staining using inserts without cells, 
containing medium only. For each experiment 3 replicates per treatment were 
performed and the experiments were repeated independently 3 times. 
 
4.2.7 Attachment assays 
To assess whether obestatin treatment had any effect on cellular attachment, the 
hOSE 17.1 normal ovarian cell line and OV-MZ-6 and SKOV3 ovarian cancer cell 
lines were treated with obestatin (0, 10 and 100 nM) and then tested for their ability 
to attach to the extracellular matrix (ECM) proteins fibronectin, vitronectin, collagen 
I and collagen IV. Attachment assays were performed as described in Chapter 2.6. 
The assay was performed in triplicate with 3 independent replicates of each ECM 
molecule per assay. 
 
4.2.8 Statistics 
Statistical analyses were undertaken as described in Chapter 2.8 using either one-way 
ANOVA, followed by Tukey's post hoc test (with P <0.05 considered to be 
statistically significant) or a two-way ANOVA, followed by Bonferoni’s post hoc 








4.3.1 Obestatin mRNA and protein is expressed by ovarian cancer tissues 
The expression of the obestatin-coding region of preproghrelin (GHRL exon 3-4) was 
examined by quantitative real-time RT-PCR using normal and ovarian cancer tissue 
from ovarian carcinoma patients (Fig. 4.1). Although levels of obestatin-containing 
transcripts varied in different ovarian cancer samples and were generally higher than 
normal ovarian tissue, there was no strong correlation between the cancer stages and 
obestatin mRNA expression. In a subset of tumours (≈ 6/40), however, expression 
was more than 10 fold the expression in normal tissue, and therefore, obestatin 
expression appears to be upregulated in a subset of ovarian cancers. Normal ovarian 
tissue in this study is likely to consist of a range of different cell types and little if 
any ovarian surface epithelium, the most common site from which tumours develop. 
The coding region for obestatin was expressed in the majority of the samples tested. 
mRNA expression of the ghrelin gene, including the coding region for obestatin, was 
demonstrated in the SKOV3 and OV-MZ-6 ovarian cancer cell lines and hOSE 17.1 
normal ovarian cell line (Chapter 3.3.1, Fig 3.3).  
 
We demonstrated that the obestatin peptide is also expressed in human ovarian 
cancers using immunohistochemistry. This antibody is raised against the obestatin 
peptide, and could also detect proghrelin and preproghrelin, (prior to processing of 
the prepropeptide into the ghrelin and obestatin peptides). The ovarian surface 
epithelium in normal ovarian tissue demonstrated very low or absent levels of 
obestatin immunoreactivity (Figure 4.2 A). Positive granular obestatin 
immunoreactivity was demonstrated in the cytoplasm of endometrioid (n = 2) and 
papillary serous ovarian tumours (n = 4) (Figure 4.2 B, C, D). Staining was observed 
throughout the cytoplasm, or concentrated in the apical region of the cell. Nests of 
epithelial cells in a benign Brenner’s tumour show cytoplasmic obestatin staining, 
and less intense staining was observed in the surrounding stroma (Fig 4.2 E). In a 
case of salphingitis, strong obestatin immunoreactivity was observed in the 
cytoplasm of inflammatory cells (Fig 4.2 F). Luteal cells of the corpus luteum of the 
normal ovary also expressed granular cytoplasmic obestatin immunoreactivity (Fig 
4.2 G). Negative controls, where the primary antibody was omitted, demonstrated no 







Figure 4.1 Quantitative RT-PCR demonstrating level of expression of the 
obestatin-coding region of the ghrelin prepropeptide mRNA (GHRL exon 3-4) in 
normal ovary and stage I to IV ovarian cancer. Quantitative real-time RT-PCR 
was carried out using an Origene TissueScan ovarian cancer panel. Negative controls 
were performed where template was substituted with water. Data were normalised to 
β-actin and are represented as fold changes, quantified as 2-(Ct sample-Ct control), relative 
to expression of transcripts in a normal (N) ovarian tissue sample (1.0). Bars indicate 
















Figure 4.2 Obestatin-like immunoreactivity is expressed in ovarian cancer and 
normal ovarian tissues.  
Ovarian specimens showing obestatin immunoreactivity (brown staining). 
Immunohistochemistry was performed using clinical specimens using the Dako 
Envision plus kit with DAB as chromagen and nuclei were counterstained blue with 
haematoxylin. A. Normal ovarian surface epithelium (OSE) with very low levels of 
obestatin immunoreactivity and some immunoreactivity in the underlying stroma (S). 
B. Grade 3 ovarian serous adenocarcinoma (endometrioid) section showing strong 
obestatin immunoreactivity in the cytoplasm of epithelial cells and non-
immunoreactive nuclei are counterstained blue. C. Obestatin immunoreactivity 
(brown) in serous ovarian cancer, with increased levels of staining in the apical 
regions of the glands. D. Papillary serous ovarian tumour demonstrating granular, 
obestatin-specific immunoreactivity in the epithelial cytoplasm and non-staining 
nuclei. E. Brenner’s tumour showing obestatin immunostaining in the cytoplasm of 
epithelial cells (Ep) and moderate staining in the stroma. F. Inflammatory cells in a 
section of tissue from a case of salphingitis show moderate to high levels (arrows) of 
cytoplasmic obestatin expression. G. Normal corpus luteum of the ovary, showing 
granular perinuclear staining (arrows) in the luteal cells. The nuclei do not show 
obestatin immunoreactivity. H. Representative negative control showing serous 

















4.3.2 Obestatin increases cell migration 
To examine if obestatin stimulates cell migration in the SKOV3 and OV-MZ-6 
serous adenocarcinoma ovarian cancer cell lines, Transwell migration assays (with 8 
µm pores) were employed. There was a statistically significant increase in cell 
migration in response to 10 nM (fold increase of 1.74 +/- 0.30 SEM) and 100 nM 
obestatin (2.08 +/- 0.54 SEM) in the SKOV3 ovarian cancer cell line (P <0.05) and 
increased in response to 10 nM (fold increase of 2.17 +/- 0.34 SEM, P <0.01) and 
100 nM obestatin (fold increase of 2.13 +/- 0.37 SEM, P <0.05) in the OV-MZ-6 
ovarian cancer cell lines (Fig. 4.3). Although cell migration was observed, there was 
no difference in cell migration in the hOSE 17.1 normal ovary-derived ovarian cell 




































































SKOV3 OV-MZ-6 hOSE 17.1
 
Figure 4.3 Obestatin treatment increases cell migration in the SKOV3 and OV-
MZ-6 ovarian cancer cell lines compared to controls, but not in the hOSE 17.1 
normal human ovary derived cell line in Transwell assays. Cells were seeded in 
Transwell inserts with 8 µm pores in growth medium with obestatin (10 and 100 nM) 
or controls (0 nM) and 10% FCS was added to the lower chamber as a 
chemoattractant. Migration was assessed by staining migrated cells with 1% crystal 
violet, and absorbance measured as a representation of the number of migrated cells. 
Graph represents mean fold change +/- SEM. *P <0.05 and **P <0.01 compared to 0 
nM control using one way ANOVA and Tukey’s post hoc comparisons. n = 3 repeat 
experiments with 3 replicates per experiment. 
 
4.3.3 Obestatin does not stimulate proliferation in ovarian cancer cell lines 
Obestatin has been shown to stimulate cell proliferation in some cancer and normal 
cell types [10-12, 465] and inhibit cell proliferation in others [13, 14] and we 


































































































































































































Figure 4.4 Obestatin treatment does not stimulate an increase in cell 
proliferation compared to controls in the SKOV3 or OV-MZ-6 ovarian cancer 
cell lines, or the normal ovarian cell line hOSE 17.1. Cell proliferation was 
determined using the CyQuant (DNA based) and Wst-1 (metabolic based) cell 
proliferation assays after treatment with obestatin for 72 h. Data is shown as mean 
proliferation +/- SEM (n = 3). Data was analysed using one way ANOVA. No 





































Although all of the cell lines in the study were observed to proliferate over the 72 
hours time period, treatment with a range of concentrations of obestatin (0.1-1000 
nM) did not stimulate a statistically significant change in cell proliferation compared 
to the untreated controls (0 nM) in the SKOV3 or OV-MZ-6 ovarian cancer cell 
lines, or in the hOSE 17.1 normal ovary derived cell line in this study (Fig. 4.4). Cell 
proliferation was determined using a CyQuant assay to measure changes in DNA 
content and a WST-1 assay to measure changes in cell metabolism. As obestatin did 
not influence cell proliferation, it is unlikely that proliferation and increased cell 
number influenced cell migration in the SKOV3 and OV-MZ-6 cell lines.  
 
4.3.4 Cell invasion assays 
As it was demonstrated that treatment with obestatin increases migration in ovarian 
cancer cell lines, Transwell assays were performed to determine if obestatin could 
also alter the rate of cell invasion through Matrigel extracellular matrix (Fig. 4.5). 
Obestatin treatment increased invasion with both 10 nM and 100 nM treatments in 
the hOSE 17.1 cells (fold change of 1.40 +/- 0.04 SEM and 1.55 +/- 0.05 SEM 






































































SKOV3 OV-MZ-6 hOSE 17.1
 
Figure 4.5 Invasion assays with ovarian cancer cell lines SKOV3 and OV-MZ-6 
and normal ovary derived hOSE 17.1 cell line in response to obestatin treatment 
using Transwell assays and Matrigel. Obestatin treatment significantly increased 
cell invasion in the OV-MZ-6 ovarian cancer cell line and hOSE 17.1 normal cell 
line, but had no statistically significant effect on invasion in the SKOV3 ovarian 
cancer cell line. Transwell assays were performed over 48 h (SKOV3 and OV-MZ-6) 
or 72 h (hOSE 17.1). Mean fold change +/- SEM. *P <0.05 and **P <0.01 compared 
to 0 nM control using one way ANOVA and Tukey’s post hoc comparisons. n = 3 
repeat experiments with 3 replicates per experiment. 
  
101 
(fold change of 1.45 +/- 0.13 SEM, P <0.05). Interestingly, the SKOV3 ovarian 
cancer cell line did not show increased invasive potential following obestatin 
treatment (Fig. 4.5).  
 
4.3.5 Cell attachment assays 
As ovarian cancer cells must attach to the mesothelium (which lines the peritoneal 
cavity) in order to metastasise [527], assays were performed to determine the effect 
of obestatin treatment on cell attachment. Cells were treated with obestatin (or 
control), and its effect on attachment to a number of ECM components that are 
important to ovarian cancer was investigated. While collagen IV  is not expressed by 
mesothelial cells it is a normal component of the basement membrane [552-554]. The 
SKOV3 and OV-MZ-6 ovarian cancer cell lines and the hOSE 17.1 normal cell line 
were cultured in the presence and absence of obestatin (10 and 100 nM) and assessed 
for their ability to adhere to fibronectin, vitronectin, collagen I and collagen IV. No 
significant difference in the number of cells attached (measured using CyQuant) was 
seen between the cell lines in response to the obestatin treatments (10 and 100nM) 
compared to the untreated controls (Fig 4.6).  
 
4.4 Discussion  
These studies have demonstrated that obestatin is expressed in ovarian cancer tissues 
at the mRNA and peptide level and that exogenous obestatin stimulates cell 
migration in the OV-MZ-6 and SKOV3 serous ovarian cancer cell lines, but not in 
the hOSE 17.1 normal ovarian surface epithelial cell line. Obestatin treatment also 
increased the rate of cell invasion through Matrigel in the OV-MZ-6 ovarian cancer 
cell line and the hOSE 17.1 normal-ovary derived cell line, but not the SKOV3 
cancer cell line in Transwell invasion assays. This is the first demonstration that 
obestatin can stimulate cell migration in cancer cell lines. These data suggest that 
obestatin, like ghrelin (which also stimulated migration, but not cell invasion) 
(Chapter 3), may be an autocrine/paracrine factor in the ovary that stimulates cancer 
progression.  
 
In the current study it was shown, for the first time that mRNA for the obestatin-












































































































































Figure 4.6 Attachment assays for SKOV3 and OV-MZ-6 ovarian cancer cell 
lines and the hOSE 17.1 normal ovarian cell line in response to obestatin 
treatment using a CyQuant assay. Results are shown as a mean percentage (minus 
background) of the total number of cells that could possibly adhere to the uncoated 
100% adherence plate with the aid of serum +/- SEM. No statistically significant 














samples of normal ovary. Obestatin mRNA levels, however, were not significantly 
different between the normal and cancer tissue. Similar findings have been reported 
for other small growth factor peptides, such as kisspeptin (or mestatin) [567], which 
suggest a favorable prognosis in ovarian clear cell cancer [568]. Epidermal growth 
factor (EGF) [569], which stimulates migration in ovarian cancer, and its receptor 
have potential as therapeutic targets for this disease [570, 571]. The normal tissue in 
the current study, however, was unlikely to contain ovarian surface epithelium, from 
which most ovarian cancers develop. In the previous chapter (3.3.1) it was shown 
that all cell lines expressed the full length preproghrelin transcript and thus, have the 
potential to produce obestatin. 
 
There have been few studies describing obestatin expression in the ovary, or in 
ovarian cancer. In a small study of patients who underwent surgery for benign 
ovarian tumours (22 patients), or ovarian cancer (31 patients), and in 32 control 
women, obestatin was shown to be elevated in the plasma of patients with both 
benign ovarian neoplasms and ovarian cancers [114]. These authors hypothesised 
that obestatin could be a useful biomarker for ovarian cancer [114]. There were a 
number of limitations to this study, however. It is unclear whether these blood 
samples were taken before, after or during surgery. Postoperative histopathology of 
the removed tumours revealed that 7 of the benign cases and 15 of the ovarian cancer 
cases were variations of the serous phenotype.  
 
Using immunohistochemistry, we demonstrated that normal ovarian surface 
epithelium expresses very low levels of obestatin, while immunoreactivity ranged 
from low to moderate levels in ovarian cancer samples. Obestatin peptide expression 
may, therefore, be elevated in ovarian cancer compared to normal ovarian surface 
epithelium. The antibody used in this study was raised against the obestatin peptide, 
which is also present in the proghrelin peptide and the C-ghrelin peptide prior to 
further processing. Obestatin immunoreactivity in the ovary is likely to be due to the 
presence of the mature form of obestatin, as it is unlikely that ghrelin processing 
intermediates would accumulate in the cells. Further studies using mass spectrometry 
or Western analysis are required in order to determine whether the mature form of 
obestatin is expressed by ovarian cancer cells. Obestatin expression has also been 
demonstrated, in a study of a range of serous ovarian cancers, benign (n = 20), 
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borderline (n = 7) and malignant (n = 20) serous tumours, using 
immunohistochemistry [380]. Further studies on larger sample sets and other types of 
ovarian cancers are required in order to determine if obestatin expression is elevated 
in ovarian cancer compared to normal ovarian surface epithelium.  
 
In the current study expression of obestatin was also demonstrated in the normal 
human corpus luteum, indicating that it may play a normal physiological role. The 
SKOV3 and OV-MZ-6 serous ovarian cancer cell lines and hOSE 17.1 normal 
ovarian cells also express preproghrelin mRNA, which contains the coding region for 
obestatin. Obestatin was highly expressed in inflammatory cells in a case of 
salphingitis, indicating that it may play a role in the immune response in the 
reproductive tract and other tissues. It is possible that novel obestatin-specific 
transcripts are also produced and these could influence the ghrelin to obestatin ratio 
[118]. 
 
In this study, it has been demonstrated for the first time that obestatin may play a role 
in ovarian cancer migration and invasion through the extracellular matrix, and we 
hypothesise that obestatin may play a similar role in other cancers. In this study the 
migration was increased SKOV3 and OV-MZ-6 ovarian cancer cell lines, however, 
obestatin had no effect on cell migration in the hOSE 17.1 normal ovarian cell line. 
This suggests that the response may be cancer specific and occurs in cells that have a 
tendency to migrate; however, further investigation with a wider range of cell lines is 
required to confirm this hypothesis. Surprisingly, obestatin treatment increased 
invasion through Matrigel in the hOSE 17.1 normal ovarian cell line. Cell invasion 
was also increased in the OV-MZ-6 ovarian cancer cell line, but not in the SKOV3 
cancer cell line. This may be suggests that obestatin may also have some roles in 
normal ovarian surface epithelium, in addition to a role in ovarian cancer 
progression. The very limited effects on invasion in the ovarian cancer cell lines, 
compared to the significiant increases observed in the normal hOSE 17.1 cell line, 
indicate that obestatin could be more involved in cell motily in ovarian caner 
metastasis rather than degradation of extracellular matrix to allow invasion into a 
new site. In ovarian cancer metastasis, metastatic cells are sloughed off as spheroids 
from the primary tumour into the peritoneal cavity and this does not require tissue 
invasion [528]. Migration and cell motility is therefore more important in the early 
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stages of cancer dissemination, than the ability to degrade and invade [551]. 
 
Since its discovery, obestatin has been shown to have a number of functions, some of 
which may be relevant in cancer [7]. Obestatin stimulates cell proliferation [10-12, 
465] which is a hallmark of cancer development and progression [393]. A major 
characteristic of cancer cells is an ability to be self-sufficient in growth signals, while 
being insensitive to growth-inhibitory signals. In cancer, many oncogenes mimic 
normal growth signalling to stimulate proliferation [393]. Obestatin can stimulate 
cell proliferation in normal retinal epithelial cells [10] and the HIT-T15 and INS-1E 
pancreatic β-cells [12]. In cancer cells, obestatin also increased proliferation in the 
KATO-III gastric cancer cell line [11], but in contrast, proliferation was reduced with 
obestatin treatment in the TT thyroid carcinoma cell line [56]. In this study, in 
normal and ovarian cancer cells, obestatin was shown to have no significant effect on 
proliferation using the WST-1 and CyQuant assays. These results contrast with 
another recent study in porcine ovarian granulosa cells that suggested that obestatin 
stimulated cell proliferation [465] and this was determined by measuring expression 
of the PCNA (proliferating cell nuclear antigen) and cyclin B1 proliferation markers 
and MAP kinase expression [465]. Direct proliferation assays were not performed in 
this study. These cells are derived from the stroma surrounding the follicle, however, 
and have a very different origin to ovarian cancer cells which are derived from the 
ovarian surface epithelium. Obestatin appears to have different effects on 
proliferation in different cell types.   
 
Cell attachment is important in ovarian cancer progression, as it allows the ovarian 
cancer cells that have shed into the peritoneal cavity to adhere to the mesothelium 
that lines the cavity, and this is its primary site of metastasis [527, 528]. The 
metastasised cells attach to the mesothelium by binding to ECM molecules 
(including fibronectin, vitronectin and collagen I) which are secreted on the surface 
of the mesothelial cells [552-554]. As the role of obestatin in promoting cancer cell 
attachment has not previously been investigated, the ability of obestatin to influence 
adhesion to the major ECM components, fibronectin, vitronectin, collagen I and 
collagen IV was measured. It was demonstrated that obestatin had no significant 
effect on adhesion in the normal or cancer ovarian cell lines. This finding is 
corroborated by a single study that investigated attachment of monocytes in the 
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development of atherosclerosis. Obestatin has previously been shown to decrease the 
expression of vascular cell adhesion molecule-1 in monocytes, but did not affect 
adhesion itself [555]. Obestatin appears to have no effect on attachment of ovarian 
cancer cells. 
 
We have demonstrated that ghrelin (Chapter 3.3.1) and the obestatin-coding region 
are expressed at the mRNA level, and that the obestatin peptide is expressed at a 
protein level in ovarian cancer [45]. This is the first report showing that the ghrelin-
gene derived peptide, obestatin, is expressed at an mRNA level in the normal ovary 
and in ovarian tumours, and that obestatin promotes cancer cell migration in vitro. 
We have demonstrated for the first time that obestatin can enhance invasion in the 
hOSE 17.1 normal human surface epithelial derived cell line and the OV-MZ-6 
ovarian cancer cell line. These data, provide further evidence that obestatin is a 


























CHAPTER 5  
 
The effect of obestatin on protein expression in 




There is increasing evidence that, like ghrelin, obestatin may act as an 
autocrine/paracrine factor in a number of systems, or it could act as an endocrine 
hormone on a range of peripheral tissues [572]. In the previous chapters it has been 
demonstrated that obestatin and ghrelin promote migration in ovarian cancer cell 
lines. As this increase in cell migration could be significant in ovarian cancer 
progression, it is important that a greater understanding of its mechanism of action is 
attained. Thus, in this chapter we endeavoured to further investigate the potential 
downstream targets, pathways and processes that may be stimulated by obestatin 
treatment in ovarian cell lines.  
 
Currently obestatin is known to stimulate proliferation and it has anti-apoptotic 
effects through the ERK1/2 MAPK signalling pathway [10-12, 462, 465, 466]. 
Obestatin signals through activation of Akt to inhibit apoptosis [12] and regulate 
adipocyte metabolism and adipogenesis [464]. An investigation into obestatin-
stimulated Akt signalling in the KATO-III and AGS gastric cancer cell lines revealed 
that obestatin induced an association between GPR39 and a β-arrestin 1/Src 
signalling complex, resulting in transactivation of the epidermal growth factor 
receptor (EGFR), which then activated Akt [472]. This was paralleled by the 
phosphorylation of mTOR (mammalian target of rapamycin), which can lead to Akt 
phosphorylation, or can occur downstream of Akt phosphorylation [472]. Although 
this study indicated that GPR39 was involved in obestatin signalling, a number of 
studies have shown that obestatin does not bind GPR39, demonstrating that GPR39 
is not the obestatin receptor [452-455]. In studies of human retinal epithelial cells 
and the KATO-III gastric cancer cell line, obestatin enhanced proliferation and 
stimulated ERK1/2 signalling, through the activation of Gi, PI3K, protein kinase C 
(PKC) and Src [10, 11]. Obestatin-stimulated growth hormone secretion in rat 
tumour somatotroph cells is also mediated by these signalling pathways [466]. The 
cardioprotective effects of obestatin in rat H9c2 cardiac cells and isolated ventricular 
myocytes are mediated by PI3K, PKC and ERK1/2 [462]. Obestatin has also been 
demonstrated to signal through adenylyl cyclase/cAMP/protein kinase A (PKA) [12] 
and AMPK [464] pathways. 
 
In order to investigate the processes and pathways stimulated by obestatin in ovarian 
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cancer, we used two dimensional-difference in gel electrophoresis (2D-DIGE). 2D-
DIGE is a broad spectrum, discovery-driven proteomics approach for comparing and 
analysing complex protein mixtures in multiple samples. 2D-DIGE is a fluorescent 
gel based method where samples, labelled by dyes (such as Cy3 or Cy5 dye), are 
initially separated by native charge in the first dimension using isoelectric focusing 
(IEF), and then separated by molecular mass in the second dimension using SDS-
PAGE [573]. Unlike other 2D gel methods, an internal Cy2 dye labelled standard 
control sample can also be used. For this method, the internal standard is a 
combination of all the samples being analysed, to allow for both accurate analysis of 
in gel differential expression and comparison of targets across gels [574].  
 
In this study, we identified 26 proteins which were differentially expressed in 
response to obestatin treatment in the SKOV3 ovarian cancer cell line, and 15 of 
these were regulated by obestatin in the hOSE 17.1 normal ovarian cell line. Further 
analysis of differentially expressed proteins in response to obestatin treatment was 
performed using Ingenuity Pathway Analysis software and revealed that the ERK1/2 




5.2.1 Cell lines and cell culture 
In this study, assays were performed using the SKOV3 and the OV-MZ-6 human 
epithelial ovarian serous adenocarcinoma cell lines [510, 511] and the hOSE 17.1 
normal surface epithelium-derived cell line [512]. The SKOV3, OV-MZ-6 and hOSE 
17.1 cell lines used in this study were propagated as described in the General 
Methods, Chapter 2.1.  
 
5.2.2 Two Dimensional-Difference in Gel Electrophoresis (2D-DIGE)  
A 12 gel 2D-DIGE (GE Healthcare, Buckinghamshire, UK) experiment was used to 
investigate the differential expression of proteins in response to obestatin treatment 
(10 or 100 nM obestatin), or a no treatment control, in the hOSE 17.1 normal ovary 
derived cell line and the SKOV3 ovarian cancer cell line. The SKOV3 and hOSE 
17.1 cell lines were passaged into T175 flasks (Nunc) and allowed to attach for 24 h. 
Cell lines were treated for 3 days with either medium only, or obestatin (10 nM and 
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100 nM; Auspep) and obestatin was replenished every 24 hours. After 3 days of 
treatment, cells were removed from the flask surface by cell scraping and collected 
into 800 µL 2D-DIGE extraction buffer (30 mM Tris, 7 M urea, 2 M thiourea, 4% 
CHAPS pH 8.8). Cell lysates were collected on ice and vortexed several times prior 
to storage at -80 ºC. Four independent replicates were prepared. Cell lysates were 
precipitated using the Ettan 2-D Clean Up Kit (GE Healthcare), and resuspended 
according to the manufacturer’s instructions. The protein concentrations of cell 
lysates for DIGE analysis were determined using a Bradford assay (BioRad) 
according to the manufacturer’s instructions. 2D-DIGE experiments were performed 
as previously described [575] and according to the manufacturer’s instructions. An 
internal standard which contained pooled, equal aliquots of all samples in the 
experiment (with aa total protein content of 600 μg) was prepared and labelled with 
Cy2 dye (GE). Protein test samples (50 μg) were labelled with 400 pmoles either 
Cy3 or Cy5 dye (GE Healthcare) for 1 h on ice in the dark, according to the 
manufacturer’s instructions. This reaction was stopped by quenching with 1 μL 10 
mM lysine (and 12 μL for the internal standard). A total of 24 test samples were 
labelled, with four replicates of each treatment of each cell line. Cross labelling of 
replicate samples (two replicates with Cy3 and two replicates with Cy5) was 
performed to avoid any bias in subsequent analysis due to labelling. For each gel, 
one Cy3 and one Cy5 labelled sample, with an equal amount of Cy2-labelled internal 
standard, were combined in rehydration buffer (7 M urea, 2 M thiourea, 4% CHAPS, 
20 mM DTT, 0.5% immobilised pH gradient (IPG) buffer pH 3-11 non-linear) to a 
final volume of 450 μL.  
 
5.2.3 Two-Dimensional Electrophoresis, gel imaging and DIGE analysis 
In the DIGE experiment, and for preparative gels for the MS analysis of proteins of 
interest, Immobiline Dry Strip immobilised pH gradient gels (IPG) (GE Healthcare), 
pH 3-11 non-linear (NL) gradient strips (24 cm) were used. Strips were rehydrated 
with 450 μL each sample, covered with Plus One Dry Strip Cover Fluid (GE 
Healthcare) and incubated at RT for 20 hours in the dark. Following rehydration, the 
IPG gels were focussed on an Ettan IPGphor 3 isoelectric focusing unit (GE 
Healthcare) at 500 V for 1 h with a gradient to 1000 V over 7 h, followed by a 
gradient to 10 000 V over 3 h, and then 10 000 V for 4 h. On completion of the first-
dimension IEF, IPG gels were reduced and alkylated (with 1% DTT in rehydration 
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buffer for 15 min, followed by 2% iodoacetamide in rehydration buffer for 15 min). 
Second dimension protein separation was performed using 12% SDS-PAGE gels 
(375 mM Tris HCl, pH 8.8, 0.1% SDS) using an Ettan DALTsix electrophoresis 
system (GE Healthcare). The strips were embedded on the top of the gels with 0.5% 
agarose (in Laemmli buffer, 25 mM Tris, 192 mM Glycine, 0.1% (w/v) SDS, pH 8.3) 
and electrophoresed at room temperature (at 2 W/gel for 1 h followed by 4-5 h at 12 
W/gel).  
 
Gel images of the combined Cy2, Cy3 and Cy 5 labelled gels were scanned using a 
Typhoon TRIO Variable Mode Imager (GE Healthcare) using excitation/emission 
wavelengths of 488/520 nm for Cy2, Cy3 532:580 nm and Cy5 633:670 nm. Images 
were initially cropped using ImageQuant TL software (GE Healthcare) prior to final 
image analysis to remove any non-essential information from the image files 
(including gel edges and background image of the scanner). Final image analysis was 
performed using DeCyder 2D software (GE Healthcare) (as per the manufacturer’s 
instructions) using both Differential-In-gel Analysis (DIA) and Biological Variation 
Analysis (BVA) modules (Fig 5.1). The DeCyder 2D software is specially designed 
for the Ettan DIGE system and is an automated image analysis software suite that 
allows for detection, quantitation, positional matching and differential protein 
abundance analysis. The DIA analysis detected protein spots on the set of images for 
each gel image and quantified them. Ten proteins were set as landmarks to allow the 
correct alignment of Cy3 and Cy5 scans of each gel to their internal standard Cy2 
scan. This part of the software also subtracts background, performs in-gel 
normalisation and removes artefacts. After processing the image sets for each gel in 
the DIA, the BVA module was used to compare differential protein abundance across 
the gels. From the BVA analysis, 42 spot were selected for picking from the 
preparative gels. Spots were chosen on the basis of having large positive or negative 
average ratios (differential expression) when comparing the treated samples to their 
media control.  
 
5.2.4 Preparative gels, protein spot picking and preparation of spots for mass 
spectrometry 
In order to maximise the success rate of protein sequencing spots of interest, (that 
have been identified using DIGE), are extracted from a preparative gel where an 
  
112 
excess amount of protein has been loaded. Six samples (including 2 samples of 
SKOV3 and hOSE 17.1 cells treated with 100 nM obestatin treatment, and one 
sample from each cell line treated with medium only), that represented all the spots 
of interest overall, were electrophoresed using the preparative gel, with 1 mg of each 
sample loaded on separate gels. Preparative gels were prepared as described above 
(5.3.2), and stained with Colloidal Coomassie Stain (0.08% Coomassie Brilliant Blue 
G-250 (CBB G250), 1.6% orthophosphoric acid, 8% ammonium sulphate and 20% 
methanol) [576]. Protein spots of interest were excised from the gels, washed twice 
in MilliQ water, then washed twice with a solution containing 25 mM ammonium 
bicarbonate and 50% Acetonitrile (ACN) (HPLC grade) followed by drying under 
vacuum at 30ºC. The desiccated gel pieces were rehydrated in 15 mL digestion 
buffer (25 mM ammonium bicarbonate, 1 mM calcium chloride) containing 20 
ng/mL sequencing grade modified trypsin (Promega, Madison, WI) for in-gel 
digestion [576]. Peptide extracts were dried using evaporative centrifugation and 
reconstituted in 25 µL 5% formic acid. The reconstituted extracts were sonicated for 
10 min prior to LC-MS/MS analysis. 
 
5.2.5 Mass spectrometry 
 
5.2.5.1 Statement of contribution for mass spectrometry 
The mass spectrometry analysis of the 2D-DIGE picked spot samples described in 
this section was performed by Peter Josh (CSIRO, Qld). 
 
5.2.5.2 LC-MS/MS analysis and database searching 
Peptide extracts were injected into a Shimadzu Prominence Ultra Fast Liquid 
Chromatograph (UFLC) system (Shimadzu, Kyoto, Japan) at a flow rate of 3 µL/min 
with a Vydac MS C18 300 Å column (150 mm x 300 µm), with a particle size of 5 
µm (Grace Davison, Deerfield, USA). Chromatographic separation was developed 
using a linear gradient of 2-45% solvent B (90% acetonitrile/10% water containing 
0.1% formic acid) in solvent A (0.1% formic acid) over 40 minutes. The HPLC 
eluent was coupled directly to a QStar Elite Hybrid liquid chromatography system 
coupled with tandem mass spectrometry (LC-MS/MS) (Applied Biosystems/MDS 
Sciex, Foster City, USA) fitted with a nano-electrospray ionization source. Source 
conditions included an ion spray voltage of 3400 V, nebuliser gas flow 20, curtain 
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gas flow 15 and interface heater temperature 120°C. Collision-induced dissociation 
settings included collision-activated dissociation (CAD) gas 4 and a declustering 
potential of 70 V. Data was collected in information-dependent acquisition mode. 
Following an MS survey scan (m/z 350-1800), MS/MS measurements were 
performed for the four most intense precursor ions (50 counts/s threshold, +2 to +5 
charge state and m/z 100-1600). Data was acquired and processed using Analyst QS 
2.0 software. 
 
ProteinPilot 3.0 software (Applied Biosystems) with the Paragon Algorithm, was 
used for the identification of proteins. Data was searched against the NCBI non-
redundant database. Search parameters included cysteine alkylation with 
iodoacetamide and trypsin as the digestion enzyme, and there was no restriction on 
taxonomy. Single amino acid substitutions and biological modifications were 
allowed. The software allows 126 possible biological modifications including 
acetylation, phosphorylation and methylation. Protein scores (a measure of the 
increase in evidence specific to each protein raising confidence in its correct 
identification) >1.3 with a confidence interval (CI) >95% were considered to be 
indicative of a positive identification.  
 
5.2.6 Pathway analysis 
 
5.2.6.1 Statement of contribution for Ingenuity Pathway Analysis 
The pathway analysis using the Ingenuity Pathway Analysis software described in 
this section was performed by Dr Inge Seim and Peter Josh. 
 
5.2.6.2 Ingenuity Pathway Analysis 
The Ingenuity Pathway Analysis tool (IPA, Ingenuity Systems, Redwood, CA) was 
used to examine the differentially expressed proteins identified from the SKOV3 cell 
line using ProteinPilot. The IPA tool analyses the input protein list in the context of 
known molecular and chemical interactions, cellular phenotypes, and disease 
processes. The list of proteins which were differentially expressed in response to 
obestatin treatment (compared to untreated cells) were mapped to the Ingenuity 
database and ranked by score. The score indicates the likelihood that the proteins 
grouped together in the network were discovered together by chance, with a 99% 
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confidence level, and scores ≥3 are considered to be significant. 
 
5.2.7 Investigation of ERK1/2 as a potential pathway for migration in SKOV3 
and OV-MZ-6 ovarian cancer cell lines 
 
5.2.7.1 Western immunoblotting using anti-active antibodies  
As pathway analysis studies demonstrated that the ERK1/2 protein expression may 
be a central pathway mediating the effects of obestatin treatment, Western analysis 
was performed in the ovarian cancer cell lines to determine if obestatin treatment 
also activates this signalling pathway, leading to ERK1/2 phosphorylation. We 
investigated whether or not ERK1/2 phosphorylation was associated with increased 
cell migration in response to obestatin (as observed in Chapter 4). Western analysis 
was performed as previously described (Chapter 2.7) using an anti-active antibody 
for phosphorylated ERK1/2 (Cell Signalling, Genesearch, Arundel, Qld, Australia) to 
determine if obestatin treatment activates this signalling pathway. SKOV3 and OV-
MZ-6 ovarian cancer cell lines were treated with obestatin (0, 0.1, 1, 10,100 and 
1000 nM) and ERK1/2 signalling was measured at 15 min for SKOV3 and 30 min 
for OV-MZ-6. These timepoints were predetermined as they gave peak ERK1/2 
signalling in these cell lines (described in Chapter 2).  
 







) and pan-Erk1/2 ELISA Kit 
To further investigate the effects of obestatin treatment on ovarian cancer cell lines 
using a more quantitative method, an anti-active ERK1/2 ELISA was performedin 
the SKOV3 ovarian cancer cell line using the Sigma phospho-ERK1/2 ELISA Kit 
(Sigma-Aldrich). SKOV3 ovarian cancer cells were seeded at 3 x10
5
 cells/well in 6-
well plates. After 8h, cells were incubated in phenol red free medium without FCS 
overnight. To investigate ERK1/2 signalling, cells were treated with obestatin (0, 10 
or 100 nM) and incubated for 0, 5, 10, 15 and 30 min. At each time-point media was 
aspirated, 250 µl lysis buffer (kit lysis buffer plus 50 nM NaF, complete protease 
inhibitor cocktail, Roche and Phosphatase Inhibitor Cocktail 2, Sigma-Aldrich) was 
added per well and the plates were placed on ice. At the end of the time course, 
plates were then incubated for 30 min at 4°C shaking, the lysates were transferred to 
tubes, centrifuged (10000 x g for 10 min at 4 ºC) and supernatant transferred to new 
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tubes. Samples were diluted 5 fold and duplicate wells per sample for phosphorylated 
and pan ERK1/2 were assayed. The ELISA assay was performed as per 
manufacturer’s instructions and absorbance was determined (450 nm) using a 
Benchmark Plus Microplate Spectrophotometer System (BioRad). 
 
5.2.8 Statistics 




5.3.1 Differential protein expression in response to obestatin treatment 
compared to control in the SKOV3 ovarian cancer cell line 
A proteomic, 2D-DIGE LC-MS/MS method was applied to the SKOV3 ovarian 
cancer cell line and the hOSE 17.1 normal ovary-derived cell line in order to identify 
proteins that are differentially regulated by obestatin treatment (Fig. 5.1). We 
identified 26 proteins that were differentially regulated by obestatin treatment 
compared to no treatment controls in the SKOV3 ovarian cancer cell line (Table 5.1). 
In the hOSE 17.1 cell line, 15 of the 26 proteins were found to be differentially 
expressed using the DeCyder software. A number of these 26 proteins have been 
previously associated with cell migration, which was shown to be stimulated by 
obestatin treatment in this thesis (Chapter 4, Tables 5.2 and 5.3). Many of the other 
proteins identified were associated with processes that could affect cell migration, 
such as remodelling of the cytoskeleton and regulation of protein expression. 
 
Ingenuity Pathway Analysis (IPA) was performed in order to place the differentially 
regulated proteins in a biological network and to determine the relationship between 
these proteins (Fig 5.2). Two networks were generated by IPA analysis, using a 99% 
confidence level (score ≥3) that peptides in a particular network were not networked 
together due to chance. The proteins identified, their major pathway functions and 
their associated networks are shown in Table 5.4. Pathway analysis demonstrated 
that the differentially regulated proteins were associated with cancer progression and 
post-translational modifications. The MAPK signalling protein, ERK1/2, was 
identified as an important protein that interconnected 16 of the 26 proteins identified 





Figure 5.1 Representative 2D-DIGE gels showing a combined image for analysis 
showing Cy3 and Cy5 fluorescencently-labelled proteins (from 2 different 
samples) and (B) a representative DeCyder software-generated image showing 
protein spots that have been selected for further analysis after removal from the 
gel (circled proteins in B). A. Representative 2D-DIGE gel of protein from the 
SKOV3 cancer cell line (labelled with Cy) and the hOSE 17.1 normal ovarian cell 
line (labelled with Cy dye) and treated with medium alone. Red and green protein 
spots represent differentially expressed proteins, while yellow spots represent 
proteins with the same abundance in the two samples that are being compared. B. 
Representative gel image of 2D gel (of SKOV3 cells treated with medium only) was 
created and analysed using DeCyder image software (GE). DeCyder software 
identified proteins differentially expressed in response to 72 h obestatin treatment 
(circled), compared to medium only treated controls. These proteins were excised 












Table 5.1 Proteins that were differentially regulated in the SKOV3 ovarian 
cancer and hOSE 17.1 normal ovarian cell lines in response to obestatin 
treatment compared to untreated controls. The effects of obestatin treatment on 
protein expression in the cell lines compared to their respective untreated controls are 
expressed as a positive or negative average ratio (representing the degree of 
difference in the standardized abundance between two groups being compared). 
SKOV3 and hOSE 17.1 were treated with 0, 10 and 100 nM obestatin treatments 
over 72 h.  = proteins downregulated by obestatin treatment compared to untreated 
controls;  = proteins upregulated by obestatin treatment compared to untreated 






Table 5.2 Proteins that were downregulated in response to obestatin treatment 
compared to untreated controls in the SKOV3 ovarian cancer cell line. Proteins 
that were downregulated are shown as a negative average ratio (the degree of 
difference in the standardized abundance between two groups or populations being 
compared). The SKOV3 cell line was treated with 10 nM obestatin for 72 h. The 
major functions of the proteins and their role in cell migration are listed.  = proteins 
downregulated by obestatin treatment compared to untreated controls. Information 
available regarding the known protein functions is summarised from Gene, Pubmed 
(http://www.ncbi.nlm.nih.gov/gene). The relationship between the identified protein 
and cell migration is summarised from the literature. N= no relationship with 
migration has been identified in the literature.  
 
 
Protein (gene) Avg. 
ratio 







↓ (-2.39) NM_001428.3/NP_001419.1 
One of three enolase isoenzymes 
found in mammals which 
function as glycolytic enzymes.  
 
In tumour cells, it is 
upregulated, cell surface 
expressed and supports 
anaerobic proliferation and 
promotes cancer invasion. A 
shorter isoform functions as a 
tumour suppressor. 
 
Gene ID: 2023, updated on 9-
Sep-2012 
Inhibition of alpha-enolase 
inhibits cell migration and 
invasion in the MDA-MB-
231 breast cancer cell line 
by inhibiting secretion of a 






↓ (-1.34) NM_001002858.2/ 
NP_001002858.1 
Belongs to the annexin family of 
calcium-dependent phospholipid 
binding proteins. Members of 
this family play a role in the 
regulation of cellular growth and 
in signal transduction pathways. 
This protein functions as an 
autocrine factor which heightens 
osteoclast formation and bone 
resorption. 
 
Gene ID: 302, updated on 15-
Sep-2012 
Annexin A2 knockdown 
decreased glioma cell line 
and MDA-MB-231 cell 
line migration. In another 
study annexin A2 induced 
increased migration of 
glioma cells toward neural 
stem cells and 






↓ (-6.60) NM_001304.4/NP_001295.2 
Part of the 
metallocarboxypeptidase family 
of enzymes with a subfamily 
classification of a regulatory B-
type carboxypeptidase. 





Protein (gene) Avg. 
ratio 





Functions in the processing of 
proteins that transit the secretory 
pathway 
 




↓ (-1.17) NM_001130053.2/ 
NP_001123525.2  
A subunit of the elongation 
factor-1 complex, which is 
responsible for the enzymatic 
delivery of aminoacyl tRNAs to 
the ribosome. Functions as 
guanine nucleotide exchange 
factor. 
 






↓ (-1.58) NM_001416.3/NP_001407.1 
ATP-dependent RNA helicase 
which is a subunit of the eIF4F 
complex involved in cap 
recognition and is required for 
mRNA binding to ribosome. 
 
Gene ID: 1973, updated on 15-
Sep-2012 
Differentially expressed in 
human colorectal 







↓ (-5.24) NM_005347.4/NP_005338.1  
A member of the heat shock 
protein 70 (HSP70) family. It is 
localized in the lumen of the 
endoplasmic reticulum (ER), 
and is involved in the folding 
and assembly of proteins in the 
ER.  
 
It is a potent anti-apoptotic 
protein and plays a critical role 
in tumour cell survival, tumour 
progression and angiogenesis, 
metastasis and resistance to 
therapy. 
 
Gene ID: 3309, updated on 23-
Sep-2012 
Silencing of GRP78 in 
head and neck cancer cell 
lines inhibits cell 
migration. 
Downregulation of GRP78 
in hepatocellular 








↓ (-3.65) NM_002156.4/NP_002147.2 
HSP60 is a mitochondrial 
protein and member of the 
chaperonin family. It is essential 
for the folding and assembly of 
newly imported proteins in the 
mitochondria 
 
It has been associated with 
carcinogenesis, specifically with 
tumour cell survival and 
proliferation. 
 
Knockdown of HSP60 in 
head and neck cancer cell 
lines enhances cell 
migration. Consistently, 
treatment of T cells with 
HSP60 inhibited 
downstream effects of 
processes required for cell 
migration. Contrastingly, 
treatment with bacterial 
HSP60 in gastric cancer 
cells and epithelial cells 
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ratio 





Gene ID: 3329, updated on 16-
Sep-2012 
Heat shock 





↓ (-2.87) NM_006597.4/NP_006588.1 
A constitutively expressed 
member of the heat shock 
protein 70 family. Functions as a 
chaperone, and binds to nascent 
polypeptides to facilitate correct 
folding. Also functions as an 
ATPase in the disassembly of 
clathrin-coated vesicles during 
transport of membrane 
components through the cell. 
 









An inducible molecular 
chaperone that functions as a 
homodimer. It aids in the proper 
folding of specific target 
proteins by use of an ATPase 
activity that is modulated by co-
chaperones. 
 
Gene ID: 3320, updated on 9-
Sep-2012 
HSP90 is essential for 
CB2-mediated signaling 
of cell migration in human 
embryonic kidney 293 
cells. Mediates MMP-2 
activation and increases 
breast cancer cell 





↓ (-9.79) NM_007355.2/NP_031381.2 
A constitutively expressed 
member of the HSP90 proteins 
that are normally associated with 
other co-chaperones and play 
important roles in folding newly 
synthesized proteins or 
stabilizing and refolding 
denatured proteins after stress. 
 
Gene ID: 3326, updated on 25-
Sep-2012 
HSP90 is essential for 
CB2-mediated signaling 
for cell migration in 









↓ (-3.65) NM_002140.3/NP_002131.2 




that are associated with pre-
mRNAs in the nucleus and 
appear to influence pre-mRNA 
processing and other aspects of 
mRNA metabolism and 
transport. This protein is also 
thought to have a role during 
cell cycle progression. 
 
Gene ID: 3190, updated on 25-
Sep-2012 
hnRNPK appears to be a 
multifunctional signaling 
protein in metastasis of 
cancer. Co-expression of 
HNRNPK with N- 
Wiskott-Aldrich syndrome 
protein (N-WASP) 
reverses the stimulation of 
cell spreading by N-
WASP during cell 









Protein (gene) Avg. 
ratio 








Belongs to the subfamily of 
ubiquitously expressed 
heterogeneous nuclear 
ribonucleoproteins (hnRNPs) as 
hnRNP K above. This protein is 
involved in the assembly of 40S 
hnRNP particles. 
 





↓ (-1.29) NM_021129.3/NP_066952.1 
A member of the inorganic 
pyrophosphatase (PPase) family. 
PPases catalyze the hydrolysis 
of pyrophosphate to inorganic 
phosphate, which is important 
for the phosphate metabolism of 
cells. 
 





↓ (-1.17) NM_002520.6/NP_002511.1 
This is a phosphoprotein which 
moves between the nucleus and 
the cytoplasm and is thought to 
be involved in several processes 
including regulation of the 
ARF/p53 pathway. 
 
Mutations in this gene are 
associated with acute myeloid 
leukemia. 
 




to the limited motility, 
migration, and 
phagocytosis capabilities 
of resting macrophages. 
Nucleophosmin gene 
activating mutations 
promote NIH3T3 acute 
myeloid leukemia cell 
migration and invasion. 
Accumulation of NPM1 
increased cellular 
migration, invasiveness, 
and colony formation in 
lung adenocarcinoma cell 
lines. 
Expression of MRJ 
(Mammalian relative of 
DnaJ) in breast cancer cell 
lines decreased migration 
and invasion and was 






↓ (-3.65) NM_002654.4/NP_002645.3 
Large allosteric enzyme that 
regulates glycolysis. Interacts 
with thyroid hormones and may 
mediate their cellular metabolic 
effects. 
 





↓ (-7.20) NM_032704.3/NP_116093.1 
Part of the tubulin superfamily, 
alpha-tubulin, with beta-tubulin, 
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Gene ID: 84790, updated on 15-
Sep-2012 
Vimentin (VIM) ↓ (-7.20) NM_003380.3/NP_003371.2 
A member of the intermediate 
filament family. It is responsible 
for maintaining cell shape, 
integrity of the cytoplasm, and 
stabilizing cytoskeletal 
interactions. Also involved in 
the immune response, and 
controls the transport of low-
density lipoprotein (LDL)-
derived cholesterol from a 
lysosome to the site of 
esterification. It functions as an 
organizer of a number of critical 
proteins involved in attachment, 
migration, and cell signalling. 
 




(EMT). Up regulation of 
vimentin in hepatocellular 
carcinoma enhances cell 
migration. Correlates with 
EGFR and Stat3 activity 
to promote migration in 

























Table 5.3 Proteins that were upregulated in the SKOV3 ovarian cancer cell line 
in response to obestatin treatment compared to untreated controls. The average 
ratio (the degree of difference in the standardized abundance between two groups or 
populations being compared) is shown. The SKOV3 cell line was treated with 10 nM 
obestatin for 72 h. The major functions of the proteins and their role in cell migration 
are listed. = proteins that were upregulated by obestatin treatment compared to 
untreated controls. Information available regarding the known protein functions is 
summarised from Gene, Pubmed (http://www.ncbi.nlm.nih.gov/gene). The 
relationship between the identified protein and cell migration is summarised from the 
literature. N= no relationship to migration has been identified in the literature.  
 
 
Protein (Gene) Avg. 
ratio 










↑ (1.56) NM_030978.1/NP_112240.1 
Function not defined. May 
function as component of the 
Arp2/3 complex which is 
involved in regulation of actin 
polymerization and together 
with an activating nucleation-
promoting factor (NPF) 
mediates the formation of 
branched actin networks 
 





↑ (1.23) NM_001153.3/NP_001144.1 
Belongs to the annexin family of 
calcium-dependent phospholipid 
binding proteins. Functions are 
still not clearly defined, may be 
involved in exocytotic and 
endocytotic pathways. ANX4 
has possible interactions with 
ATP, and has in vitro 
anticoagulant activity and also 
inhibits phospholipase A2 
activity. 
 
Gene ID: 307, updated on 9-
Sep-2012 
Transient transfection of 
microRNA-7 into glioma 
cell lines causes inhibition 
of cell migration and 
invasion and suppression 
of tumorigenesis, 2-DE 
analysis identified down-
regulated ANXA4 among 
the protein spots 
differentially expressed. In 
renal cell carcinoma over-
expressed annexin IV 
promotes cell migration 
[606, 607] 
Cofilin-1 (CFL1) ↑ (1.56) NM_005507.2/ NP_005498.1 
A widely distributed 
intracellular actin-modulating 
protein that binds and 
depolymerizes filamentous F-
actin and inhibits the 
polymerization of monomeric 
G-actin in a pH-dependent 
manner. 
 
Cofilin-1 is involved in 
filopodium disassembly a 
process of cell migration. 
Increase in the level of 
cofilin in human colon 
adenocarcinoma cells, 
along with a reduction of 
inactive phosphorylated 
form of cofilin, was linked 
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expression induced cell 
migration in human 
nasopharyngeal carcinoma 
cells. Phosphorylation and 
inactivation of CFL1 in 
basal breast cancer cell 




↑ (1.47) NM_000852.3/NP_000843.1 
Glutathione S-transferases 
(GSTs) are a family of enzymes 
that play an important role in 
detoxification by catalyzing the 
conjugation of many 
hydrophobic and electrophilic 
compounds with reduced 
glutathione. 
 
GSTP1 variant proteins are 
thought to function in xenobiotic 
metabolism and play a role in 
susceptibility to cancer and other 
diseases. 
 
Gene ID: 2950, updated on 23-
Sep-2012 
Enhances migration in 






↑ (2.14) NM_005809.4/NP_005800.3 
A member of the peroxiredoxin 
family of antioxidant enzymes, 
which reduce hydrogen peroxide 
and alkyl hydroperoxides. This 
protein may play an antioxidant 
protective role in cells, and may 
contribute to the antiviral 
activity of CD8 (+) T-cells.  
 
This protein may have a 
proliferative effect and play a 
role in cancer development or 
progression. 
 
Gene ID: 7001, updated on 15-
Sep-2012 
Aloe-emodin (the main 
bioactive anthraquinones 
of Rheum palmatum) 
causes decreased cell 
migration along with 
enhanced oxidation of 
PRDX2 in HepG2 cells. 
PRDX2 is a negative 
regulator of PDGF 
signalling. Deficiency 
results in increased 
production of H2O2, 
enhanced activation of 
PDGF receptor and 
phospholipase Cgamma1, 






↑ (2.17) NM_002790.3/NP_002781.2 
A proteasome is a multicatalytic 
proteinase complex that cleaves 
peptides in an ATP/ubiquitin-
dependent process in a non-
lysosomal pathway. This protein 
is a member of the peptidase 
T1A family. 
 






↑ (1.47) NM_006793.2/NP_006784.1 
A mitochondrial protein with 
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protective role in cells through 
its peroxidase activity by 
reducing hydrogen peroxide, 
peroxynitrite, and organic 
hydroperoxides. 
 




↑ (1.23) NM_178014.2/NP_821133.1 
Part of the tubulin superfamily, 
beta-tubulin, with alpha-tubulin, 
make up the major components 
of microtubules 
 
Gene ID: 203068, updated on 9-
Sep-2012 
Upregulated in metastatic 
axillary lymph node breast 









↑ (4.19) NM_004181.4/NP_004172.2 
Belongs to the peptidase C12 
family. This enzyme is a thiol 
protease that hydrolyzes a 
peptide bond at the C-terminal 
glycine of ubiquitin. 
 

















Figure 5.2 The top biological network identified using IPA analysis highlights 
ERK1/2 (shown in red) as a central hub relating to other proteins from the 
connectivity map. Nodes with blue background are the proteins differentially 
regulated by obestatin treatment in the SKOV3 ovarian cancer cell line. A line 
indicates interactions, with the arrow-head indicating the direction of the interaction  
(i.e. the protein that is being influenced). The absence of arrowheads refers to a 












Table 5.4 Top two networks generated, from the identified proteins, by the 
Ingenuity Pathway Analysis software. Proteins that were differentially regulated 
by obestatin treatment in response obestatin treatment were entered into the IPA 
software for network generation and analysis. Proteins shown in bold are 
differentially expressed proteins which were identified in this study. The score is a 
number generated by the Ingenuity Pathway Analysis software to represent the 
likelihood that the proteins are grouped together functionally in the network, rather 
than being discovered together by chance, with a 99% confidence level. The higher 
the score the stronger the grouping, and scores ≥3 are considered to be significant. 
Focus molecules indicate the number of proteins from the list of proteins entered into 
the analysis that are represented in the network. 
 
ID Molecules in Network Score Focus 
Molecules 
Top Functions of 
pathway 
1 Actin, Alpha tubulin, ANXA2, ANXA4, Caspase, 
CFL1, Ck2, DNAJB3, DNAJC22, DNAJC25, 
DNAJC28, ERK1/2, GSTP1, HNRNPC, HSP, 
Hsp70, Hsp90, HSP90AA1, HSP90AB1, HSPA5, 
HSPA7, HSPA8, HSPA12B, HSPD1, Insulin, 
NFkB (complex), NPM1, Pkc(s), PKM2, PRDX2, 
TUBA1C, TUBB, VIM 





2 AGTR1, ANKRD12, ARPC5L, BAI3, CDKN2A, 
CLEC2A, CPD, Cytochrome c, EEF1D, EIF4A1, 
EIF4E, EMR3, ENO1, FFAR3, GIP2 (human), 
GPR21, GPR87, HS3ST1, IFNG, LGMN, 
MORC2, Myb, MYC, PPA1, PRDX3, PSMA5, 
RARRES1, Rpl9 (includes others), RT1-B, 
SCPEP1, TP53, tretinoin, UCHL1, VSIG4, 
ZNF385A 
















known protein interactions (Fig. 5.2 and Table 5.4). Proteins were also associated 
with a network which consists of a number of molecules related to cell cycle control, 
cell death and cancer (Table 5.4).  
 
5.3.2 Obestatin stimulates a reduction in ERK1/2 phosphorylation in ovarian 
cancer cell lines 
In this study, the application of proteomic approaches was used to demonstrate that a 
number of proteins were differentially expressed in response to obestatin treatment in 
the SKOV3 ovarian cancer cell line. Further analysis using the IPA software 
identified the ERK1/2 MAPK pathway as a potentially important mediator of 
obestatin action, as it was associated with a number of proteins that were regulated 
by obestatin treatment. To determine if obestatin also stimulated the activation 
(phosphorylation) of the ERK1/2 signalling pathway Western blot analyses were 
performed using anti-active antibodies. Time-points with the most significant 
responses to obestatin were chosen after performing time course assays (for 0, 5, 15, 
30, 45, or 60 min). Experiments were then performed to investigate ERK1/2 
signalling in response to a range of concentrations of obestatin in the SKOV3 and 
OV-MZ-6 ovarian cancer cell lines (Fig. 5.3). Western blot analysis of a range of 
obestatin concentrations showed that ERK1/2 phosphorylation was significantly 
decreased with the 1000 nM obestatin treatment in both the SKOV3 (0.69 fold +/- 
0.25) and OV-MZ-6 (0.40 fold +/- 0.18) cell lines and with the 100 nM treatment in 
the SKOV3 cell line (0.78 fold +/- 0.10).  
 
To confirm this result using a highly quantitative assay, the effects of obestatin 
treatment on ERK1/2 signalling in the SKOV3 ovarian cancer cell line was 
performed across a range of time-points using a phospho-ERK1/2 ELISA kit (Sigma-
Aldrich). Serum starved SKOV3 cells were treated with 0, 10 and 100 nM 
concentrations of obestatin for 5-30 min (Fig. 5.4). No statistically significant 
changes in phosphorylation were observed with obestatin treatment, compared to the 
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Figure 5.3 Western immunoblot analysis of ERK1/2 phosphorylation after 
obestatin treatment in the SKOV3 and OV-MZ-6 ovarian cancer cell lines. 
Serum-starved cells were treated with a range of obestatin concentrations (0, 0.1, 1, 
10,100, and 1000 nM) for 15 min in the SKOV3 cell line and 30 mins in the OV-
MZ-6 cell line (determined as the peak ERK1/2 signalling timepoints for these cell 
lines, see Chapter 2). Representative Western immunoblot of triplicate experiments 
showing cell lysates analysed using anti-phospho ERK1/2 and anti-Total ERK 
antibodies in the (A) SKOV3 and (B) OV-MZ-6 ovarian cancer cell lines. 
Densitometry was performed to quantify the changes in protein expression with 
different obestatin treatments in the (C) SKOV3 and (D) OV-MZ-6 cell lines. The 
densitometry data are an average of the triplicate experiment expressed as histograms 
(mean ±SEM) corrected total ERK1/2 in each protein extract. *P < 0.05 compared to 










































) + Erk2 (pTyr
185/187
) and pan-Erk1/2 ELISA Kit in the SKOV3 
ovarian cancer cell line. Serum-starved cells were treated with 0, 10 and 100 nM 
concentrations of obestatin for 0, 5, 10, 15 and 30 min. Graph represents a single 
experiment with phosphorylated ERK1/2 absorbance values normalised to pan 
ERK1/2 (mean ±SEM). Samples were assayed in duplicate (n=2) for each treatment 
at each timepoint. 
 
5.4 Discussion 
Using a proteomic approach in this study, we identified 26 proteins that were 
differentially regulated by obestatin compared to medium-only controls. The 
differentially expressed proteins were analysed using the Ingenuity Pathway Analysis 
(IPA) software to predict the pathways that are activated by obestatin. The two top 
networks associated with obestatin treatment that were identified were cancer 
progression and cell cycle regulation, providing further evidence that obestatin plays 
a role in cancer progression.  
 
Using IPA, the ERK1/2 pathway was determined to be a key, central component in 
the mediation of these functions, and, therefore, this signalling pathway was further 
investigated in the ovarian cancer cell lines. Surprisingly, however, although 
treatment with obestatin was expected to activate ERK1/2 phosphorylation in the 
OV-MZ-6 or SKOV3 cell lines, it decreased phosphorylation at the time points 
tested. Taken together, these data suggest that obestatin, like ghrelin, could play a 





2D-DIGE proteomic analysis of normal (hOSE 17.1) and ovarian cancer (SKOV3) 
cells treated with (+/-) obestatin revealed that a number of proteins were 
differentially expressed. On the basis of the known or putative functions of these 
proteins, they can be grouped into a number of broad functional categories; including 
roles in the cytoskeleton, cellular motility and plasticity (vimentin, tubulin alpha-1C 
chain, tubulin beta chain, ARPC5L, cofilin-1, annexins), protein folding, 
modification and degradation (glucose regulated protein 78, proteasome subunit 
alpha type-5, heat shock proteins, ubiquitin carboxyl-terminal hydrolase isozyme L1, 
carboxypeptidase D), metabolism and enzymatic capabilities (glutathione S-
transferase P, alpha-enolase, pyruvate kinase isozyme M1/M2), 
transcription/translation factors (EEF1D, EIF4A1, heterogeneous nuclear 
ribonucleoproteins), regulation of apoptosis (nucleophosmin, heat shock proteins) 
and antioxidant proteins (peroxiredoxin-2, thioredoxin-dependent peroxide 
reductase).  
 
Some of the proteins identified in this study have previously been associated with 
cell migration in other studies (Tables 5.2 and 5.3). Additionally, a number of the 
proteins that were differentially expressed in this study in response to obestatin 
treatment have also been previously reported to be associated with increased cell 
migration, or related functions. Increases in annexin A4 [607], CFL1 [608-611] and 
GSTP1 [612] expression, or inhibition of hnRNPK [597], HSPD1/HSP60 [588] and 
HSPA5 [586, 588, 589] have been shown to stimulate cell migration. Increased 
expression of annexin 4 in renal clear cell carcinoma cells was shown to increase cell 
migration [607] and annexin 4 may also play a role in increased cell migration in 
SKOV3 cells. A similar link between annexin A4 and migration was found in glioma 
cells, where it was shown that microRNA-7 decreased annexin 4 expression and 
decreased migration in the glioma cell lines [606]. In neck cancer cell lines, the 
combined knockdown/inhibition of HSPD1 and HSPA5 was found to considerably 
enhance cell migration [588]. Knockdown of these proteins in ovarian cancer cell 
lines, followed treatment with obestatin, would help to determine the role of these 




For some of these proteins there has been conflicting data regarding their role in cell 
migration, however, suggesting that there may be tissue specific responses. In head 
and neck cancer, knockdown of the gene for Heat shock protein 60, HSPD1 was 
correlated with increased migration [588]. Similarly, in our study obestatin led to a 
decrease in Hsp60 protein expression and this coincided with increased cell 
migration. In purified human T cells [591] and the AGS gastric cancer cell line 
[592], however, Hsp60 treatment was linked to enhanced migration. Not all of the 
changes observed in our study are consistent with an increase in cell migration with 
obestatin treatment, and obestatin may have additional functions in ovarian cancer 
cell lines. Although not all of the differentially regulated proteins were associated 
with cell migration, some proteins, including EIF4A [584] and TUBB [615] have 
been linked to metastasis. 
 
A number of proteins, that have been associated with increased cell migration, were 
regulated by obestatin, but the response did not support their role in obestatin-
mediated migration. It is likely that obestatin has other cellular effects in addition to 
the stimulation of cell migration. An upregulation of alpha-enolase [577, 578], 
annexin A2 [579], Hsp90 alpha and Hsp90 beta [594, 595], nucleophosmin [598-
601], and vimentin [586, 587, 602-605] is usually associated with an increase in cell 
migration, however, their expression in response to obestatin was decreased in the 
current study (Table 5.3). Conversely, periredoxin-2 was elevated with obestatin 
treatment (Table 5.4), however, in vascular remodelling a deficiency of PRDX2 
indirectly enhanced cell migration [614]. Aloe-emodin treatment of the HepG2 cell 
line enhanced oxidation of PRDX2 and was associated with decreased migration 
[613]. The majority of these studies, however, observed these proteins during 
interactions with other proteins and/or drugs and their effect and response may differ 
under different circumstances.  
 
An increase in vimentin expression is frequently associated with increased migration 
[586, 587, 602-605], but protein expression was reduced in the SKOV3 and hOSE 
17.1 cell lines in response to obestatin treatment. Upregulation of vimentin 
expression coincided with the downregulation GRP78 in hepatocellular carcinoma 
cells and is associated with increased cell migration [586, 587], whereas in the 
current work, obestatin treatment downregulated both proteins. In a study on aortic 
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valve disease the secretion of cytokines by invading inflammatory cells induced 
myofibroblastic activation, characterised by decreased vimentin expression and 
increased migration [616].  
 
Although obestatin stimulates cell migration in the SKOV3 ovarian cancer cell line, 
as indicated not all of the changes seen in protein expression correlated with 
expected changes. In this study, cells were treated with obestatin for 3 days (and this 
was consistent with the pre-treatment and treatment for migration assays) in flasks 
(80-90% confluent upon harvest) and migrating cells were not harvested from 
Transwell migration assays. The collection of cells in an assay that allows cell 
migration in response to obestatin would select for proteins related to this process. 
To investigate this, the 2D-DIGE experiment and analysis could be repeated with 
obestatin treated cells in Transwell assays and gene expression could also be 
determined using oligonucleotide microarrays.  
 
With obestatin treatment, significant increases in cell invasion were also observed in 
the OV-MZ-6 ovarian cancer cell line and the hOSE 17.1 normal ovarian cell line, 
but not in the SKOV3 cell line (see Chapter 4). While a number of molecules 
associated with cell invasion were differentially regulated by obestatin, including 
annexin A2 [579, 617], HSP60 [588], GRP78 [588], α-enolase [577] and 
nucleophosmin [599], the direction of change (up or downregulation) did not 
correspond with previously described changes. In the current study, obestatin 
treatment caused a decrease in annexin A2, HSP60, GPR78, α-enolase and 
nucleophosmin. Conversely, accumulation, or activation, of nucleophosmin has been 
linked to a more invasive phenotype [599-601]. The combined downregulation of 
HSP60 and GRP78 significantly reduced invasiveness of head and neck cancer cell 
lines [588]. Similarly, inhibition of α-enolase [577] decreased invasive potential of 
the MDA-MB-231 breast cancer cell line. Annexin A2 is normally up regulated on 
the cell surface in cancer cells, influencing cancer related processes including 
angiogenesis, proliferation, apoptosis, adhesion, cell migration and also increasing 
cell invasion [617]. In ovarian cancer, annexin A2 is upregulated in the conditioned 
medium from cultured ovarian cancer cells. In the current study proteins were 
measured from cell lysates, and this could explain the observed difference in 
expression for this protein [617]. As discussed earlier, the difference in expression of 
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these proteins observed from the results of the 2D-DIGE, compared to other studies, 
may be the result of the cells not being collected under migrating conditions. 
Subsequently, this may change their response to obestatin if they were migrating 
upon collection.  
 
Additionally, the cancer related proteins, α-enolase and hnRNP K, were 
downregulated by obestatin in this study (Table 5.3). Alpha-enolase is upregulated in 
cancer, supporting anaerobic proliferation and invasion of the tumour [577]. 
hnRNPK, a multifunctional signalling protein, has been shown to be crucial for 
metastasis in HT1080 (human fibrosarcoma) and HEK293T (human embryonic 
kidney carcinoma) cancer cell lines [596]. The expression of these proteins may 
change if collected from cells in a migration assay. 
 
It is important to consider that the differentially expressed proteins were identified by 
2D-DIGE, and therefore, their change in expression is not necessarily due to a 
change in the level of protein expression. Changes in apparent abundance of a 
protein in response to a treatment may result from a shift in the position of a protein 
on a gel due to altered post-translational modifications, causing changes in pI or the 
size of the protein. In a two-dimensional gel electrophoresis (2DGE) analysis of 
oxidative stress in cardiac myocytes, for example, changes in the abundance of 
peroxiredoxins and two small heat shock protein (Hsp) family members were 
observed, however, this was not due to a change in protein level [618], but due to 
altered protein modification. The shift in abundance of peroxiredoxins is 
hypothesized to result from the over-oxidation of active site Cys residues. The Hsp 
may have become phosphorylated, causing a shift to lower pI values [618]. The 
observed upregulation of cofilin-1 after obestatin treatment may also indicate a 
change in phosphorylation status. Phosphorylation of cofilin-1 inactivates it and 
would also change its pI value. An increase in cofilin-1, in addition to a reduction in 
its phosphorylated form, was linked to the stimulation of cell migration in human 
colon adenocarcinoma cell lines compared to more motile adenocarcinoma sublines 
(EB3, 3LNLN, 5W) and cell lines derived from the parental LS180 adenocarcinoma 
cell line and the fibroblastic normal rat kidney (NRK) cell line [609]. Increased 
migration was also correlated with decreased cofilin-1 phosphorylation in 
nasopharyngeal carcinoma cell lines in response to siRNA knockdown of p57kip2, a 
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CDK inhibitor [610]. Similarly, increases in the phosphorylated form of this protein 
inhibited cell migration in breast cancer cell lines [611]. It is possible that obestatin 
could have effects by influencing protein modifications. 
 
2D-DIGE analysis without prior fractionation of the sample may lead to under-
representation of low abundance and small proteins. Further fractionation of the 
sample prior to 2D separation can increase the protein coverage of the method and 
allow the identification of these proteins and the application of other methods can 
complement this method [619]. Liquid chromatographic separation, coupled with 
mass spectrometry and labelling of proteins (or label-free methods), can lead to the 
identification of a different range of differentially expressed proteins and 
complementary coverage of the proteome and further studies could employ these 
methods.   
 
The IPA of the 26 proteins identified the ERK1/2 pathways as major mediating 
pathway for the obestatin regulated proteins. Western blot analysis in the ovarian 
cancer cell lines showed a significant decrease in ERK1/2 phosphorylation with 100 
nM and 1000 nM obestatin treatments, indicating that treatment downregulated this 
signalling pathway. This contrasts the results of the 2D-DIGE experiment which 
showed the most significant changes were induced by 10 nM obestain treatment, 
while significant downregulation of ERK1/2 phosphorylation occurred with 100 and 
1000-nM treatments. This discrepancy may be attributed to an accumulative effect in 
the 2D-DIGE experiment, as these cells received 3 treatments of obestatin, as 
opposed to the signalling study where the cell received a single treatment. 
Additionally, it should be noted that expression of the ERK1/2 protein itself was not 
demonstrated using 2D DIGE, although it was a central pathway identified using 
pathway analysis. Quantitative assays using ERK1/2 ELISAs did not demonstrate a 
significant change in phosphoyrlation in response to obestatin treatment at a range of 
time points in the SKOV3 cell line. Although these results appear to contradict the 
software analysis it should be noted that the IPA analysis draws on information from 
a database of all known protein interactions from the literature, in all tissue types. 
The responses we observed may be specific to the ovary. In the previous chapter, it 
was demonstrated that obestatin significantly increased cell migration in both the 
SKOV3 and OV-MZ-6 ovarian cancer cell lines, but not the hOSE 17.1 normal 
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ovarian cell line (Chapter 4.3.3). These results suggest that it is unlikely that 
obestatin-stimulated migration in the ovarian cancer cell lines is mediated by the 
ERK1/2 pathway. Obestatin signalling pathways have not been widely explored [7]. 
ERK1/2 has previously been shown to be associated with obestatin signalling in cell 
proliferation and the anti-apoptotic effects of obestatin [10-12, 45, 462, 465, 466], 
but there have been no studies demonstrating that obestatin stimulates cell migration. 
 
ERK1/2 phosphorylation was determined 15 mins after treatment in the SKOV3 cell 
line and 30 mins after treatment in the OV-MZ-6 cell line, as the overall peak 
signalling response for ERK1/2 was seen at these timepoints. This is consistent with 
another study in porcine ovarian co-culture cells that observed maximum stimulation 
of phospho-ERK1/2 levels after a 15 min incubation [509]. Further studies are 
required to investigate of ERK1/2 signalling at a range of timepoints, however, 
would confirm the lack stimulation is not due to the timepoint chosen. Using a 
phospho-ERK1/2 ELISA kit (Sigma), no statistically significant change in 
phosphorylation was observed with treatment. This study also suggests that ERK1/2 
signalling is not associated with obestatin-stimulated cell migration.  
 
Through IPA, the PKC signalling pathway and the NF-κB signalling complex were 
associated with obestatin treatment. These two pathways have been previously 
shown to be involved in ghrelin-stimulated migration [16, 55] and should be 
investigated as pathways that may regulate obestatin-stimulated migration in ovarian 
cancer cell lines. 
 
This is the first report showing that the ghrelin-gene derived peptide, obestatin, 
differentially regulates a range of proteins related to cancer and cell functions, 


































There is an expanding body of research providing evidence for a role of the ghrelin 
axis in cancer development and progression [15], and this study has provided 
evidence that it has a role in ovarian cancer. This study has demonstrated for the first 
time that both ghrelin and obestatin promote cell migration in the SKOV3 and OV-
MZ-6 serous ovarian cancer cell lines, but not in the hOSE 17.1 normal ovarian 
epithelial cell line, and these peptides may play a role in ovarian cancer progression. 
Ghrelin treatment also decreased SKOV3 attachment to collagen IV. In both the 
SKOV3 and OV-MZ-6 ovarian cancer cell lines, obestatin treatment led to a decrease 
in ERK1/2 phosphorylation. Obestatin also stimulated invasion in the OV-MZ-6 
ovarian cancer and hOSE 17.1 normal ovarian cell lines, however, no change in 
invasion was observed in the SKOV3 ovarian cancer cell line. Interestingly, neither 
ghrelin or obestatin had any effect on proliferation in any of the cell lines studied, 
although they have been shown to influence cell proliferation in a number of other 
types [7, 15].  
 
It is well established that ghrelin is an orexigen and a growth hormone secretagogue, 
however, this multi-functional peptide also has roles in cardiac function, immunity, 
growth, appetite, sleep and cellular functions including proliferation, migration and 
apoptosis [4, 15, 381]. The peptide, obestatin, is also derived from the ghrelin gene 
and the ghrelin preprohormone [6]. Despite initial controversy, a number of studies 
have demonstrated that obestatin, like ghrelin, has a diverse range of functions and 
some roles may be similar to those of ghrelin [7]. Components of the ghrelin axis are 
expressed in a wide range of cancer types, and in some cases, expression is altered in 
cancer (see Chapter 1) [15]. Ghrelin and obestatin have been shown to influence a 
number of cellular functions associated with the hallmarks of cancer [7, 15].  
 
In this thesis, the expression and function of ghrelin and the preproghrelin derived 
hormone, obestatin, were investigated in ovarian cancer. There is some evidence that 
ghrelin and obestatin levels may be elevated in ovarian cancer. In a small, 
independent study of patients undergoing surgery for benign ovarian tumours (22 
patients), or ovarian cancer (31 patients), plasma concentrations of both acylated 
ghrelin and obestatin were elevated, compared to 32 control women. This suggested 
that these peptides could play a role in ovarian cancer, and obestatin could be a 
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useful biomarker for ovarian cancer [114]. There were, however, a number of 
limitations to this study, including small sample size and the measurement of 
acylated ghrelin may have been unreliable due to the pre-treatment of the plasma 
samples [114]. In addition, acyl ghrelin levels were not correlated with BMI in this 
study. An immunohistochemical study of serous ovarian tumours observed increased 
expression of ghrelin, but not obestatin, in malignant samples compared to benign 
tissues [380]. We investigated the expression of ghrelin, GHSR1a and obestatin 
mRNA in ovarian cancers (including serous, papillary serous, endometrioid, clear 
cell and mucinous adenocarcinomas) of a range of stages (from I to IV) and in 
ovarian cancer cell lines (Chapter 3.3.1 and 4.3.1). Although expression of ghrelin 
and obestatin transcripts was demonstrated in normal and tumour tissue, their 
expression was not correlated with cancer grade, or consistently elevated in all 
samples compared to the normal tissue. Our data suggests that obestatin and ghrelin 
expression may be upregulated in a subset of ovarian cancers, however.  
 
As most ovarian cancers are derived from the single layer of ovarian surface 
epithelium (which is often detached during dissection of the ovary), and the normal 
samples in this study are derived from whole ovary, which is a heterogenous organ, it 
was not possible to compare expression of normal ovarian epithelium and cancer 
using RT-PCR in this study, however. Using immunohistochemistry for obestatin we 
have demonstrated that obestatin is expressed at very low or absent levels in ovarian 
surface epithelium, and expression is higher in ovarian cancers and benign tumours. 
A recent study also showed no change in obestatin expression, but an increase in 
ghrelin expression in malignant serous ovarian tumours tissues compared to benign 
tissues [380]. As this study only investigated one type of ovarian cancer, serous, 
further immunohistochemical studies of ghrelin expression in other types of ovarian 
cancer and benign tissue are required. 
 
Interestingly, the cell lines studied expressed the GHSR1b (the truncated ghrelin 
receptor) isoform, but not the ghrelin receptor, GSHR1a. This is consistent with our 
previous studies showing that high grade serous cystadenocarcinomas did not 
express GHSR1a [45]. Although we have demonstrated that GHSR1a is not 
expressed at the mRNA level in a panel of ovarian tumours, we have previously 
demonstrated GHSR1a expression in ovarian cancer using an immunohistochemical 
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approach [45] and these results are difficult to reconcile. It is surprising that the 
GHSR1a protein was demonstrated in ovarian cancer [45], but the mRNA is not 
expressed. The mRNA isoforms expressed by ovarian cancer may be different to the 
wildtype receptor isoform and could not be detected using our RT-PCR assays, 
which we have used to demonstrate GHSR1a expression in prostate [39], breast [17] 
and endometrial cancer [49]. Conversely, the antibodies used in 
immunohistochemical studies were generated against the C-terminal region of the 
GHSR1a and it might cross react with undescribed variants of the receptor, or it may 
lack specificity and bind to related GPCRs. Further protein analysis, using more 
sensitive and specific methods, such as tandem mass spectrometry, are required to 
investigate these results.  
 
As the ovarian cell lines in this study do not appear to express the GHSR1a, it is 
likely that the effects of ghrelin are mediated through the alternative ghrelin receptor. 
Given the identity of this receptor is unknown, we are unable to investigate this 
further by targeting the alternative receptor specifically. It would be useful to 
determine if these cell lines showed the same response to desacyl ghrelin treatment, 
as it acts through the alternative ghrelin receptor. The use of GHSR1a antagonists to 
ensure inhibition of any residual GHSR1a action, may also prove difficult, as it is 
possible that the alternative receptor may have similar binding sites to GHSR1a. 
Indeed, the GHSR1a inverse agonist, D-Lys3-GHRP-6, has been shown to inhibit the 
action of desacyl ghrelin [549]. By reintroducing the GHSR1a receptor to these cell 
lines using expression constructs, we can investigate whether any of the results seen 
may be altered due to the overexpression of GHSR1a. Similarly, the identity of the 
obestatin receptor is currently unknown, although it appears to be a G protein 
coupled receptor. Although the identity of the receptor is unknown, the signalling 
pathways involved in obestatin function in ovarian cancer could be investigated 
further.  
 
There is evidence that ghrelin and obestatin may play a role in a number of processes 
related to cancer progression [7, 15, 381]. The progression and development of 
cancer is characterised by a number of predictable steps and processes, defined as the 
hallmarks of cancer [392, 393]. These hallmarks of cancer include self-sufficiency in 
growth signals, insensitivity to growth-inhibitory (antigrowth) signals, evasion of 
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programmed cell death (apoptosis), limitless replicative potential, sustained 
angiogenesis, and increased tissue invasion and metastasis [392, 393]. Few studies 
have investigated the role of obestatin in cancer. As obestatin levels may be elevated 
in the circulation of patients with ovarian tumours [114], and it is expressed in 
ovarian cancer cells [380, 465, 620], (Chapter 4), we hypothesise that it may play an 
endocrine or autocrine/paracrine role in ovarian cancer.  
 
The most significant finding of this study was that both ghrelin and obestatin 
increased cell migration by approximately 2 fold in the SKOV3 and OV-MZ-6 
ovarian cancer cell lines. This is the first demonstration that the peptide hormone, 
obestatin, stimulates cell migration in any cell line, and this provides a novel avenue 
for further research. The response to both acylated ghrelin and obestatin treatment 
was investigated in two ovarian cancer cell lines and a normal cell line in this study, 
and indicated that the response may be cancer specific, however, further studies in 
additional normal and cancer cell lines are required. In this study, ovarian cancer cell 
lines were derived from serous ovarian adenocarcinomas cells that had metastasised 
to the ascites, rather than from the primary tumour site, and thus, they are likely to 
have been an actively migrating phenotype. Cell lines representing a number of other 
ovarian cancer subtypes could also be tested. In vivo xenograft metastasis assays, 
including the injection of cells into the peritoneal cavity of immunocompromised 
mice, could provide further insights into the ability of ovarian cancer cells to migrate 
and metastasise in response to acylated ghrelin and obestatin. 
 
Although ghrelin has been demonstrated to increase cell migration in other cancer 
cell lines [48, 54], this is the first demonstration that exogenous ghrelin treatment 
increases cell migration in ovarian cancer cell lines. In a previous study using 
Boyden chambers (BD Bioscience, Bedford, MA), increased migration and invasion 
(Matrigel coated) was seen in poorly differentiated PANC1 and MIAPaCa2, and 
well-differentiated BxPC3 and Capan2 human pancreatic cancer cell lines with 
ghrelin treatment [54]. Treatment with the GHSR inverse agonist, D-Lys-3-GHRP-6, 
inhibited ghrelin-stimulated cell migration [54]. Inhibition of migration using D-Lys-
3-GHRP-6 suggests that ghrelin-stimulated cell migration may be mediated by 
GHSR1a, and both GHSR1a and GHSR1b were expressed in these pancreatic cancer 
cell lines [48, 54]. It is possible, however, that this inverse agonist may also bind the 
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alternative ghrelin receptor as it has been shown to inhibit the response to desacyl 
ghrelin [210, 549], which does not act through the GHSR1a receptor. Treatment with 
an antibody against endogenous ghrelin in the SW-48 and ROK colon cancer cell 
lines also inhibited cell migration [48]. Similar studies could be performed in ovarian 
cell lines to determine if the GHSR1a and endogenous (autocrine/paracrine) ghrelin 
play a role in ovarian cancer cell migration, although our studies indicate that this 
receptor might not be expressed in ovarian cancer. We hypothesise that in ovarian 
cancer, ghrelin stimulates cell migration through the alternative ghrelin receptor, the 
identity of which is currently unknown.  
 
This is the first study to indicate that obestatin may play a role in cell migration. In 
this study, we investigated the effect of obestatin treatment on protein expression 
using 2D-DIGE (two dimensional-difference in gel electrophoresis) and mass 
spectroscopy (Chapter 5.3.1) to provide insight into the mechanism of action of 
obestatin. This study revealed that 26 proteins were differentially expressed by the 
obestatin-treated SKOV3 ovarian cancer cell line, compared to the untreated 
controls. Proteins that were regulated by obestatin treatment were analysed using 
Ingenuity Pathway Analysis. The top two networks identified suggested that the 
proteins identified from the 2D-DIGE experiment were likely to be involved in 
cellular processes including post-translational modification, the cell cycle and cell 
death. The differentially expressed proteins belonged to a number of functional 
groups. Some were associated with the cytoskeleton, cellular motility and plasticity 
and included: vimentin, tubulin alpha-1C chain, tubulin beta chain, ARPC5L, cofilin-
1 and the annexins. Other proteins were identified as having a role in protein folding, 
modification and degradation (including GRP78, proteasome subunit alpha type-5, 
heat shock proteins, ubiquitin carboxyl-terminal hydrolase isozyme L1, 
carboxypeptidase D), or as having metabolic and enzymatic capabilities (including 
glutathione S-transferase P, alpha-enolase, pyruvate kinase isozyme M1/M2). As 
expected, given the fact that obestatin stimulated cell migration in our in vitro 
studies, a number of these proteins were identified as being involved in cell 
migration, processes related to migration or were other cancer related proteins. These 
findings warrant further investigation by Western blot analysis and inhibitor assays 
to confirm their involvement and differential expression. Further validation in the 
SKOV3 and other ovarian cancer cell lines will be useful in confirming these results, 
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and knockdown studies could be used to investigate the role of these molecules in 
obestatin-stimulated cell migration. Obestatin may have other effects on cell 
physiology that have not previously been identified, and not all of the differentially 
expressed proteins identified in this study would be directly related to its role in cell 
migration, however.  
 
Ingenuity pathway analysis indicated that obestatin may regulate cell death in 
ovarian cancer cell lines. Obestatin has been shown to have anti-apoptotic effects in 
cardiomyocytes [462] and HIT-T15 and INS-1E beta cell pancreatic cell lines [12]. 
Obestatin has been associated with increased apoptosis in porcine ovarian granulosa 
cells, which showed increased expression of apoptotic markers Bax, p53 and Caspase 
3 [465]. Interestingly, none of these markers were identified in the current study, 
however, cell death was a process identified by the Ingenuity Pathway Analysis. 
Obestatin may, therefore, play a role in regulating apoptosis in ovarian cancer cell 
lines, and this should be investigated using functional assays.  
 
As obestatin has not previously been shown to stimulate cell migration, the signalling 
pathways involved were investigated in this study. The ERK1/2 signalling protein 
was identified as a key molecule in response to obestatin treatment in this study 
using 2D-DIGE and Ingenuity Pathway Analysis (Chapter 5.3.1) and, therefore, the 
effect of obestatin on ERK1/2 signalling was investigated. Western immunoblot 
analysis was performed in order to investigate the effects of obestatin on ERK1/2 
phosphorylation. While an increase in phosphorylation would be expected if 
obestatin signals through this pathway, there was no increase in ERK1/2 
phosphorylation with obestatin treatment, and a decrease in phosphorylation was 
observed at higher concentrations. This suggests that ERK1/2 is not a signalling 
pathway stimulated by obestatin in ovarian cancer and it is unlikely to be playing a 
part in obestatin-stimulated cell migration. 
 
Ghrelin treatment had a similar effect on ERK1/2 signalling, showing no change in 
phosphorylation with treatment and decreased phosphorylation in the SKOV3 
ovarian cancer cell line. The ERK1/2 pathway is a recognised as an important ghrelin 
signalling pathway, and is stimulated by ghrelin in porcine ovarian follicular [509] 
and granulosa cells [395], chicken ovarian granulosa cells [508, 621] and the SKOV3 
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ovarian cancer cell line [524], although the effects of ghrelin on ERK1/2 
phosphorylation in human ovarian cancer have not been previously investigated. The 
results of this study, however, suggest that that ERK1/2 does not play a role in the 
response of ovarian cancer cell lines to ghrelin. In endothelial cells, however, 
ghrelin-mediated cell migration coincided with increased phosphorylation of ERK1/2 
[171, 172, 174].  
 
As it appears to be unlikely that ERK1/2 is involved in signalling and cell migration 
in response to ghrelin and obestatin, other pathways need to be investigated. There 
have been a few studies investigating the signalling pathways that are activated by 
ghrelin which lead to cell migration. Ghrelin increases migration in a range of 
endothelial cells by stimulating increased calcium mobilisation [190]. Migration in 
these cells could be attenuated by cAMP and protein kinase A (PKA) inhibitors 
[190]. A study of astrocytoma cell lines, U-118, U-87, CCFSTTG1 and SW1008, 
also showed that calcium mobilisation increased, and protein kinase C (PKC) was 
stimulated in response to ghrelin treatment [16]. Ghrelin-stimulated migration in rat 
C6 and human U251 glioma cell lines was mediated through the calmodulin-
dependent protein kinase II (CaMKII), AMP-activated protein kinase (AMPK), and 
nuclear factor-kappa B (NF-κB) pathways [55], and these pathways could also be 
involved in ghrelin stimulated cell migration in ovarian cell lines. Some ghrelin 
signalling molecules and pathways, including PKA [12], PKC [10, 11, 462, 466], 
ERK1/2 [10-12, 462, 465, 466] and AMPK [464], are also activated by obestatin (as 
discussed in Chapter 1.4.3). Interestingly, the PKC pathway and the NF-κB complex 
were also associated with the network of proteins identified from the 2D-DIGE 
experiment, generated in the Ingenuity Pathway Analysis (discussed in Chapter 
5.3.1). This 2D-DIGE method did not investigate the activation (phosphorylation) of 
signalling molecules, however. These signalling pathways should be investigated for 
their potential involvement in ghrelin- and obestatin-stimulated cell migration. This 
could be achieved using Western blot analyses or phosphorylated protein arrays to 
demonstrate activation (phosphorylation) in response to treatment with ghrelin and 
obestatin. It would be useful to perform Transwell migration assays in the presence 
of signalling pathway inhibitors to determine their role in migration. It is likely that a 




The role of ghrelin in cell invasion, a hallmark of cancer that is essential for 
metastasis, has been the subject of little study, and there have been no studies into the 
role of obestatin in invasion. Ghrelin increases the invasiveness of the poorly 
differentiated PANC1 and MIAPaCa2, the well-differentiated BxPC3 and Capan2 
pancreatic adenocarcinoma cell lines [54] and the SW-48 and ROK colorectal cancer 
cell lines [48]. Ghrelin treatment caused no change in cell invasion in the normal 
ovarian and ovarian cancer cell lines in this study. Obestatin treatment did, however, 
cause a significant increase in invasion in the OV-MZ-6 ovarian cancer cell line and 
the hOSE 17.1 normal ovarian cell line. This suggests that obestatin may play a role 
in normal ovarian epithelial cell invasion, and a study in a wider range of cell lines is 
required 
 
Cell attachment is also a key process in cancer progression. Epithelial ovarian cancer 
spreads primarily by the implantation of spheroids of tumour cells onto the 
mesothelium that lines the peritoneal cavity [527, 528]. The ovarian cancer cells 
attach to mesothelial cells by binding to a number of molecules, including 
extracellular matrix (ECM) ligands such as fibronectin which are expressed by the 
mesothelial cells themselves [551]. Mesothelial cells secrete an array of ECM 
molecules, including fibronectin, vitronectin and collagen I, expressing them on their 
cell surface and secreting them into the peritoneal cavity [552-554]. Cancer cells then 
gain access to the submesothelial extracellular matrix, allowing the cells to attach 
with a high affinity [551]. The role of ghrelin and obestatin in cancer cell attachment 
has not been studied. Obestatin had no effect on attachment to any of the ECM 
molecules tested in this study in any of the cell lines. Ghrelin also had no effect on 
cell attachment to the ECM molecules, fibronectin, vitronectin, collagen I, or 
collagen IV in the hOSE17.1 and OV-MZ-6 ovarian cell lines. In the SKOV3 ovarian 
cancer cell line, there was a significant decrease in attachment to collagen IV with 10 
nM ghrelin treatment only. Although collagen IV is not normally expressed by 
mesothelial cells, it is expressed by the basement membrane and this could affect 
attachment to the submesothelial layer. As this result was only observed in one cell 
line and at one ghrelin concentration this finding might not be physiologically 
relevant and and further investigation may be warranted in other ovarian cancer cell 




It has previously been demonstrated that ghrelin and obestatin play a role in cell 
proliferation [381]. Ghrelin influences cell proliferation in a large number of normal 
and cancer cell types [15]. We have previously shown that exogenous ghrelin 
treatment increases proliferation in breast [17], prostate [39, 40] and endometrial [49] 
cancer cell lines and ghrelin also  increases cell proliferation in a number of cancer 
cell lines, colon [48], liver [25], pancreas [54, 56], pituitary [57] and thyroid [56]. In 
the ovary, studies of porcine ovarian follicular cells have demonstrated that ghrelin 
treatment increases cell proliferation [395, 509]. Obestatin, has also been shown to 
play a role, increasing cell proliferation in some cell lines, while having no effect in 
others [7]. In this thesis, however, neither peptide had an effect on proliferation in 
ovarian cancer cells or in the normal hOSE 17.1 cell line (Chapter 3.3.4 and 4.3.3). 
Although ghrelin has been shown to stimulate cell proliferation in a large number of 
cell lines, it has also been shown to have no effect on cell proliferation in a number 
of cell types, including the MCF-10A normal-derived breast cell line, the MCF7 
breast cancer cell line [17], the KATO-III gastric cancer cell line [11], the SupT1 
leukemic cell line [51] and the CALU-1 lung carcinoma cell line [27].  
 
Initial studies suggest that obestatin may have similar functions to ghrelin, and it also 
increases cell proliferation in the KATO-III gastric cancer cell line [11] and prostate 
cancer cell lines (personal communication Dr Laura De Amorim, Ghrelin Research 
Group, QUT). Obestatin treatment had no effect on ovarian cancer cell proliferation 
in this study and obestatin also had no effect on cell proliferation in other studies in 
the BON-1 pancreatic neuroendocrine tumour cell line [56], the AGS gastric cancer 
cell line [466], or the GC rat somatotroph tumour cell line [466]. Ghrelin and 
obestatin may, therefore, increases cell migration, but has no influence on cell 
proliferation in the ovarian cancer cell lines in this study.  
 
This study has focused on the role of ghrelin and obestatin in serous ovarian cancer 
cell lines compared to a normal ovarian surface epithelial cell line (hOSE 17.1). 
Serous carcinomas represent 75%-80% of ovarian cancer cases diagnosed [61]. 
Although other epithelial ovarian cancer subtypes are less common, it would be 
useful to perform these assays using cell lines representing other types of epithelial 
ovarian cancers and additional normal epithelial-derived ovarian cell lines. These 





In conclusion, this thesis has demonstrated for the first time that ghrelin and 
obestatin may play a role in ovarian cancer progression. Treatment with the 
hormones, ghrelin or obestatin, stimulates a significant increase in cell migration, a 
key process related to metastasis, in human ovarian cancer cell lines. Obestatin 
increased cell invasion in the hOSE 17.1 cell line, which may suggest that it plays a 
role in the normal ovary and in the OV-MZ-6 cancer ce3ll line which may indicate 
that it promotes the invasion in cancer [392, 393]. Ovarian cancer is the leading 
cause of death among gynaecological cancers [58]. This is largely because two thirds 
of ovarian cancer cases are not diagnosed until the late stages of cancer development 
(either stage III or IV), after metastases have developed, resulting in limited 
treatment choices and a poor prognosis for the patient [61]. Our studies, indicating 
that ghrelin and obestatin play a role in cell migration, suggest that the ghrelin axis 
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